

6m

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
2 June 2005 (02.06.2005)

PCT

(10) International Publication Number
WO 2005/049033 A1

(51) International Patent Classification⁷: **A61K 31/506**,
C07D 403/12, 409/14, 495/04, 487/04, 471/04, 401/14,
417/04, 403/14, A61P 35/00

(21) International Application Number:
PCT/GB2004/004784

(22) International Filing Date:
15 November 2004 (15.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/520,581 17 November 2003 (17.11.2003) US
60/556,213 25 March 2004 (25.03.2004) US

(71) Applicant (for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW only): **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BLOCK, Michael, Howard** [GB/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **HAN, Yongxin** [CN/US]; Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301 (US). **JOSEY, John Anthony** [US/US]; Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301 (US). **LEE, John W** [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham,

Massachusetts 02451 (US). **SCOTT, David** [GB/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **WANG, Bin** [CN/US]; Array BioPharma Inc, 3200 Walnut Street, Boulder, Colorado 80301 (US). **WANG, Haixia** [CN/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **WANG, Tao** [CN/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **YU, Dingwei** [CN/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, SE-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: **PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES**

(57) Abstract: Compounds of formula (I): and their use in the inhibition of Trk activity are described.



WO 2005/049033 A1



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES

Field of the invention

The present invention relates to novel pyrazole derivatives, their pharmaceutical
5 compositions and methods of use. In addition, the present invention relates to therapeutic
methods for the treatment and prevention of cancers and to the use of these pyrazole
derivatives in the manufacture of medicaments for use in the treatment and prevention of
cancers.

Background of the invention

10 Receptor tyrosine kinases (RTK's) are a sub-family of protein kinases that play a
critical role in cell signalling and are involved in a variety of cancer related processes
including cell proliferation, survival, angiogenesis and metastasis. Currently up to 100
different RTK's including tropomyosin-related kinases (Trk's) have been identified.

Trk's are the high affinity receptors activated by a group of soluble growth factors
15 called neurotrophins (NT). The Trk receptor family has three members - TrkA, TrkB and
TrkC. Among the NTs there are (i) nerve growth factor (NGF) which activates TrkA, (ii)
brain-derived growth factor (BDNF) and NT-4/5 which activate TrkB and (iii) NT3 which
activates TrkC. Each Trk receptor contains an extra-cellular domain (ligand binding), a
trans-membrane region and an intra-cellular domain (including kinase domain). Upon binding
20 of the ligand, the kinase catalyzes auto-phosphorylation and triggers downstream signal
transduction pathways.

Trk's are widely expressed in neuronal tissue during its development where Trk's are
critical for the maintenance and survival of these cells. A post-embryonic role for the
Trk/neurotrophin axis (or pathway), however, remains in question. There are reports showing
25 that Trk's play important role in both development and function of the nervous system
(Patapoutian, A. et al *Current Opinion in Neurobiology*, 2001, 11, 272-280).

In the past decade, a considerable number of literature documentations linking Trk
signalling with cancer have published. For example, while Trk's are expressed at low levels
outside the nervous system in the adult, Trk expression is increased in late stage prostate
30 cancers. Both normal prostate tissue and androgen- dependent prostate tumours express low
levels of Trk A and undetectable levels of Trk B and C. However, all isoforms of Trk
receptors as well as their cognate ligands are up-regulated in late stage, androgen-
independent prostate cancer. There is additional evidence that these late stage prostate cancer

cells become dependent on the Trk/neurotrophin axis for their survival. Therefore, Trk inhibitors may yield a class of apoptosis-inducing agents specific for androgen- independent prostate cancer (Weeraratna, A. T. et al *The Prostate*, 2000, 45, I40-I48).

Furthermore, very recent literature also shows that over-expression, activation,
5 amplification and/or mutation of Trk's are associated with secretory breast carcinoma (*Cancer Cell*, 2002, 2, 367-376), colorectal cancer (Bardelli et al *Science*, 2003, 300, 949-949) and ovarian cancer (Davidson, B. et al *Clinical Cancer Research*, 2003, 9, 2248-2259).

There are a few reports of selective Trk tyrosine kinase inhibitors. Cephalon described CEP-751, CEP-701 (George, D. et al *Cancer Research*, 1999, 59, 2395-2341) and other
10 indolocarbazole analogues (WO0114380) as Trk inhibitors. It was shown that CEP-701 and/or CEP751, when combined with surgically or chemically induced androgen ablation, offered better efficacy compared with mono-therapy alone. GlaxoSmithKline disclosed certain oxindole compounds as TrkA inhibitors in WO0220479 and WO0220513. Recently, Japan Tobacco reported pyrazolyl condensed cyclic compounds as Trk inhibitors
15 (JP2003231687A).

In addition to the above, Vertex Pharmaceuticals have described pyrazole compounds as inhibitors of GSK3, Aurora, etc. in WO0250065, WO0262789 and WO03027111; and AstraZeneca have reported pyrazole compounds as inhibitors against IGF-1 receptor kinase (WO0348133).

20 Summary of the invention

In accordance with the present invention, the applicants have hereby discovered novel pyrazole compounds, or pharmaceutically acceptable salts thereof, which possess Trk kinase inhibitory activity and are accordingly useful for their anti-proliferation and/or proapoptotic (such as anti-cancer) activity and in methods of treatment of the human or animal body. The
25 invention also relates to processes for the manufacture of said pyrazole compounds, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-proliferation and/or proapoptotic effect in warm-blooded animals such as man.

Also in accordance with the present invention the applicants provide methods of using
30 such pyrazole compounds, or pharmaceutically acceptable salts thereof, in the treatment of cancer.


The properties of the compounds claimed in this invention are expected to be of value in the treatment of disease states associated with cell proliferation such as cancers (solid

tumours and leukaemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

- 5 Furthermore, the compounds, or pharmaceutically acceptable salts thereof, of the invention are expected to be of value in the treatment or prophylaxis of cancers selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposi sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), and
 10 small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma and leukaemia; particularly ovarian cancer, breast cancer, colorectal cancer, prostate cancer and lung cancer - NSCLC and SCLC; more particularly prostate cancer; and more particularly hormone refractory prostate cancer.

Detailed description of the invention

- 15 Accordingly, the present invention provides a compound of formula (I):



wherein:

- A is a direct bond or C₁₋₂alkylene; wherein said C₁₋₂alkylene may be optionally
 20 substituted by one or more R²²;

Ring C is carbocyclyl or heterocyclyl;

- R¹ and R⁴ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino,
 25 *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl,

N,N-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R¹ and R⁴ independently of each other may be optionally substituted on carbon by one or more R⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R⁹;

R² is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R² may be optionally substituted on carbon by one or more R¹⁰; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹¹;

R³ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R³ may be optionally substituted on carbon by one or more R¹²; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹³;

R⁵ is hydrogen or optionally substituted C₁₋₆alkyl; wherein said optional substituents are selected from one or more R¹⁴;

R⁶ and R⁷ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted

on carbon by one or more R^{15} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{16} ;

or R^6 and R^7 together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R^{17} ; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{18} ;

$n = 0, 1, 2$ or 3 ; wherein the values of R^3 may be the same or different;

$R^8, R^{10}, R^{12}, R^{14}, R^{15}, R^{17}$ and R^{22} are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein $R^8, R^{10}, R^{12}, R^{14}, R^{15}, R^{17}$ and R^{22} independently of each other may be optionally substituted on carbon by one or more R^{19} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{20} ;

$R^9, R^{11}, R^{13}, R^{16}, R^{18}$ and R^{20} are independently selected from C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein $R^9, R^{11}, R^{13}, R^{16}, R^{18}$ and R^{20} independently of each other may be optionally substituted on carbon by one or more R^{21} ;

R^{19} and R^{21} are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R^{19} and R^{21} independently of each other may be optionally

substituted on carbon by one or more R^{23} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{24} ;

R^{23} is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphonamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylaminomethyl, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphonyl, ethylsulphonyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphonamoyl, *N*-ethylsulphonamoyl, *N,N*-dimethylsulphonamoyl, *N,N*-diethylsulphonamoyl or *N*-methyl-*N*-ethylsulphonamoyl; and

R^{24} is selected from C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, *N*-(C_{1-6} alkyl)carbamoyl, *N,N*-(C_{1-6} alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not:


5-bromo- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;
5-chloro- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;
5-bromo- N^2 -[1-(3-methyl-5-isoxazolyl)ethyl]- N^4 -(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine;

5-chloro- N^2 -[1-(3-methyl-5-isoxazolyl)ethyl]- N^4 -(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine;

5-bromo- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
5-chloro- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
5-chloro- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine;

5-bromo- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine; or
5-bromo- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(2-pyridinyl)ethyl]-2,4-pyrimidinediamine.

In a further aspect of the invention there is provided a compound of formula (Ia) wherein:



wherein:

A is a valence bond or C₁₋₂ alkyl;

5 C is a C₅₋₉aryl, C₅₋₉heteroaryl, or C₅₋₉cycloalkyl ring;

R¹ and R⁴ are H, optionally substituted C₁₋₆alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl;

10 R² is optionally substituted C₁₋₆alkyl, optionally substituted cycloalkyl, optionally substituted C₁₋₆ether, optionally substituted C₁₋₆amine; optionally substituted, optionally substituted C₁₋₆ester, or optionally substituted C₁₋₆amide or R² and C in combination form a fused 9 or 10 membered aryl optionally substituted with R⁸;

R³ is H, F, Cl, Br, I, CF₃, NH₂, NO₂, OH, OCF₃, C₁₋₆alkyl, OC₁₋₆alkyl, SC₁₋₆alkyl, Nalkyl, SO₂NH₂, C(=O)Oalkyl;

15 R⁵ is H or optionally substituted C₁₋₆alkyl;

R⁶ and R⁷ are independently selected from: H, F, Cl, Br, I, CF₃, CN, NH₂, NO₂, OH, CH₂OH, OCF₃, C₁₋₆alkyl, OC₁₋₆alkyl, SC₁₋₆alkyl, SO₂NH₂, C(=O)OC₁₋₆alkyl, C₅₋₆aryl C₅₋₇heterocyclyl or R⁶ and R⁷ in combination form an optionally substituted fused 5 or 6-membered aryl or heteroaromatic ring, said heteroaromatic ring having at least one nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom or two nitrogen atoms wherein such fused ring is optionally substituted with R⁸;

20 R⁸ is H, F, Cl, Br, I, CF₃, CN, NH₂, NO₂, OH, CH₂OH, OCF₃, C₁₋₆alkyl, OC₁₋₆alkyl, SC₁₋₆alkyl, SO₂NH₂, C(=O)OC₁₋₆alkyl, C₅₋₆aryl, C₅₋₇heterocyclyl, optionally substituted C₁₋₆alkyl, optionally substituted cycloalkyl, optionally substituted C₁₋₆ether, optionally

substituted C₁₋₆amine; optionally substituted, optionally substituted C₁₋₆ester, or optionally substituted C₁₋₆amide.

In a further aspect of the invention there is provided a compound of formula (I) wherein:

5 A is a direct bond or C₁₋₂alkylene; wherein said C₁₋₂alkylene may be optionally substituted by one or more R²²;

Ring C is carbocyclyl or heterocyclyl;

R¹ and R⁴ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R¹ and R⁴ independently of each other may be optionally substituted on carbon by one or more R⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R⁹;

R² is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R² may be optionally substituted on carbon by one or more R¹⁰; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹¹;

R³ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R³ may be optionally substituted on carbon by one or more R¹²; and wherein if said

heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹³;

R⁵ is hydrogen or optionally substituted C₁₋₆alkyl; wherein said optional substituents are selected from one or more R¹⁴;

- 5 R⁶ and R⁷ are independently selected from selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, 10 *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁶;

- or R⁶ and R⁷ together with the pyrimidine bond to which they are attached form a 5 or 15 6 membered carbocyclic ring or heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R¹⁷; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁸;

n = 0, 1, 2 or 3; wherein the values of R³ may be the same or different;

- 20 R⁸, R¹⁰, R¹², R¹⁴, R¹⁵, R¹⁷ and R²² are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, 25 *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R⁸, R¹⁰, R¹², R¹⁴, R¹⁵, R¹⁷ and R²² independently of each other may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

- 30 R⁹, R¹¹, R¹³, R¹⁶, R¹⁸ and R²⁰ are independently selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein

R^9 , R^{11} , R^{13} , R^{16} , R^{18} and R^{20} independently of each other may be optionally substituted on carbon by one or more R^{21} ;

R^{19} and R^{21} are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R^{19} and R^{21} independently of each other may be optionally substituted on carbon by one or more R^{23} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{24} ;

R^{23} is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, N -methyl- N -ethylamino, acetylamino, N -methylcarbamoyl, N -ethylcarbamoyl, N,N -dimethylcarbamoyl, N,N -diethylcarbamoyl, N -methyl- N -ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N -methylsulphamoyl, N -ethylsulphamoyl, N,N -dimethylsulphamoyl, N,N -diethylsulphamoyl or N -methyl- N -ethylsulphamoyl; and

R^{24} is selected from C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not:

- 5-bromo- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-chloro- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-bromo- N^2 -[1-(3-methyl-5-isoxazolyl)ethyl]- N^4 -(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine;
 5-chloro- N^2 -[1-(3-methyl-5-isoxazolyl)ethyl]- N^4 -(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine;
 5-bromo- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-chloro- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-chloro- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine;

5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine; or
 5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)ethyl]-2,4-pyrimidinediamine.

Preferred values of the variable groups contained in formula (I) are as follows. Such values may be used, where appropriate, with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

A is a direct bond.

A is C₁₋₂alkylene.

A is C₁₋₂alkylene optionally substituted by one or more R²².

Ring C is carbocyclyl.

10 Ring C is heterocyclyl.

Ring C is phenyl or thienyl.

Ring C is phenyl.

Ring C is thienyl.

Ring C is thienyl, pyridyl, thiazolyl.

15 Ring C is thien-2-yl, pyrid-2-yl, thiazol-2-yl.

Ring C is phenyl or thien-2-yl.

Ring C is phenyl, thienyl, pyridyl, thiazolyl.

Ring C is phenyl, thien-2-yl, pyrid-2-yl, thiazol-2-yl.

Ring C is not pyridyl or isoxazolyl.

20 Ring C is not pyrid-2-yl, pyrid-3-yl or isoxazol-5-yl.

Ring C and (R³)_n together are 4-fluorophenyl.

R¹ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkylS(O)_a wherein a is 0 or carbocyclyl; wherein R¹ may be optionally substituted on carbon by one or more R⁸; wherein

25 R⁸ is selected from halo or carbocyclyl.

R¹ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkylS(O)_a wherein a is 0 or carbocyclyl.

R¹ is selected from hydrogen, methyl, ethyl, isopropyl, *t*-butyl, methoxy, ethoxy, propoxy, isopropoxy, sec-butoxy, dimethylamino, methylthio or cyclopropyl; wherein

30 R⁸ is selected from fluoro, cyclopropyl or phenyl.

R¹ is selected from hydrogen, methyl, ethyl, *t*-butyl, methoxy, ethoxy, dimethylamino, methylthio or cyclopropyl.

R¹ is selected from hydrogen, methyl, ethyl, isopropyl, *t*-butyl, trifluoromethyl, cyclopropylmethyl, benzyl, methoxy, ethoxy, propoxy, isopropoxy, sec-butoxy, dimethylamino, methylthio or cyclopropyl.

R¹ is selected from hydrogen, methyl, ethyl, *t*-butyl, methoxy, dimethylamino, methylthio or cyclopropyl.

R¹ is cyclopropyl.

R⁴ is hydrogen.

R² is selected from C₁₋₆alkyl.

R² is selected from methyl, ethyl or isopropyl.

R² is selected from C₁₋₆alkyl; wherein R² may be optionally substituted on carbon by one or more R¹⁰.

R² is selected from methyl, ethyl or isopropyl; wherein R² may be optionally substituted on carbon by one or more R¹⁰.

R² is selected from C₁₋₆alkyl; wherein R² may be optionally substituted on carbon by one or more R¹⁰;

R¹⁰ is selected from halo, hydroxy, carboxy, amino, C₁₋₆alkoxy, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl or heterocyclyl; wherein R¹⁰ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

R¹⁹ is selected from hydroxy or C₁₋₆alkoxy;

R²⁰ is selected from C₁₋₆alkyl.

R² is selected from C₁₋₆alkyl; wherein R² may be optionally substituted on carbon by one or more R¹⁰; wherein

R¹⁰ is selected from hydroxy, carboxy, C₁₋₆alkoxy, *N,N*-(C₁₋₆alkyl)₂amino or heterocyclyl; wherein R¹⁰ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

R²⁰ is selected from C₁₋₆alkyl; and

R¹⁹ is selected from hydroxy or C₁₋₆alkoxy.

R² is selected from methyl, ethyl or isopropyl; wherein R² may be optionally substituted on carbon by one or more R¹⁰;

R^{10} is selected from fluoro, hydroxy, carboxy, amino, methoxy, dimethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, pyrrolidin-1-yl, piperazinyl or morpholino; wherein R^{10} may be optionally substituted on carbon by one or more R^{19} ; and wherein if said piperazinyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{20} ;

R^{19} is selected from hydroxy or methoxy;

R^{20} is selected from methyl.

R^2 is selected from methyl, ethyl or isopropyl; wherein R^2 may be optionally substituted on carbon by one or more R^{10} ; wherein

R^{10} is selected from hydroxy, carboxy, methoxy, *N*-methyl-*N*-ethylamino, diethylamino, pyrrolidinyl, piperazinyl or morpholinyl; wherein R^{10} may be optionally substituted on carbon by one or more R^{19} ; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R^{20} ;

R^{20} is selected from methyl; and

R^{19} is selected from hydroxy or methoxy.

R^2 is selected from methyl, ethyl or isopropyl; wherein R^2 may be optionally substituted on carbon by one or more R^{10} ; wherein

R^{10} is selected from hydroxy, carboxy, methoxy, *N*-methyl-*N*-ethylamino, diethylamino, pyrrolidin-1-yl, piperazin-1-yl or morpholino; wherein R^{10} may be optionally substituted on carbon by one or more R^{19} ; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R^{20} ;

R^{20} is selected from methyl; and

R^{19} is selected from hydroxy or methoxy.

R^2 is selected from methyl, ethyl, trifluoromethyl, hydroxymethyl, carboxymethyl, aminomethyl, methoxymethyl, morpholinomethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-carboxyethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl, acetamidomethyl, 2-[*N*-methyl-*N*-(2-methoxyethyl)amino]ethyl, 2-[*N*-methyl-*N*-(2-hydroxyethyl)amino]ethyl, 2-(*N*-methylcarbamoyl)ethyl, 2-[*N*-(2-hydroxyethyl)carbamoyl]ethyl, 2-(*N,N*-dimethylcarbamoyl)ethyl, 2-morpholinoethyl, 2-pyrrolidin-1-ylethyl or 2-(1-methylpiperazin-4-yl)ethyl, 1-methyl-2-hydroxyethyl.

R^2 is selected from methyl; wherein R^2 may be optionally substituted on carbon by one or more R^{10} ; wherein

R^{10} is selected from hydroxy.

R^3 is selected from halo, nitro, C_{1-6} alkyl or C_{1-6} alkoxy; wherein R^3 may be optionally substituted on carbon by one or more R^{12} ; wherein

R^{12} is selected from halo.

R^3 is selected from halo, nitro or C_{1-6} alkoxy.

5 R^3 is selected from fluoro, nitro, methyl or methoxy; wherein R^3 may be optionally substituted on carbon by one or more R^{12} ; wherein

R^{12} is selected from fluoro.

R^3 is selected from fluoro, nitro, trifluoromethyl or methoxy.

R^3 is selected from fluoro, nitro or methoxy.

10 R^3 is selected from fluoro.

R^5 is hydrogen.

R^5 is C_{1-6} alkyl.

R^5 is optionally substituted C_{1-6} alkyl; wherein said optional substituents are selected from one or more R^{14} .

15 R^5 is hydrogen or optionally substituted C_{1-6} alkyl; wherein said optional substituents are selected from one or more R^{14} ; wherein

R^{14} is selected from hydroxy.

R^5 is hydrogen, methyl or optionally substituted ethyl; wherein said optional substituents are selected from one or more R^{14} ; wherein

20 R^{14} is selected from hydroxy.

R^5 is hydrogen or optionally substituted ethyl; wherein said optional substituents are selected from one or more R^{14} ; wherein

R^{14} is selected from hydroxy.

R^5 is hydrogen, methyl or 2-hydroxyethyl.

25 R^5 is hydrogen or 2-hydroxyethyl.

R^5 is hydrogen.

R^6 and R^7 are independently selected from hydrogen, halo, nitro, cyano, amino, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R^6 and R^7 independently of each other may be optionally substituted

on carbon by one or more R¹⁵; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁶.

R⁶ and R⁷ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁶.

R⁶ and R⁷ are independently selected from hydrogen, halo, C₁₋₆alkyl, *N*-(C₁₋₆alkyl)amino, *N*-(C₁₋₆alkyl)carbamoyl or C₁₋₆alkoxycarbonyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵.

R⁶ and R⁷ are independently selected from hydrogen, halo, nitro, cyano, amino, C₁₋₆alkyl, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, *N*-(C₁₋₆alkyl)carbamoyl, C₁₋₆alkoxycarbonyl or heterocyclyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁶.

R⁶ and R⁷ are independently selected from hydrogen, fluoro, chloro, bromo, methyl, methylamino, ethylamino, propylamino, *N*-(ethyl)carbamoyl, methoxycarbonyl, ethoxycarbonyl or butoxycarbonyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵.

R⁶ and R⁷ are independently selected from hydrogen, fluoro, chloro, bromo, nitro, cyano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, *N*-methyl-*N*-propylamino, *N*-ethylcarbamoyl, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morpholino, pyrrolidinyl or piperazinyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R¹⁶.

R⁶ and R⁷ are independently selected from hydrogen, fluoro, chloro, bromo, methyl, ethylamino, propylamino, *N*-(ethyl)carbamoyl, methoxycarbonyl, ethoxycarbonyl or

butoxycarbonyl; wherein R^6 and R^7 independently of each other may be optionally substituted on carbon by one or more R^{15} .

5 R^6 and R^7 together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R^{17} ; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{18} .

10 R^6 and R^7 together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyclic ring or heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R^{17} ; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{18} .

15 R^6 and R^7 together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyclic ring or heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R^{17} .

20 R^6 and R^7 together with the pyrimidine to which they are attached form a bicyclic ring selected from quinazolinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrazolo[3,4-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidinyl; and wherein said bicyclic ring may be optionally substituted on carbon by one or more R^{17} ; and wherein said 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidinyl may be optionally substituted on nitrogen by a group selected from R^{18} .

25 R^6 and R^7 together with the pyrimidine to which they are attached form quinazolinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, 1H-pyrazolo[3,4-d]pyrimidinyl or pyrido[2,3-d]pyrimidinyl; and wherein said quinazolinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, 1H-pyrazolo[3,4-d]pyrimidinyl or pyrido[2,3-d]pyrimidinyl may be optionally substituted on carbon by one or more R^{17} .

R^6 and R^7 are independently selected from hydrogen, halo, nitro, cyano, amino, C_{1-6} alkyl, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, N -(C_{1-6} alkyl)carbamoyl, C_{1-6} alkoxycarbonyl or heterocyclyl; wherein R^6 and R^7 independently of each other may be optionally substituted on carbon by one or more R^{15} ; and wherein if said heterocyclyl contains
5 an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{16} ;

or R^6 and R^7 together with the pyrimidine bond to which they are attached form a 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring
10 or heterocyclic ring may be optionally substituted on carbon by one or more R^{17} ; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{18} .

R^6 and R^7 are independently selected from hydrogen, halo, C_{1-6} alkyl, N -(C_{1-6} alkyl)amino, N -(C_{1-6} alkyl)carbamoyl or C_{1-6} alkoxycarbonyl; wherein R^6 and R^7
15 independently of each other may be optionally substituted on carbon by one or more R^{15} ;

or R^6 and R^7 together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyclic ring or heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R^{17} .

R^6 and R^7 are independently selected from hydrogen, fluoro, chloro, bromo, nitro, cyano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, N -methyl- N -propylamino, N -ethylcarbamoyl, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morpholino, pyrrolidinyl or piperazinyl; wherein R^6 and R^7 independently of each other may be optionally substituted on carbon by one or more R^{15} ; and
20 wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R^{16} ;

or R^6 and R^7 together with the pyrimidine to which they are attached form a bicyclic ring selected from quinazolinyl, thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, 1*H*-pyrazolo[3,4-*d*]pyrimidinyl, thieno[3,4-*d*]pyrimidinyl, pyrido[2,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[4,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-*d*]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-*d*]pyrimidinyl; and wherein said bicyclic ring may be optionally substituted on carbon by one or more R^{17} ; and wherein said 5,6,7,8-tetrahydro-pyrido[4,3-
30

d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidinyl may be optionally substituted on nitrogen by a group selected from R¹⁸.

R⁶ and R⁷ are independently selected from hydrogen, fluoro, chloro, bromo, methyl, methylamino, ethylamino, propylamino, *N*-(ethyl)carbamoyl, methoxycarbonyl, ethoxycarbonyl or butoxycarbonyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵;

or R⁶ and R⁷ together with the pyrimidine to which they are attached form quinazolinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl or pyrido[2,3-d]pyrimidinyl; and wherein said quinazolinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl or pyrido[2,3-d]pyrimidinyl may be optionally substituted on carbon by one or more R¹⁷.

R⁶ and R⁷ are independently selected from hydrogen, fluoro, chloro, bromo, methyl, ethylamino, propylamino, *N*-(ethyl)carbamoyl, methoxycarbonyl, ethoxycarbonyl or butoxycarbonyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵;

or R⁶ and R⁷ together with the pyrimidine to which they are attached form quinazolinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl or pyrido[2,3-d]pyrimidinyl; and wherein said quinazolinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl or pyrido[2,3-d]pyrimidinyl may be optionally substituted on carbon by one or more R¹⁷.

R⁶ and R⁷ are independently selected from hydrogen, halo, nitro, cyano, amino, C₁₋₆alkyl, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, *N*-(C₁₋₆alkyl)carbamoyl, C₁₋₆alkoxycarbonyl or heterocyclyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁶;

or R⁶ and R⁷ together with the pyrimidine bond to which they are attached form a 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R¹⁷; and wherein

if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁸;

R¹⁵ is selected from halo, hydroxy, amino, C₁₋₆alkoxy, *N,N*-(C₁₋₆alkyl)₂amino, carbocyclyl or heterocyclyl; wherein R¹⁵ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

R¹⁷ is selected from halo, C₁₋₆alkyl or C₁₋₆alkoxy; wherein R¹⁷ may be optionally substituted on carbon by one or more R¹⁹;

R¹⁶ is selected from C₁₋₆alkyl;

R¹⁸ is selected from C₁₋₆alkanoyl;

R¹⁹ is selected from halo, hydroxy, C₁₋₆alkoxy or heterocyclyl; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴;

R²⁰ is selected from C₁₋₆alkyl; and

R²⁴ is selected from C₁₋₆alkyl.

R⁶ and R⁷ are independently selected from hydrogen, halo, C₁₋₆alkyl, *N*-(C₁₋₆alkyl)amino, *N*-(C₁₋₆alkyl)carbamoyl or C₁₋₆alkoxycarbonyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵;

or R⁶ and R⁷ together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyclic ring or heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R¹⁷; wherein

R¹⁵ is selected from halo, hydroxy, carbocyclyl or heterocyclyl; wherein R¹⁵ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

R¹⁷ is selected from halo, C₁₋₆alkyl or C₁₋₆alkoxy; wherein R¹⁷ may be optionally substituted on carbon by one or more R¹⁹;

R²⁰ is selected from C₁₋₆alkyl;

R¹⁹ is selected from halo, C₁₋₆alkoxy or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴; and

R²⁴ is selected from C₁₋₆alkyl.

R⁶ and R⁷ are independently selected from hydrogen, fluoro, chloro, bromo, nitro, cyano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, *N*-methyl-*N*-propylamino, *N*-ethylcarbamoyl, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morpholino, pyrrolidinyl or piperazinyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R¹⁶;

or R⁶ and R⁷ together with the pyrimidine to which they are attached form a bicyclic ring selected from quinazolinyl, thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, 1*H*-pyrazolo[3,4-*d*]pyrimidinyl, thieno[3,4-*d*]pyrimidinyl, pyrido[2,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[4,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-*d*]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-*d*]pyrimidinyl; and wherein said bicyclic ring may be optionally substituted on carbon by one or more R¹⁷; and wherein said 5,6,7,8-tetrahydro-pyrido[4,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-*d*]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-*d*]pyrimidinyl may be optionally substituted on nitrogen by a group selected from R¹⁸;

R¹⁵ is selected from fluoro, hydroxy, amino, ethoxy, dimethylamino, phenyl, pyrrolidinyl, piperazinyl or morpholino; wherein R¹⁵ may be optionally substituted on carbon by one or more R¹⁹; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R²⁰;

R¹⁷ is selected from fluoro, chloro, methyl, methoxy, ethoxy or propoxy; wherein R¹⁷ may be optionally substituted on carbon by one or more R¹⁹;

R¹⁶ is selected from methyl;

R¹⁸ is selected from acetyl;

R¹⁹ is selected from fluoro, hydroxy, methoxy, piperazinyl, pyrrolidinyl or morpholino; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R²⁴;

R²⁰ is selected from methyl; and

R²⁴ is selected from methyl.

R⁶ and R⁷ are independently selected from hydrogen, fluoro, chloro, bromo, methyl, ethylamino, propylamino, *N*-(ethyl)carbamoyl, methoxycarbonyl, ethoxycarbonyl or butoxycarbonyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵;

or R⁶ and R⁷ together with the pyrimidine to which they are attached form quinazolinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl or pyrido[2,3-d]pyrimidinyl; and wherein said quinazolinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl or pyrido[2,3-d]pyrimidinyl may be optionally substituted on carbon by one or more R¹⁷; wherein

R¹⁵ is selected from fluoro, hydroxy, phenyl, piperazinyl, pyrrolidinyl or morpholino; wherein R¹⁵ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said piperazinyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

R¹⁷ is selected from fluoro, chloro, methyl, methoxy or ethoxy; wherein R¹⁷ may be optionally substituted on carbon by one or more R¹⁹;

R²⁰ is selected from methyl;

R¹⁹ is selected from fluoro, methoxy, piperazinyl, pyrrolidinyl or morpholino; wherein if said piperazinyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴; and

R²⁴ is selected from methyl.

R⁶ and R⁷ are independently selected from hydrogen, chloro, bromo or propylamino; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵; wherein R¹⁵ is selected from hydroxy;

or R⁶ and R⁷ together with the pyrimidine to which they are attached form quinazolinyl.

R¹⁰ is selected from halo, hydroxy, carboxy, amino, C₁₋₆alkoxy, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl or heterocyclyl; wherein R¹⁰ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰.

R¹⁰ is selected from hydroxy, carboxy, C₁₋₆alkoxy, *N,N*-(C₁₋₆alkyl)₂amino or heterocyclyl; wherein R¹⁰ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰.

R¹⁰ is selected from fluoro, hydroxy, carboxy, amino, methoxy, dimethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl,

N,N-dimethylcarbamoyl, pyrrolidin-1-yl, piperazinyl or morpholino; wherein R¹⁰ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said piperazinyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰.

R¹⁰ is selected from hydroxy, carboxy, methoxy, *N*-methyl-*N*-ethylamino, diethylamino, pyrrolidinyl, piperazinyl or morpholinyl; wherein R¹⁰ may be optionally substituted on carbon by one or more R¹⁹; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R²⁰.

R¹⁰ is selected from hydroxy, carboxy, methoxy, *N*-methyl-*N*-ethylamino, diethylamino, pyrrolidin-1-yl, piperazin-1-yl or morpholino; wherein R¹⁰ may be optionally substituted on carbon by one or more R¹⁹; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R²⁰.

R¹⁴ is selected from hydroxy.

R¹⁵ is selected from halo, hydroxy, carbocyclyl or heterocyclyl; wherein R¹⁵ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰.

R¹⁵ is selected from fluoro, hydroxy, phenyl, piperazinyl, pyrrolidinyl or morpholino; wherein R¹⁵ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said piperazinyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰.

R¹⁷ is selected from halo, C₁₋₆alkyl or C₁₋₆alkoxy; wherein R¹⁷ may be optionally substituted on carbon by one or more R¹⁹.

R¹⁷ is selected from fluoro, chloro, methyl, methoxy or ethoxy; wherein R¹⁷ may be optionally substituted on carbon by one or more R¹⁹.

R²⁰ is selected from C₁₋₆alkyl.

R²⁰ is selected from methyl.

R¹⁹ is selected from halo, C₁₋₆alkoxy or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴.

R¹⁹ is selected from fluoro, methoxy, piperazinyl, pyrrolidinyl or morpholino; wherein if said piperazinyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴.

R¹⁹ is selected from hydroxy or C₁₋₆alkoxy.

R¹⁹ is selected from hydroxy or methoxy.

R^{24} is selected from C_{1-6} alkyl.

R^{24} is selected from methyl.

$n = 0$ or 1 .

$n = 0$.

5 $n = 1$.

Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:

A is a direct bond;

Ring C is carbocyclyl or heterocyclyl;

10 R^1 is selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkylS(O)_a wherein a is 0 or carbocyclyl; wherein R^1 may be optionally substituted on carbon by one or more R^8 ;

R^2 is selected from C_{1-6} alkyl; wherein R^2 may be optionally substituted on carbon by one or more R^{10} ;

15 R^3 is selected from halo, nitro, C_{1-6} alkyl or C_{1-6} alkoxy; wherein R^3 may be optionally substituted on carbon by one or more R^{12} ;

R^4 is hydrogen;

R^5 is hydrogen or optionally substituted C_{1-6} alkyl; wherein said optional substituents are selected from one or more R^{14} ;

20 R^6 and R^7 are independently selected from hydrogen, halo, nitro, cyano, amino, C_{1-6} alkyl, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, N -(C_{1-6} alkyl)carbamoyl, C_{1-6} alkoxycarbonyl or heterocyclyl; wherein R^6 and R^7 independently of each other may be optionally substituted on carbon by one or more R^{15} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{16} ;

25 or R^6 and R^7 together with the pyrimidine bond to which they are attached form a 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R^{17} ; and wherein
30 if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{18} ;

R^8 is selected from halo or carbocyclyl;

- R^{10} is selected from halo, hydroxy, carboxy, amino, C_{1-6} alkoxy, N,N -(C_{1-6} alkyl) $_2$ amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl) $_2$ carbamoyl or heterocyclyl; wherein R^{10} may be optionally substituted on carbon by one or more R^{19} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{20} ;
- R^{12} is selected from halo;
- R^{14} is selected from hydroxy;
- R^{15} is selected from halo, hydroxy, amino, C_{1-6} alkoxy, N,N -(C_{1-6} alkyl) $_2$ amino, carbocyclyl or heterocyclyl; wherein R^{15} may be optionally substituted on carbon by one or more R^{19} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{20} ;
- R^{16} is selected from C_{1-6} alkyl;
- R^{17} is selected from halo, C_{1-6} alkyl or C_{1-6} alkoxy; wherein R^{17} may be optionally substituted on carbon by one or more R^{19} ;
- R^{18} is selected from C_{1-6} alkanoyl;
- R^{19} is selected from halo, hydroxy, C_{1-6} alkoxy or heterocyclyl; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{24} ;
- R^{20} is selected from C_{1-6} alkyl;
- R^{24} is selected from C_{1-6} alkyl; and
- $n = 0$ or 1 .
- or a pharmaceutically acceptable salt thereof;
- with the proviso that said compound is not:
- 5-bromo- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;
- 5-chloro- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;
- 5-bromo- N^2 -[1-(3-methyl-5-isoxazolyl)ethyl]- N^4 -(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine;
- 5-chloro- N^2 -[1-(3-methyl-5-isoxazolyl)ethyl]- N^4 -(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine;
- 5-bromo- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
- 5-chloro- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
- 5-chloro- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine;
- 5-bromo- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine; or

5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)ethyl]-2,4-pyrimidinediamine.

Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:

A is a direct bond;

5 Ring C is carbocyclyl or heterocyclyl;

R¹ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkylS(O)_a wherein a is 0 or carbocyclyl;

R² is selected from C₁₋₆alkyl; wherein R² may be optionally substituted on carbon by one or more R¹⁰;

10 R³ is selected from halo, nitro or C₁₋₆alkoxy;

R⁴ is hydrogen;

R⁵ is hydrogen or optionally substituted C₁₋₆alkyl; wherein said optional substituents are selected from one or more R¹⁴;

15 R⁶ and R⁷ are independently selected from hydrogen, halo, C₁₋₆alkyl, *N*-(C₁₋₆alkyl)amino, *N*-(C₁₋₆alkyl)carbonyl or C₁₋₆alkoxycarbonyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵;

or R⁶ and R⁷ together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyclic ring or heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R¹⁷;

20 R¹⁰ is selected from hydroxy, carboxy, C₁₋₆alkoxy, *N,N*-(C₁₋₆alkyl)₂amino or heterocyclyl; wherein R¹⁰ may be optionally substituted on carbon by one or more hydroxy or C₁₋₆alkoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

25 R¹⁴ is selected from hydroxy;

R¹⁵ is selected from halo, hydroxy, carbocyclyl or heterocyclyl; wherein R¹⁵ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

30 R¹⁷ is selected from halo, C₁₋₆alkyl or C₁₋₆alkoxy; wherein R¹⁷ may be optionally substituted on carbon by one or more R¹⁹; wherein R¹⁹ is selected from halo, C₁₋₆alkoxy or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴;

R²⁰ is selected from C₁₋₆alkyl;

R^{24} is selected from C_{1-6} alkyl; and

$n = 0$ or 1 ;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not:

- 5 5-bromo- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-chloro- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-bromo- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-chloro- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-chloro- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine;
 10 5-bromo- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine; or
 5-bromo- N^4 -(5-methyl-1H-pyrazol-3-yl)- N^2 -[1-(2-pyridinyl)ethyl]-2,4-pyrimidinediamine.

Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:

A is a direct bond;

- 15 Ring C is phenyl, thienyl, pyridyl, thiazolyl;

R^1 is selected from hydrogen, methyl, ethyl, isopropyl, *t*-butyl, trifluoromethyl, cyclopropylmethyl, benzyl, methoxy, ethoxy, propoxy, isopropoxy, sec-butoxy, dimethylamino, methylthio or cyclopropyl;

- R^2 is selected from methyl, ethyl, trifluoromethyl, hydroxymethyl, carboxymethyl,
 20 aminomethyl, methoxymethyl, morpholinomethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-carboxyethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl, acetamidomethyl, 2-[*N*-methyl-*N*-(2-methoxyethyl)amino]ethyl, 2-[*N*-methyl-*N*-(2-hydroxyethyl)amino]ethyl, 2-(*N*-methylcarbamoyl)ethyl, 2-[*N*-(2-hydroxyethyl)carbamoyl]ethyl, 2-(*N,N*-dimethylcarbamoyl)ethyl, 2-morpholinoethyl, 2-pyrrolidin-1-ylethyl or 2-(1-methylpiperazin-
 25 4-yl)ethyl, 1-methyl-2-hydroxyethyl;

R^3 is selected from fluoro, nitro, trifluoromethyl or methoxy;

R^4 is hydrogen;

R^5 is hydrogen, methyl or 2-hydroxyethyl;

- R^6 and R^7 are independently selected from hydrogen, fluoro, chloro, bromo, nitro,
 30 cyano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, *N*-methyl-*N*-propylamino, *N*-ethylcarbamoyl, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morpholino, pyrrolidinyl or piperazinyl; wherein R^6 and R^7 independently of each other may be optionally substituted on carbon by one or more R^{15} ; and

wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R¹⁶;

or R⁶ and R⁷ together with the pyrimidine to which they are attached form a bicyclic ring selected from quinazolinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrazolo[3,4-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidinyl; and wherein said bicyclic ring may be optionally substituted on carbon by one or more R¹⁷; and wherein said 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidinyl may be optionally substituted on nitrogen by a group selected from R¹⁸;

R¹⁵ is selected from fluoro, hydroxy, amino, ethoxy, dimethylamino, phenyl, pyrrolidinyl, piperazinyl or morpholino; wherein R¹⁵ may be optionally substituted on carbon by one or more R¹⁹; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R²⁰;

R¹⁶ is selected from methyl;

R¹⁷ is selected from fluoro, chloro, methyl, methoxy, ethoxy or propoxy; wherein R¹⁷ may be optionally substituted on carbon by one or more R¹⁹;

R¹⁸ is selected from acetyl;

R¹⁹ is selected from fluoro, hydroxy, methoxy, piperazinyl, pyrrolidinyl or morpholino; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R²⁴;

R²⁰ is selected from methyl;

R²⁴ is selected from methyl;

n = 0 or 1;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not:

5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;
5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;
5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine;
5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine; or
5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)ethyl]-2,4-pyrimidinediamine.

Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted herein above) wherein:

A is a direct bond;

Ring C is phenyl or thien-2-yl;

5 R¹ is selected from hydrogen, methyl, ethyl, t-butyl, methoxy, dimethylamino, methylthio or cyclopropyl;

R² is selected from methyl, ethyl or isopropyl; wherein R² may be optionally substituted on carbon by one or more R¹⁰;

R³ is selected from fluoro, nitro or methoxy;

10 R⁴ is hydrogen;

R⁵ is hydrogen or 2-hydroxyethyl;

R⁶ and R⁷ are independently selected from hydrogen, fluoro, chloro, bromo, methyl, ethylamino, propylamino, *N*-(ethyl)carbamoyl, methoxycarbonyl, ethoxycarbonyl or butoxycarbonyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted
15 on carbon by one or more R¹⁵;

or R⁶ and R⁷ together with the pyrimidine to which they are attached form quinazolinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, 1*H*-pyrazolo[3,4-d]pyrimidinyl or pyrido[2,3-d]pyrimidinyl; and wherein said quinazolinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, 1*H*-
20 pyrazolo[3,4-d]pyrimidinyl or pyrido[2,3-d]pyrimidinyl may be optionally substituted on carbon by one or more R¹⁷;

R¹⁰ is selected from hydroxy, carboxy, methoxy, *N*-methyl-*N*-ethylamino, diethylamino, pyrrolidin-1-yl, piperazin-1-yl or morpholino; wherein R¹⁰ may be optionally substituted on carbon by one or more hydroxy or methoxy; and wherein said piperazinyl may
25 be optionally substituted on nitrogen by a group selected from R²⁰;

R¹⁵ is selected from fluoro, hydroxy, phenyl, piperazinyl, pyrrolidinyl or morpholino; wherein R¹⁵ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said piperazinyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

30 R¹⁷ is selected from fluoro, chloro, methyl, methoxy or ethoxy; wherein R¹⁷ may be optionally substituted on carbon by one or more R¹⁹;

R^{19} is selected from fluoro, methoxy, piperazinyl, pyrrolidinyl or morpholino; wherein if said piperazinyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{24} ;

R^{20} is selected from methyl;

5 R^{24} is selected from methyl;

$n = 0$ or 1 ;

or a pharmaceutically acceptable salt thereof.

Particular values of the variable groups contained in formula (Ia) are as follows. Such values may be used, where appropriate, with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein A is a valence bond.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein C is C_{5-9} aryl.

15 In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein R^1 is C_{3-6} cycloalkyl.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein R^2 is $-C(=O)OH$, $-C(=O)OCH_3$, $C(=O)NHCH_3$, $-C(=O)N(CH_3)_2$, $-C(=O)NHSO_2CH_3$, $C(=O)NHSO_2CF_3$, $C(=O)NHSO_2Ph$, or C_{1-4} alkyl optionally substituted with $-OH$, $-NHCH_3$, $-N(CH_3)_2$, heterocycle or C_{2-5} ether optionally substituted with heterocycle or C_{2-5} amine optionally substituted with heterocycle.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein R^3 is F, Cl, Br, I, CF_3 .

25 In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein R^4 is H or optionally substituted C_{1-4} alkyl.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein R^5 is H.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein R^6 is H, F, Cl, Br, I, CF_3 , C_{1-6} alkyl, OC_{1-6} alkyl, or $C(=O)OC_{1-6}$ alkyl.

30 In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein R^7 is H, F, Cl, Br, I, CF_3 , C_{1-6} alkyl, OC_{1-6} alkyl, or $C(=O)OC_{1-6}$ alkyl.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein R⁶ and R⁷ in combination form a fused phenyl which is optionally substituted with F, Cl, Br, I, C₁₋₄alkyl, OC₁₋₄alkyl OC₁₋₄alkylOCH₃.

5 In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein R⁶ and R⁷ in combination form a fused 5-membered heteroaromatic ring having at least one nitrogen or one sulfur atom, but no more than 2 nitrogen atoms or 2 sulfur atoms or 1 nitrogen and 1 sulfur atom.

10 In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein R⁶ and R⁷ in combination form a fused 6-membered heteroaromatic ring having at least one nitrogen or one sulfur atoms, but no more than 2 nitrogen atoms or 2 sulfur atoms or 1 nitrogen and 1 sulfur atom.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein:

A is a valence bond;
15 C is C₅₋₉aryl, C₅₋₉heteroaryl;
R¹ is C₃₋₆cycloalkyl, C₅₋₉aryl;
R² is -C(=O)OH, -C(=O)OCH₃, -C(=O)NHCH₃, -C(=O)N(CH₃)₂, -C(=O)NHSO₂CH₃, C(=O)NHSO₂CF₃, C(=O)NHSO₂Ph, or C₁₋₄alkyl optionally substituted with -OH, -NHCH₃, -N(CH₃)₂, heterocycle or C₂₋₅ether optionally substituted with heterocycle or C₂₋₅amine
20 optionally substituted with heterocycle;
R³ is F, Cl, Br, I, CF₃, NH₂, NO₂, OH, OCF₃, C₁₋₆ alkyl, OC₁₋₆ alkyl;
R⁴ is H, or optionally substituted C₁₋₄alkyl;
R⁵ is H, or optionally substituted C₁₋₄alkyl;
R⁶ and R⁷ are independently selected from: H, F, Cl, Br, I, CF₃, C₁₋₆ alkyl, OC₁₋₆alkyl,
25 or C(=O)OC₁₋₆alkyl.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein:

A is a valence bond;
C is C₅₋₉aryl, C₅₋₉heteroaryl;
30 R¹ is C₃₋₆cycloalkyl;
R² is -C(=O)OH, -C(=O)OCH₃, -C(=O)NHCH₃, -C(=O)N(CH₃)₂, -C(=O)NHSO₂CH₃, C(=O)NHSO₂CF₃, C(=O)NHSO₂Ph, or C₁₋₄alkyl optionally substituted with -OH, -NHCH₃, -N(CH₃)₂, morpholine, piperazine, pyrrolidine or C₂₋₅ether optionally substituted with

morpholine, piperazine, pyrroline or C₂₋₅amine optionally substituted with morpholine, piperazine, pyrroline;

R³ is F, Cl, Br, I, CF, OH, OCF₃;

R⁴ is H;

5 R⁵ is H, or C₁₋₄alkyl optionally substituted with -OH;

R⁶ and R⁷ are independently selected from: H, F, Cl, Br, I, CF₃, C₁₋₆ alkyl, or OC₁₋₆alkyl.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein:

10 A is a valence bond;

C is phenyl;

R¹ is cyclopropyl;

R² is C₁₋₄alkyl optionally substituted with -OH;

R³ is F, Cl, Br, or I;

15 R⁴ and R⁵ are H;

R⁶ and R⁷ are independently selected from: H, F, Cl, Br, I, CF₃, C₁₋₆ alkyl, or OC₁₋₆alkyl.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein:

20 A is a valence bond;

C is C₅₋₉aryl, C₅₋₉heteroaryl;

R¹ is C₃₋₆cycloalkyl, C₅₋₉aryl;

R² is -C(=O)OH, -C(=O)OCH₃, -C(=O)NHCH₃, -C(=O)N(CH₃)₂, -C(=O)NHSO₂CH₃, C(=O)NHSO₂CF₃, C(=O)NHSO₂Ph, or C₁₋₄alkyl optionally substituted with -OH, -NHCH₃,

25 -N(CH₃)₂, heterocycle or C₂₋₅ether optionally substituted with heterocycle or C₂₋₅amine optionally substituted with heterocycle;

R³ is F, Cl, Br, I, CF₃, NH₂, NO₂, OH, OCF₃, C₁₋₆ alkyl, OC₁₋₆ alkyl;

R⁴ is H, or optionally substituted C₁₋₄alkyl;

R⁵ is H, or optionally substituted C₁₋₄alkyl;

30 R⁶ and R⁷ in combination form a fused phenyl, which is optionally substituted with CH₃, OCH₃, F, Cl, Br, I or OC₁₋₃OCH₃ or R⁶ and R⁷ in combination form a fused 5 or 6-membered heteroaromatic ring having 1 or 2 nitrogen atoms or 1 sulfur atom.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein:

- A is a valence bond;
- C is C₅₋₉aryl, C₅₋₉heteroaryl;
- 5 R¹ is C₃₋₆cycloalkyl;
- R² is -C(=O)OH, -C(=O)OCH₃, -C(=O)NHCH₃, -C(=O)N(CH₃)₂, -C(=O)NHSO₂CH₃, C(=O)NHSO₂CF₃, C(=O)NHSO₂Ph, or C₁₋₄alkyl optionally substituted with -OH, -NHCH₃, -N(CH₃)₂, morpholine, piperazine, pyrroline or C₂₋₅ether optionally substituted with morpholine, piperazine, pyrroline or C₂₋₅amine optionally substituted with morpholine,
- 10 piperazine, pyrroline;
- R³ is F, Cl, Br, I, CF, OH, OCF₃;
- R⁴ is H;
- R⁵ is H, or C₁₋₄alkyl optionally substituted with -OH;
- R⁶ and R⁷ in combination form a fused phenyl, which is optionally substituted with
- 15 CH₃, OCH₃, F, Cl, Br, I or OC₁₋₃OCH₃ or R⁶ and R⁷ in combination form a fused 5-membered heteroaromatic ring having 2 nitrogen atoms or 1 sulfur atom.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein:

- A is a valence bond;
- 20 C is phenyl;
- R¹ is cyclopropyl;
- R² is C₁₋₄alkyl optionally substituted with -OH;
- R³ is F, Cl, Br, or I;
- R⁴ and R⁵ are H;
- 25 R⁶ and R⁷ in combination form a fused phenyl, which is optionally substituted with CH₃ or OCH₃.

In an additional embodiment the present invention provides a compound having a formula (Ia) as recited above wherein:

- A is a valence bond;
- 30 C is phenyl;
- R¹ is cyclopropyl;
- R² is C₁₋₄alkyl optionally substituted with -OH;
- R³ is F, Cl, Br, or I;

R⁴ and R⁵ are H;

R⁶ and R⁷ in combination form a fused 5-membered heteroaromatic ring having 2 nitrogen atoms or 1 sulfur atom.

Additional embodiments of the invention are as follows. These embodiments relate to
5 compounds of formula (I) and (Ia) and it is to be understood were compounds of formula (I) are referred to this statement also applies in the alternative to compounds of formula (Ia).

In another aspect of the invention, preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt thereof.

In an additional embodiment the present invention provides a compound of formula
10 (I), or a pharmaceutically acceptable salt thereof, for use as a medicament.

In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the inhibition of Trk activity.

In an additional embodiment the present invention provides a compound of formula
15 (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.

In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment of cancer in a warm-blooded animal such as man.

20 In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial
25 restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man.

In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for use in the production of an anti-proliferative effect.

30 In an additional embodiment the present invention provides a method of inhibiting Trk activity comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

In an additional embodiment the present invention provides a method for the treatment of cancer comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

In an additional embodiment the present invention provides a method for the treatment or prophylaxis of cancer comprising administering a therapeutically effective amount of a
5 compound of formula (I) or a pharmaceutically acceptable salt thereof.

In an additional embodiment the present invention provides a method for the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic
10 nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

In an additional embodiment the present invention provides a method of producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such treatment
15 which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt
20 thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient.

In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the inhibition of Trk activity.

25 In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment of cancer.

In an additional embodiment the present invention provides a pharmaceutical
30 composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancer.

In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

In an additional embodiment the present invention provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.

In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the inhibition of Trk activity.

In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancer.

In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a warm-blooded animal such as man.


In an additional embodiment the present invention provides a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of cancers (solid tumors and leukemia), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation in a warm-blooded animal such as man.

In an additional embodiment the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the production of an anti-proliferative effect.

Where the inhibition of Trk activity is referred to particularly this refers to the inhibition of TrkB activity.

Where the treatment (or prophylaxis) of cancer is referred to, particularly it refers to the treatment (or prophylaxis) of oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposi sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small
 5 cell lung cancer (NSCLC), and small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, leukaemia, tumours of the central and peripheral nervous system, melanoma, fibrosarcoma and osteosarcoma. More particularly it refers to prostate cancer. In addition, more particularly it refers to SCLC, NSCLC, colorectal cancer, ovarian cancer and / or breast cancer. In a further aspect it refers to hormone refractory prostate
 10 cancer.


In an additional embodiment the present invention provides a process for preparing a compound of structural formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof which process comprises:



15 In a further aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof which process (wherein variable groups are, unless otherwise specified, as defined in formula (I)) comprises of:


Process a) reaction of a pyrimidine of formula (II):

- 37 -



(II)

wherein L is a displaceable group; with an pyrazole amine of formula (III):




(III)

5


or

Process b) reacting a pyrimidine of formula (IV):



(IV)


10 wherein L is a displaceable group; with a compound of formula (V):



(V)


Process c) reacting a compound of formula (VI):

- 38 -



(VI)

with a compound of formula (VII):




(VII)

5

wherein X is an oxygen atom and q is 1; or X is a nitrogen atom and q is 2; and wherein each R²⁰ independently represents a C₁₋₆alkyl group; or

Process d) reacting a compound of formula (VIII):



(VIII)

10

with hydrazine; or

and thereafter if necessary:

i) converting a compound of the formula (I) into another compound of the formula (I);

ii) removing any protecting groups;

15 iii) forming a pharmaceutically acceptable salt.

L is a displaceable group, suitable values for L are for example, a halo or


sulphonyloxy group, for example a chloro, bromo, methanesulphonyloxy or toluene-4-sulphonyloxy group.

Specific reaction conditions for the above reactions are as follows.

Process a) Pyrimidines of formula (II) and pyrazole amine of formula (III) may be reacted together:

- a) in the presence of a suitable solvent for example a ketone such as acetone or an alcohol such as ethanol or butanol or an aromatic hydrocarbon such as toluene or *N*-methyl pyrrolid-2-one, optionally in the presence of a suitable acid for example an inorganic acid such as hydrochloric acid or sulphuric acid, or an organic acid such as acetic acid or formic acid (or a suitable Lewis acid) and at a temperature in the range from 0°C to reflux, particularly reflux; or
- b) under standard Buchwald conditions (for example see *J. Am. Chem. Soc.*, **118**, 7215; *J. Am. Chem. Soc.*, **119**, 8451; *J. Org. Chem.*, **62**, 1568 and 6066) for example in the presence of palladium acetate, in a suitable solvent for example an aromatic solvent such as toluene, benzene or xylene, with a suitable base for example an inorganic base such as caesium carbonate or an organic base such as potassium-*t*-butoxide, in the presence of a suitable ligand such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl and at a temperature in the range from 25 to 80°C.

Pyrimidines of the formula (II) may be prepared according to *Scheme 1*:




Scheme 1

Pyrazole amines of formula (III) and compound of formula (IIa) and (IIb) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

- Process b)* Compounds of formula (IV) and formula (V) may be reacted together under the same conditions as outlined in *Process a)*.

Compounds of the formula (IV) may be prepared according to *Scheme 2*:




Scheme 2

Compounds of the formula (V) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

- 5 *Process c)* may conveniently be carried out in a suitable solvent such as *N*-methylpyrrolidinone or butanol at a temperature in the range from 100-200°C, in particular in the range from 150-170°C. The reaction is preferably conducted in the presence of a suitable base such as, for example, sodium methoxide or potassium carbonate.


Compounds of the formula (VI) may be prepared according to *Scheme 3*:



(VIb)

Scheme 3

Compounds of the formula (VII) may be prepared according to *Scheme 4*:



(VIIa)

(VIIb)


Scheme 4

- 15 wherein Pg is a suitable nitrogen protecting group. Suitable values for Pg are defined below.

Compounds of the formula (VIa), (VIb), (VIIa) and (VIIb) are commercially available compounds, or they are known in the literature, or they are prepared by standard processes known in the art.

Process d) may be carried out in a suitable solvent, for example, an alcohol such as ethanol or butanol at a temperature in the range from 50-120°C, in particular in the range from 70-100°C.

Compounds of the formula (VIII) may be prepared according to Scheme 5:



Scheme 5

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

10
15
20

It will also be appreciated that in some of the reactions mentioned herein it may be necessary/desirable to protect any sensitive groups in the compounds. The instances where

protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, *Protective Groups in Organic Synthesis*, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may
5 be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection
10 conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *t*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid
15 as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by
20 treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl
25 group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group,
30 for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic

acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

5 **Definitions**

In this section the definition applies to both compounds of formula (I) and compounds of formula (Ia) unless otherwise stated.

In this specification the term "alkyl" includes both straight and branched chain alkyl groups but references to individual alkyl groups such as "propyl" are specific for the straight chain version only. For example, "C₁₋₆alkyl" and "C₁₋₄alkyl" include methyl, ethyl, propyl, isopropyl and *t*-butyl. However, references to individual alkyl groups such as 'propyl' are specific for the straight-chained version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched-chain version only. A similar convention applies to other radicals. The term "halo" refers to fluoro, chloro, bromo and iodo.

Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH₂- group can optionally be replaced by a -C(O)-, and a ring sulphur atom may be optionally oxidised to form the S-oxides. Examples and suitable values of the term "heterocyclyl" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, *N*-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-*N*-oxide and quinoline-*N*-oxide. Further examples and suitable values of the term "heterocyclyl" are morpholino, piperazinyl and pyrrolidinyl. In one aspect of the invention a "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH₂- group can optionally be replaced by a -C(O)- and a ring sulphur atom may be optionally oxidised to form the S-oxides.

A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH₂- group can optionally be replaced by a -C(O)-. Particularly "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl.

Where "R⁶ and R⁷ together with the bond to which they are attached form a 5 or 6 membered heterocyclic ring" said ring is a partially saturated or unsaturated, mono or bicyclic carbon ring that contains 5 or 6 atoms two atoms of which are shared with the pyrimidine ring of formula (I); of which at least one atom is chosen from nitrogen, sulphur or oxygen; wherein a -CH₂- group can optionally be replaced by a -C(O)-, and a ring sulphur atom may be optionally oxidized to form the S-oxides. Said ring is fused to the pyrimidine ring of formula (I) to make a 9 or 10 membered bicyclic ring. Suitable values for "R⁶ and R⁷ together with the bond to which they are attached form a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I)" are pteridinyl, purinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, 1H-pyrazolo[3,4-d]pyrimidinyl or pyrido[2,3-d]pyrimidinyl. Further suitable values for "R⁶ and R⁷ together with the bond to which they are attached form a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I)" are thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, 1H-pyrazolo[3,4-d]pyrimidinyl or pyrido[2,3-d]pyrimidinyl. Additional suitable values for "R⁶ and R⁷ together with the bond to which they are attached form a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I)" are thieno[3,2-d]pyrimidinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrazolo[3,4-d]pyrimidinyl, thieno[3,4-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidinyl and 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidinyl.

Where "R⁶ and R⁷ together with the bond to which they are attached form a 5 or 6 membered carbocyclic ring" said ring is a partially saturated or unsaturated, mono or bicyclic carbon ring that contains 5 or 6 atoms two atoms of which are shared with the pyrimidine ring of formula (I); wherein a -CH₂- group can optionally be replaced by a -C(O)-. Said ring is fused to the pyrimidine ring of formula (I) to make a 9 or 10 membered bicyclic ring. Suitable values for "R⁶ and R⁷ together with the bond to which they are attached form a 5 or 6

membered carbocyclic ring wherein said ring is fused to the pyrimidine of formula (I)" are quinazolinyl.

The term " C_{m-n} " or " C_{m-n} group" used alone or as a prefix, refers to any group having m to n carbon atoms.

5 For compounds of formula (Ia) the term "hydrocarbon" used alone or as a suffix or prefix, refers to any structure comprising only carbon and hydrogen atoms up to 14 carbon atoms.

For compounds of formula (Ia) the term "hydrocarbon radical" or "hydrocarbyl" used alone or as a suffix or prefix, refers to any structure as a result of removing one or more
10 hydrogens from a hydrocarbon.

For compounds of formula (Ia) the term "alkyl" used alone or as a suffix or prefix, refers to monovalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms. Unless otherwise specified, "alkyl" general includes both saturated alkyl and unsaturated alkyl.

15 For compounds of formula (Ia) the term "cycloalkyl," used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms.

For compounds of formula (Ia) the term "aryl" used alone or as suffix or prefix, refers to a hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic
20 character, (e.g., $4n + 2$ delocalized electrons) and comprising 5 up to about 14 carbon atoms, wherein the radical is located on a carbon of the aromatic ring.

For compounds of formula (Ia) the term "non-aromatic group" or "non-aromatic" used alone, as suffix or as prefix, refers to a chemical group or radical that does not contain a ring having aromatic character (e.g., $4n + 2$ delocalized electrons).

25 For compounds of formula (Ia) the term "heterocycle" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s). Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than
30 one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms there between. Heterocycle may have aromatic character or may not have aromatic character.

For compounds of formula (Ia) the term "heteroaromatic" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s), wherein the ring-containing
5 structure or molecule has an aromatic character (*e.g.*, $4n + 2$ delocalized electrons).

For compounds of formula (Ia) the term "heterocyclo" used alone or as a suffix or prefix, refers to a radical derived from a heterocycle by removing one or more hydrogens therefrom.

For compounds of formula (Ia) the term "heterocyclyl" used alone or as a suffix or
10 prefix, refers a radical derived from a heterocycle by removing one hydrogen from a carbon of a ring of the heterocycle.

For compounds of formula (Ia) the term "heteroaryl" used alone or as a suffix or prefix, refers to a heterocyclyl having aromatic character, wherein the radical of the heterocyclyl is located on a carbon of an aromatic ring of the heterocyclyl.

15 For compounds of formula (Ia) the term "six-membered" used as prefix refers to a group having a ring that contains six ring atoms.

For compounds of formula (Ia) the term "five-membered" used as prefix refers to a group having a ring that contains five ring atoms.

For compounds of formula (Ia) the term "substituted" used as a prefix refers to a
20 structure, molecule or group, wherein one or more hydrogens are replaced with one or more C_{1-12} hydrocarbon groups, or one or more chemical groups containing one or more heteroatoms selected from N, O, S, F, Cl, Br, I, and P. Exemplary chemical groups containing one or more heteroatoms include heterocyclyl, heterocycle, $-NO_2$, $-OR$, $-Cl$, $-Br$, $-I$, $-F$, $-CF_3$, $-C(=O)R$, $-C(=O)OH$, $-NH_2$, $-SH$, $-NHR$, $-NR_2$, $-SR$, $-SO_3H$, $-SO_2R$, $-SO_2CF_3$, $-SO_2Ph$, $-$
25 $S(=O)R$, $-CN$, $-OH$, $-C(=O)OR$, $-C(=O)NR_2$, $-NRC(=O)R$, oxo ($=O$), imino ($=NR$), thio ($=S$), and oximino ($=N-OR$), wherein each "R" is a C_{1-12} hydrocarbyl. For example, substituted phenyl may refer to nitrophenyl, pyridylphenyl, methoxyphenyl, chlorophenyl, aminophenyl, etc., wherein the nitro, pyridyl, methoxy, chloro, and amino groups may replace any suitable hydrogen on the phenyl ring.

30 For compounds of formula (Ia) the term "substituted" used as a suffix of a first structure, molecule or group, followed by one or more names of chemical groups refers to a second structure, molecule or group, which is a result of replacing one or more hydrogens of

the first structure, molecule or group with the one or more named chemical groups. For example, a "phenyl substituted by nitro" refers to nitrophenyl.

The term "optionally substituted" refers to either groups, structures, or molecules that are substituted and those that are not substituted.

5 For compounds of formula (Ia) heterocycle includes, for example, monocyclic heterocycles such as: aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, pyrazoline, dioxolane, sulfolane 2,3-dihydrofuran, 2,5-dihydrofuran tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydro-pyridine, piperazine, morpholine, thiomorpholine, pyran, thiopyran, 2,3-dihydropyran, tetrahydropyran, 1,4-
10 dihydropyridine, 1,4-dioxane, 1,3-dioxane, dioxane, homopiperidine, 2,3,4,7-tetrahydro-1*H*-azepine homopiperazine, 1,3-dioxepane, 4,7-dihydro-1,3-dioxepin, and hexamethylene oxide.

For compounds of formula (Ia) in addition, heterocycle includes aromatic heterocycles, for example, pyridine, pyrazine, pyrimidine, pyridazine, thiophene, furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, 1,2,3-triazole,
15 tetrazole, 1,2,3-thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4-triazole, 1,3,4-thiadiazole, and 1,3,4- oxadiazole.

For compounds of formula (Ia) additionally, heterocycle encompass polycyclic heterocycles, for example, indole, indoline, isoindoline, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, 1,4-benzodioxan, coumarin, dihydrocoumarin,
20 benzofuran, 2,3-dihydrobenzofuran, isobenzofuran, chromene, chroman, isochroman, xanthene, phenoxathiin, thianthrene, indolizine, isoindole, indazole, purine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, phenanthridine, perimidine, phenanthroline, phenazine, phenothiazine, phenoxazine, 1,2-benzisoxazole, benzothiophene, benzoxazole, benzthiazole, benzimidazole, benztriazole, thioxanthine, carbazole, carboline,
25 acridine, pyrolizidine, and quinolizidine.

For compounds of formula (Ia) in addition to the polycyclic heterocycles described above, heterocycle includes polycyclic heterocycles wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidine,
30 diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2.2.1]heptane.

For compounds of formula (Ia) heterocyclyl includes, for example, monocyclic heterocyclyls, such as: aziridinyl, oxiranyl, thiiranyl, azetidiny, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl,

2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1,2,3,6-tetrahydro-pyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3-dihydropyranyl, tetrahydropyranyl, 1,4-dihydropyridinyl, 1,4-dioxanyl, 1,3-dioxanyl, dioxanyl, homopiperidinyl, 2,3,4,7-tetrahydro-1*H*-azepinyl, homopiperazinyl, 1,3-dioxepanyl, 4,7-dihydro-1,3-dioxepinyl, and hexamethylene oxidyl.

For compounds of formula (Ia) in addition, heterocyclyl includes aromatic heterocyclyls or heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4 oxadiazolyl.

For compounds of formula (Ia) additionally, heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indolinyl, isoindolinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1,4-benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl, isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indolizynyl, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, phenanthridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxazinyl, 1,2-benzisoxazolyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrolizidinyl, and quinolizidinyl.

For compounds of formula (Ia) in addition to the polycyclic heterocyclyls described above, heterocyclyl includes polycyclic heterocyclyls wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and 7-oxabicyclo[2.2.1]heptyl.

For compounds of formula (Ia) the term "amine" or "amino" used alone or as a suffix or prefix, refers to radicals of the general formula -NRR', wherein R and R' are independently selected from hydrogen or a hydrocarbon radical.

An example of "C₁₋₆alkanoyloxy" is acetoxy. Examples of "C₁₋₆alkoxycarbonyl" include C₁₋₄alkoxycarbonyl, methoxycarbonyl, ethoxycarbonyl, *n*- and *t*-butoxycarbonyl. Examples of "C₁₋₆alkoxy" include C₁₋₄alkoxy, C₁₋₃alkoxy, methoxy, ethoxy and propoxy. Examples of "C₁₋₆alkoxyimino" include C₁₋₄alkoxyimino, C₁₋₃alkoxyimino, methoxyimino, ethoxyimino and propoxyimino. Examples of "C₁₋₆alkanoylamino" include formamido,

acetamido and propionylamino. Examples of "C₁₋₆alkylS(O)_a wherein a is 0 to 2" include C₁₋₄alkylsulphonyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of "C₁₋₆alkylthio" include methylthio and ethylthio. Examples of "C₁₋₆alkylsulphonylamino" include methylsulphonylamino and ethylsulphsulphonylamino.

- 5 Examples of "C₁₋₆alkanoyl" include C₁₋₄alkanoyl, propionyl and acetyl. Examples of "N-(C₁₋₆alkyl)amino" include methylamino and ethylamino. Examples of "N,N-(C₁₋₆alkyl)₂amino" include di-N-methylamino, di-(N-ethyl)amino and N-ethyl-N-methylamino. Examples of "C₂₋₆alkenyl" are vinyl, allyl and 1-propenyl. Examples of "C₂₋₆alkynyl" are ethynyl, 1-propynyl and 2-propynyl. Examples of
- 10 "N-(C₁₋₆alkyl)sulphamoyl" are N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl. Examples of "N-(C₁₋₆alkyl)₂sulphamoyl" are N,N-(dimethyl)sulphamoyl and N-(methyl)-N-(ethyl)sulphamoyl. Examples of "N-(C₁₋₆alkyl)carbamoyl" are N-(C₁₋₄alkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl. Examples of "N,N-(C₁₋₆alkyl)₂carbamoyl" are N,N-(C₁₋₄alkyl)₂carbamoyl, dimethylaminocarbonyl and
- 15 methylethylaminocarbonyl.

"RT" or "rt" means room temperature.

A first ring group being "fused" with a second ring group means the first ring and the second ring share at least two atoms there between.

- A suitable pharmaceutically acceptable salt of a compound of the invention is, for
- 20 example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline
- 25 earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

- It should be noted that the pyrazoles claimed in this invention are capable to exist in
- 30 different resonance structures and thus the pyrazoles claimed herein include all possible resonance structures, for example optical isomers, diastereoisomers and geometric isomers and all tautomeric forms of the compounds of the formula (I).

It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms.

Formulations

5 Compounds of the present invention may be administered orally, parenteral, buccal, vaginal, rectal, inhalation, insufflation, sublingually, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracically, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.

10 The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level as the most appropriate for a particular patient.

15 An effective amount of a compound of the present invention for use in therapy of cancer is an amount sufficient to symptomatically relieve in a warm-blooded animal, particularly a human the symptoms of cancer, to slow the progression of cancer, or to reduce in patients with symptoms of cancer the risk of getting worse.

20 For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.

A solid carrier can be one or more substance, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.

25 In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

30 For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.

Suitable carriers include magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.

Some of the compounds of the present invention are capable of forming salts with various
5 inorganic and organic acids and bases and such salts are also within the scope of this invention. Examples of such acid addition salts include acetate, adipate, ascorbate, benzoate, benzenesulfonate, bicarbonate, bisulfate, butyrate, camphorate, camphorsulfonate, choline, citrate, cyclohexyl sulfamate, diethylenediamine, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2-hydroxyethylsulfonate, heptanoate, hexanoate, hydrochloride,
10 hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate, methanesulfonate, meglumine, 2-naphthalenesulfonate, nitrate, oxalate, pamoate, persulfate, phenylacetate, phosphate, diphosphate, picrate, pivalate, propionate, quinate, salicylate, stearate, succinate, sulfamate, sulfanilate, sulfate, tartrate, tosylate (p-toluenesulfonate), trifluoroacetate, and undecanoate. Base salts include ammonium salts, alkali metal salts such as sodium, lithium
15 and potassium salts, alkaline earth metal salts such as aluminum, calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, ornithine, and so forth. Also, basic nitrogen-containing groups may be quaternized with such agents as: lower alkyl halides, such as methyl, ethyl, propyl, and butyl halides; dialkyl sulfates like dimethyl, diethyl, dibutyl;
20 diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl halides; aralkyl halides like benzyl bromide and others. Non-toxic physiologically-acceptable salts are preferred, although other salts are also useful, such as in isolating or purifying the product.

The salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or
25 medium in which the salt is insoluble, or in a solvent such as water, which is removed *in vacuo* or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion-exchange resin.

In order to use a compound of the formula (I) or a pharmaceutically acceptable salt thereof for the therapeutic treatment (including prophylactic treatment) of mammals including
30 humans, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

In addition to the compounds of the present invention, the pharmaceutical composition of this invention may also contain, or be co-administered (simultaneously or sequentially)

with, one or more pharmacological agents of value in treating one or more disease conditions referred to herein.

The term composition is intended to include the formulation of the active component or a pharmaceutically acceptable salt with a pharmaceutically acceptable carrier. For example
5 this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions, suspensions, emulsions, creams, ointments, gels, nasal sprays, suppositories, finely divided powders or aerosols or nebulisers for inhalation, and for parenteral use (including intravenous, intramuscular or infusion) sterile aqueous or oily solutions or suspensions or sterile emulsions.

10 Liquid form compositions include solutions, suspensions, and emulsions. Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution. Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding
15 suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.

20 The pharmaceutical compositions can be in unit dosage form. In such form, the composition is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparations, for example, packeted tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can
25 be the appropriate number of any of these packaged forms.

Combinations

The anti-cancer treatment defined herein may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of
30 anti-tumour agents:

- (i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for

example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca

5 alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);

(ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifene), oestrogen receptor down regulators (for example

10 fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuporelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 α -reductase such as finasteride;

15 (iii) agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);

(iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erb2 antibody

20 trastuzumab [HerceptinTM] and the anti-erb1 antibody cetuximab [C225]), farnesyl transferase inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as

N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine

25 (erlotinib, OSI-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;

(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial

30 growth factor, (for example the anti-vascular endothelial cell growth factor antibody bevacizumab [AvastinTM], compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and

compounds that work by other mechanisms (for example linomide, inhibitors of integrin $\alpha v \beta 3$ function and angiostatin);

(vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO

5 01/92224, WO 02/04434 and WO 02/08213;

(vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;

(viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug
10 therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and

(ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such
15 as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.

Such conjoint treatment may be achieved by way of the simultaneous, sequential or
20 separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention, or pharmaceutically acceptable salts thereof, within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.

Synthesis

25 The compounds, or pharmaceutically acceptable salts thereof, of the present invention can be prepared in a number of ways well known to one skilled in the art of organic synthesis. The compounds, or pharmaceutically acceptable salts thereof, of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the
30 art. Such methods include, but are not limited to, those described below. All references cited herein are hereby incorporated in their entirety by reference.

The novel compounds, or pharmaceutically acceptable salts thereof, of this invention may be prepared using the reactions and techniques described herein. The reactions are

performed in solvents appropriate to the reagents and materials employed and are suitable for the transformations being effected. Also, in the description of the synthetic methods described below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the substituents, which are compatible with the reaction conditions, will be readily apparent to one skilled in the art and alternate methods must then be used.

The invention will now be further described with reference to the following illustrative examples in which, unless stated otherwise:

- (i) temperatures are given in degrees Celsius (°C); operations are carried out at room temperature or ambient temperature, that is, in a range of 18-25 °C;
- (ii) organic solutions were dried over anhydrous sodium sulfate; evaporation of organic solvent was carried out using a rotary evaporator under reduced pressure (4.5 – 30 mmHg) with a bath temperature of up to 60 °C;
- (iii) chromatography means flash chromatography on silica gel; thin layer chromatography (TLC) was carried out on silica gel plates;
- (iv) in general, the course of reactions was followed by TLC or liquid chromatography/mass spectroscopy (LC/MS) and reaction times are given for illustration only;
- (v) final products have satisfactory proton nuclear magnetic resonance (NMR) spectra and/or mass spectra data;
- (vi) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;
- (vii) when given, NMR data is in the form of delta values for major diagnostic protons, given in part per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz in d6-DMSO unless otherwise stated;
- (viii) chemical symbols have their usual meanings;
- (ix) solvent ratio was given in volume:volume (v/v) terms.

(x) Purification of the compounds were carried out using one or more of the following methods:

a) flash chromatography on regular silica gel;

b) flash chromatography on silica gel using Isco Combiflash® separation system:

5 RediSep normal phase flash column, flow rate, 30-40 ml/min;

c) Gilson semiprep HPLC separation system: YMC pack ODS-AQ column, 100x20 mm, S 5µm 12 nm, water (0.1% trifluoroacetic acid) and acetonitrile (0.1% trifluoroacetic acid) as solvents, 20 min run; and

(xvi) the following abbreviations have been used:

10	DMF	dimethylformamide;
	EtOAc	ethyl acetate;
	ether	diethyl ether;
	EtOH	ethanol;
	THF	tetrahydrofuran;
15	MeOH	methanol; and
	DCM	dichloromethane.

Example 1

5-Chloro-N⁴-(5-cyclopropyl-1H-pyrazol-3-yl)-N²-(1-phenylethyl)pyrimidine-2,4-diamine

20 A mixture of 1-phenylethylamine (73 µL, 0.56 mmol), 2,5-dichloro-4-(5-cyclopropyl-1H-pyrazole-3-ylamino)pyrimidine (Method 1, 76 mg, 0.28 mmol) in 1-butanol (1.0 ml) was heated at 110°C for 18 hrs. The solvent was removed and EtOAc was added. The solution was washed with water and was concentrated. Semi-prep HPLC (Gilson system) provided product as a solid (91 mg, 92 %). ¹H NMR (CDCl₃): 0.72 (m, 2 H), 0.96 (m, 2 H), 1.56 (d, 3 H), 1.85
25 (m, 1 H), 5.08 (m, 1 H), 5.41 (br s, 1 H), 6.08 (br s, 1 H), 7.22-7.41 (m, 5 H), 7.92 (s, 1 H).

Example 2-127

Following a similar procedure to Example 1, the following compounds were synthesized via reaction of a suitable pyrimidine (method of production of which is also
30 listed) and a suitable amine.

Ex.	Compound	¹ H NMR	SM
2	5-Bromo-N ⁴ -(3-ethyl-1H-pyrazol-5-yl)-N ² -(1-phenylethyl) pyrimidine-2,4-diamine	1.19 (t, J = 9 Hz, 3 H), 1.45 (d, J = 9 Hz, 3 H), 2.59 (q, J = 9 Hz, 2 H), 4.99 (t, J = 9 Hz, 1 H), 6.04 (s, 1 H), 7.30 (m, 5 H), 8.18 (1 br s, 1H), 8.48 (s, 1 H), 9.36 (s, 1 H)	Method 2
3	N ⁴ -(3-tert-Butyl-1H-pyrazol-5-yl)-5-chloro-N ² -(1-phenylethyl)pyrimidine-2,4-diamine	1.27 (s, 9 H), 1.48 (d, J = 6 Hz, 3 H), 5.04 (t, J = 6 Hz, 1 H), 6.25 (s, 1 H), 7.29 (m, 5 H), 8.18 (s, 1 H), 8.77 (s, 1 H), 10.02 (s, 1 H)	Method 3
4	N ⁴ -(3-Cyclopropyl-1H-pyrazol-5-yl)-N ² -(1-phenylethyl)-5-(trifluoromethyl) pyrimidine-2,4-diamine	0.66 (m, 2 H), 0.94 (m, 2 H), 1.44 (d, J = 9 Hz, 3 H), 1.90 (m, 1 H), 4.96 (m, 1 H), 5.95 (s, 1 H), 7.28 (m, 5 H), 8.28 (s, 1 H), 8.53 (s, 1 H), 8.87 (s, 1 H)	Method 4
5	5-Bromo-N ⁴ -(3-cyclopropyl-1H-pyrazol-5-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl] pyrimidine-2,4-diamine	0.66 (s, 2 H), 0.92 (m, 2 H), 1.44 (d, 3 H), 1.88 (m, 1 H), 4.95 (m, 1 H), 5.95 (s, 1 H), 7.12 (m, 2 H), 7.31 (m, 2 H), 8.14 (s, 1 H), 8.27 (s, 1 H), 8.92 (br s, 1 H), 9.23 (br s, 1 H)	Method 5
6	5-Bromo-N ⁴ -(3-cyclopropyl-1H-pyrazol-5-yl)-N ² -[(1S)-1-phenylpropyl]pyrimidine-2,4-diamine	0.69 (s, 2 H), 0.85-1.00 (m, 5 H), 1.78-1.91 (m, 3 H), 4.72 (m, 1 H), 6.03 (s, 1 H), 7.24-7.31 (m, 5 H), 8.02 (br s, 1 H), 8.14 (s, 1 H), 8.24 (br s, 1 H), 9.29 (br s, 1 H)	Method 5
7	5-Bromo-N ⁴ -(3-cyclopropyl-1H-pyrazol-5-yl)-N ² -[(1S)-1-(4-nitrophenyl)ethyl] pyrimidine-2,4-diamine	0.65 (m, 2 H), 0.94 (m, 2 H), 1.49 (d, J = 9 Hz, 3 H), 1.89 (m, 1 H), 5.01 (m, 1 H), 5.82 (s, 1 H), 6.27 (s, 1 H), 7.63 (m, 2 H), 8.16 (m, 3 H), 8.41 (br s, 1 H), 9.14 (br s, 1 H)	Method 5
8	(2R)-2-({5-Bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-phenylethanol	0.69 (m, 2 H), 0.95 (m, 2 H), 1.90 (m, 1 H), 3.68 (d, 2 H), 4.93 (t, 1 H), 5.95 (s, 1 H), 7.30 (m, 5 H), 8.22 (s, 1 H), 8.40 (br s, 1 H), 9.45 (br s, 1 H)	Method 5

Ex.	Compound	¹ H NMR	SM
9	5-Bromo-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -(1-phenylethyl)pyrimidine-2,4-diamine	(CDCl ₃): 0.71 (m, 2 H), 0.95 (m, 2 H), 1.56 (d, 3 H), 1.85 (m, 1 H), 5.08 (m, 1 H), 5.63 (br s, 1 H), 6.05 (br s, 1 H), 7.22-7.41 (m, 5 H), 7.99 (s, 1 H).	Method 5
10	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -(1-phenylpropyl)pyrimidine-2,4-diamine	(CDCl ₃): 0.89 (m, 2 H), 1.00 (t, 3 H), 1.17 (m, 2 H), 2.00 (m, 3 H), 4.85 (dt, 1 H), 6.34 (s, 1 H), 7.28-7.39 (m, 5 H), 7.86 (s, 1 H), 8.88 (s, 1 H), 10.10 (d, 1 H).	Method 1
11	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-phenylethyl]pyrimidine-2,4-diamine	(CDCl ₃): 0.72 (m, 2 H), 0.98 (m, 2 H), 1.58 (d, 3 H), 1.86 (m, 1 H), 5.07 (m, 1 H), 6.08 (br s, 1 H), 7.23-7.41 (m, 5 H), 7.53 (br s, 1 H), 7.88 (s, 1 H)	Method 1
12	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1R)-1-phenylethyl]pyrimidine-2,4-diamine	(CDCl ₃): 0.72 (m, 2 H), 0.99 (m, 2 H), 1.51 (d, 3 H), 1.93 (m, 1 H), 5.04 (m, 1 H), 6.04 (br s, 1 H), 7.26-7.50 (m, 5 H), 8.19 (s, 1 H), 7.53 (br s, 1 H), 8.65 (br s, 1 H), 9.95 (br s, 1 H)	Method 1
13	5-Bromo-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -(1-phenylpropyl)pyrimidine-2,4-diamine	(CDCl ₃): 0.75 (m, 2 H), 0.90 (t, 3 H), 0.99 (m, 2 H), 1.84 (m, 2 H), 1.96 (m, 1 H), 4.77 (m, 1 H), 6.08 (s, 1 H), 7.29-7.39 (m, 5 H), 8.25 (s, 1 H), 8.60 (br s, 1 H), 9.48 (br s, 1 H)	Method 5
14	5-Bromo-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-phenylethyl]pyrimidine-2,4-diamine	0.66 (m, 1 H), 0.75 (m, 1 H), 0.87 (m, 1 H), 0.99 (m, 1 H), 1.46 (d, 3 H), 1.92 (m, 1 H), 5.04 (m, 1 H), 5.88 (br s, 1 H), 7.20-7.44 (m, 5 H), 7.95 (s, 1 H), 8.01 (s, 1 H), 12.14 (s, 1 H)	Method 5
15	N ⁴ -(5-tert-Butyl-1H-pyrazol-3-yl)-5-chloro-N ² -[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine	1.26 (s, 9 H), 1.46 (d, 3 H), 5.01 (m, 1 H), 6.22 (br s, 1 H), 7.11 (m, 2 H), 7.32 (m, 2 H), 8.07 (s, 1 H)	Method 3

Ex.	Compound	¹ H NMR	SM
16	5-Bromo-N ⁴ -(5-tert-butyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine	1.26 (s, 9 H), 1.46 (d, 3 H), 4.99 (m, 1 H), 6.20 (br s, 1 H), 7.10 (m, 2 H), 7.28 (m, 2 H), 8.17 (s, 1 H), 8.38 (br s, 1 H), 9.42 (br s, 1 H)	Method 6
17	5-Bromo-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-6-methylpyrimidine-2,4-diamine	0.64 (m, 2 H), 0.96 (m, 2 H), 1.47 (d, 3 H), 1.90 (m, 1 H), 2.39 (s, 3 H), 4.94 (m, 1 H), 5.92 (s, 1 H), 7.13 (m, 2 H), 7.29 (m, 2 H), 8.37 (br s, 1 H), 9.63 (br s, 1 H)	Method 7
18	(2R)-2-({5-Bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methylpyrimidin-2-yl} amino)-2-phenylethanol	(CD ₃ OD): 0.74 (m, 2 H), 1.05 (m, 2 H), 1.93 (m, 1 H), 3.84 (m, 2 H), 5.05 (m, 1 H), 5.99 (br s, 1 H), 7.33 (m, 5 H)	Method 7
19	N ⁴ -(3-Cyclopropyl-1H-pyrazol-5-yl)-N ² -(1-phenylethyl)pyrimidine-2,4-diamine	0.6 (m, 2 H), 0.9 (m, 2 H), 1.5 (m, 3 H), 1.9 (m, 1 H), 5.1 (m, 1 H), 6.1 (m, 1 H), 6.3 (m, 1 H), 7.3-7.4 (m, 5 H), 7.6 (m, 1 H), 8.7 (s, 1 H)	Method 8
20	N ⁴ -(3-Cyclopropyl-1H-pyrazol-5-yl)-5-methyl-N ² -(1-phenylethyl)pyrimidine-2,4-diamine	0.6 (m, 2 H), 0.9 (m, 2 H), 1.5 (m, 3 H), 1.9 (m, 1 H), 2.0 (s, 3 H), 5.1 (m, 1 H), 6.1 (m, 1 H), 6.3 (m, 1 H), 7.3-7.4 (m, 5 H), 7.7 (m, 1 H), 8.6 (s, 1 H), 10.1 (s, 1 H)	Method 9
21	(2S)-2-({5-Bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl} amino)-2-phenylethanol	0.9 (m, 2 H), 1.2 (m, 2 H), 2.0 (m, 1 H), 4.1 (m, 2 H), 4.2 (m, 1 H), 5.3 (m, 1 H), 6.2 (m, 1 H), 7.3-7.4 (m, 5 H), 8.1 (m, 1 H), 8.7 (s, 1 H), 10.1 (m, 1 H)	Method 5
22	5-Chloro-N ⁴ -(3-cyclopropyl-1H-pyrazol-5-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine	0.6 - 0.8 (m, 2 H), 0.9-1.2 (m, 2 H), 1.6 (m, 3 H), 2.0 (m, 1 H), 5.1 (m, 1 H), 6.4 (m, 1 H), 7.0-7.4 (m, 4 H), 7.7 (m, 1 H), 8.2 (s, 1 H), 8.4 (m, 1 H), 10.4 (m, 1 H)	Method 1

Ex.	Compound	¹ H NMR	SM
23 ¹	Butyl 6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[[1-(4-fluorophenyl)-2-hydroxyethyl]amino]pyrimidine-4-carboxylate	0.69 (m, 2 H), 0.95 (m, 5 H), 1.41 (m, 2 H), 1.67 (m, 2 H), 1.87 (m, 1 H), 3.69 (m, 2 H), 4.33 (m, 2 H), 5.06 (m, 1 H), 6.02 (s, 1 H), 7.17 (m, 2 H), 7.41 (m, 2 H), 8.29 (br s, 1 H), 12.33 (br s, 1 H)	Method 10
24	(2R)-2-({5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.62-0.71 (m, 2 H), 0.82-0.94 (m, 2 H), 1.88 (m, 1 H), 3.60 (m, 2 H), 4.88-4.93 (m, 2 H), 5.79 (s, 1 H), 6.07-6.47 (m, 1 H), 7.10 (m, 2 H), 7.35 (m, 2 H), 7.89 (s, 1 H), 8.36 (s, 1 H), 12.08 (s, 1 H)	Method 1, and Method 104
25	(2S)-2-({5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.69 (m, 2 H), 0.85-0.94 (m, 2 H), 1.88 (m, 1 H), 3.60 (m, 2 H), 4.88-4.93 (m, 2 H), 5.77 (s, 1 H), 6.01-6.44 (m, 1 H), 7.10 (m, 2 H), 7.35 (m, 2 H), 7.89 (s, 1 H), 8.36 (s, 1 H), 12.08 (s, 1 H)	Method 1, and Method 105
26	(2R)-2-({5-Bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.68 (m, 2 H), 0.98 (m, 2 H), 1.87 (m, 1 H), 3.60 (m, 2 H), 4.90 (m, 1 H), 5.99 (br s, 1 H), 7.10 (m, 2 H), 7.36 (m, 2 H), 7.98 (s, 1 H), 8.19 (br s, 1 H), 12.08 (br s, 1 H)	Method 5, and Method 104
27	(2S)-2-({5-Bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.68 (m, 2 H), 0.98 (m, 2 H), 1.87 (m, 1 H), 3.60 (m, 2 H), 4.90 (m, 1 H), 5.93 (m, 1 H), 7.10 (m, 2 H), 7.35 (m, 2 H), 7.97 (s, 1 H), 9.30 (br s, 1 H), 12.10 (br s, 1 H)	Method 5, and Method 105
28	Methyl 6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[[1-(4-fluorophenyl)-2-hydroxyethyl]amino]pyrimidine-4-carboxylate	0.65 (m, 2 H), 0.95 (m, 2 H), 1.88 (m, 1 H), 3.72 (m, 5 H), 5.07 (m, 1 H), 6.02 (s, 1 H), 6.79 (s, 1 H), 7.19 (m, 2 H), 7.39 (m, 2 H), 8.39 (s, 1 H), 11.41 (s, 1 H), 12.40 (br s, 1 H)	Method 10, and Method 104

Ex.	Compound	¹ H NMR	SM
29	6-[(3-Cyclopropyl-1H-pyrazol-5-yl)amino]-N-[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]-2-[[[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}pyrimidine-4-carboxamide	(Acetone-d ₆): 0.76 (m, 2 H), 1.06 (m, 2 H), 2.58 (m, 1 H), 3.90 (m, 4 H), 5.11-5.29 (m, 2 H), 6.07 (s, 0.5 H), 6.17 (s, 0.5 H), 6.83 (s, 0.5 H), 7.07 (m, 4 H), 7.26 (s, 0.5 H), 7.54 (m, 4 H)	Method 10, and Method 104
30	(2R)-2-({5-Bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-2-phenylethanol	(CD ₃ OD): 2.34 (s, 3 H), 3.88 (m, 1 H), 3.92 (m, 1 H), 5.03 (m, 1 H), 6.03 (br s, 1 H), 7.36 (m, 5 H), 8.15 (s, 1 H)	Method 11
31	5-Chloro-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-N ⁴ -(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine	(CD ₃ OD): 1.57 (d, 3 H), 2.34 (s, 3 H), 5.05 (m, 1 H), 6.08 (br s, 1 H), 7.07 (m, 2 H), 7.33 (m, 2 H), 8.02 (s, 1 H)	Method 12
32	5-Bromo-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-N ⁴ -(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine	(CD ₃ OD): 1.57 (d, 3 H), 2.34 (s, 3 H), 5.02 (m, 1 H), 6.08 (br s, 1 H), 7.07 (m, 2 H), 7.32 (m, 2 H), 8.09 (s, 1 H)	Method 11
33	(2R)-2-({4-[(3-Cyclopropyl-1H-pyrazol-5-yl)amino]-5-fluoropyrimidin-2-yl}amino)-2-phenylethanol	0.64 (m, 2 H), 0.92 (m, 2 H), 1.82 (m, 1 H), 3.63 (m, 2 H), 4.88 (m, 1 H), 5.99 (s, 1 H), 7.27 (m, 5 H), 8.03 (s, 1 H)	Method 13
34	Ethyl 6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino}pyrimidine-4-carboxylate	0.65 (m, 2 H), 0.95 (m, 2 H), 1.30 (t, 3 H), 1.46 (d, 3 H), 1.87 (m, 1 H), 4.34 (m, 2 H), 5.11 (m, 1 H), 6.05 (s, 1 H), 6.79 (s, 1 H), 7.15 (m, 2 H), 7.42 (m, 2 H), 8.02 (br s, 1 H)	Method 17

Ex.	Compound	¹ H NMR	SM
35	2-({5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.69 (m, 2 H), 0.96 (m, 2 H), 1.91 (m, 1 H), 3.67 (m, 2 H), 4.93 (m, 1 H), 5.98-6.24 (m, 1 H), 7.14 (m, 2 H), 7.33 (m, 2 H), 8.22 (s, 1 H), 8.76 (s, 1 H), 10.07 (br s, 1 H)	Method 1, and Method 106
36	N ⁴ -(3-Cyclopropyl-1H-pyrazol-5-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-6-methylpyrimidine-2,4-diamine	0.66 (m, 2 H), 0.95 (m, 2 H), 1.51 (d, 3 H), 1.87 (m, 1 H), 2.25 (s, 3 H), 5.14 (m, 1 H), 6.08 (m, 1 H), 7.18 (m, 2 H), 7.41 (m, 2 H), 8.78 (s, 1 H), 10.99 (br s, 1 H), 12.34 (br s, 1 H), 12.72 (br s, 1 H)	Method 14
37	2-({5-Bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.45 (m, 2 H), 0.71 (m, 2 H), 1.65 (m, 1 H), 3.41 (d, 2 H), 4.96 (m, 1 H), 5.72 (br s, 1 H), 6.89 (m, 2 H), 7.09 (m, 2 H), 7.88 (br s, 1 H)	Method 5, and Method 106
38	6-Chloro-N ⁴ -(3-cyclopropyl-1H-pyrazol-5-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine	0.66 (m, 2 H), 0.92 (m, 2 H), 1.40 (d, 3 H), 1.84 (m, 1 H), 5.03 (m, 1 H), 5.93-6.17 (m, 1 H), 7.12 (m, 2 H), 7.38 (m, 2 H), 7.78 (br s, 1 H), 9.63 (br s, 1 H)	Method 15
39	5,6-Dichloro-N ⁴ -(3-cyclopropyl-1H-pyrazol-5-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine	0.67 (m, 2 H), 0.92 (m, 2 H), 1.39 (m, 3 H), 1.87 (m, 1 H), 4.92 (m, 1 H), 5.93-6.21 (m, 1 H), 7.10 (m, 2 H), 7.33 (m, 2 H), 7.95 (m, 1 H), 8.83 (br s, 1 H), 9.19 (br s, 1 H)	Method 16
40	N ⁴ -(3-Cyclopropyl-1H-pyrazol-5-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-5-methylpyrimidine-2,4-diamine	0.66 (m, 2 H), 0.95 (m, 2 H), 1.49 (d, 3 H), 1.90 (m, 1 H), 2.05 (s, 3 H), 5.01 (m, 1 H), 6.03 (br s, 1 H), 7.16 (m, 2 H), 7.35 (m, 2 H), 7.70 (s, 1 H), 8.65 (br s, 1 H), 10.04 (s, 1 H), 12.01 (br s, 1 H)	Method 9

Ex.	Compound	¹ H NMR	SM
41	N ⁴ -(3-Cyclopropyl-1H-pyrazol-5-yl)-5-fluoro-N ² -[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine	0.66 (m, 2 H), 0.95 (m, 2 H), 1.46 (d, 3 H), 1.88 (m, 1 H), 4.98 (m, 1 H), 6.07 (br s, 1 H), 7.15 (m, 2 H), 7.38 (m, 2 H), 8.04 (s, 1 H)	Method 13
42	N ⁴ -(3-Cyclopropyl-1H-pyrazol-5-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine	0.66 (m, 2 H), 0.95 (m, 2 H), 1.52 (d, 3 H), 1.86 (m, 1 H), 5.12 (m, 1 H), 6.06 (s, 1 H), 6.28 (m, 1 H), 7.19 (m, 2 H), 7.41 (m, 2 H), 7.83 (m, 1 H), 8.91 (br s, 1 H), 11.11 (s, 1 H), 12.02 (br s, 1 H)	Method 8
43	(2S)-2-({5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-phenylethanol	0.70 (m, 2 H), 0.95 (m, 2 H), 1.90 (m, 1 H), 3.67 (m, 2 H), 4.93 (m, 1 H), 5.97 (s, 1 H), 7.31 (m, 5 H), 8.16 (s, 1 H), 8.46 (br s, 1 H), 9.97 (br s, 1 H)	Method 1
44	(2R)-2-({5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-phenylethanol	0.69 (m, 2 H), 0.95 (m, 2 H), 1.89 (m, 1 H), 3.66 (m, 2 H), 4.92 (m, 1 H), 5.97 (s, 1 H), 7.31 (m, 5 H), 8.15 (s, 1 H), 9.88 (br s, 1 H)	Method 1
45	3-({5-Bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-3-(4-fluorophenyl)propanoic acid	0.69 (m, 2 H), 0.93 (m, 2 H), 1.87 (m, 1 H), 2.64 (d, 2 H), 5.5 (m, 1 H), 6.10-6.20 (m, 1 H), 7.12 (m, 2 H), 7.36 (m, 2 H), 8.07 (m, 1 H), 8.78 (br s, 1 H)	Method 5
46	2-[{5-Bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}(1-phenylethyl)amino]ethanol	(CD ₃ OD): 0.60 (m, 1 H), 0.75 (m, 1 H), 1.64 (d, J = 9.0 Hz, 3 H), 1.86 (m, 1 H), 3.51 (m, 4 H), 5.94 (q, J = 9.0 Hz, 1 H), 6.12 (s, 1 H), 7.35 (m, 5 H), 8.18 (s, 1 H)	Method 5
47	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1R)-1-(4-fluorophenyl)-2-methoxyethyl]pyrimidine-2,4-diamine	(CD ₃ OD): 0.6 (m, 2 H), 0.9 (m, 2 H), 1.8 (m, 1 H), 3.2 (s, 3 H), 3.5 (m, 2 H), 5.0 (br s, 1 H), 5.9 (br s, 1 H), 6.9 (m, 2 H), 7.2 (m, 2 H), 7.9 (m, 1 H)	Method 1, and Method 113

Ex.	Compound	¹ H NMR	SM
48	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[1-(4-fluorophenyl)-2-morpholin-4-ylethyl]pyrimidine-2,4-diamine	(CD ₃ OD): 0.9 (m, 2 H), 1.1 (m, 2 H), 2.0 (m, 1 H), 3.5 (m, 4 H), 3.9 (m, 6 H), 5.5 (br s, 1 H), 6.1 (br s, 1 H), 7.1 (m, 2 H), 7.5 (m, 2 H), 8.1 (s, 1 H)	Method 1, and Method 114
49	2-({5-Chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-2-(2-thienyl)ethanol	0.67 (m, 2 H), 0.93 (m, 2 H), 1.88 (m, 1 H), 3.73 (m, 2 H), 4.65–4.80 (m, 1 H), 5.20 (m, 1 H), 6.07 (s, 1 H), 6.98 (m, 2 H), 7.46 (m, 1 H), 8.10 (br s, 1 H), 8.20 (s, 1 H), 8.65 (m, 1 H), 10.22 (m, 1 H)	Method 1, and Method 108
50	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-phenylethyl]quinazoline-2,4-diamine	0.67 (m, 2 H), 0.96 (m, 2 H), 1.57 (m, 3 H), 1.93 (m, 1 H), 5.27 (m, 1 H), 6.17 (br s, 1 H), 7.38 (m, 7 H), 7.82 (m, 1 H), 8.59 (d, 1 H), 8.96 (br s, 1 H), 11.40 (br s, 1 H), 12.67 (br s, 1 H)	Method 55
51	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]quinazoline-2,4-diamine	0.65 (m, 2 H), 0.98 (m, 2 H), 1.56 (m, 3 H), 1.93 (m, 1 H), 5.25 (m, 1 H), 6.15 (br s, 1 H), 7.18 (m, 2 H), 7.42 (m, 4 H), 7.82 (m, 1 H), 8.58 (d, 1 H), 9.05 (br s, 1 H), 11.40 (br s, 1 H), 12.87 (br s, 1 H)	Method 55
52	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)-2-phenylethanol	0.77 (m, 2 H), 0.99 (m, 2 H), 1.94 (m, 1 H), 3.80 (m, 2 H), 5.20 (m, 1 H), 6.16 (s, 1 H), 7.38 (m, 7 H), 7.83 (m, 1 H), 8.57 (d, 1 H), 8.70 (br s, 1 H), 11.43 (br s, 1 H), 12.52 (br s, 1 H)	Method 55
53	N ⁴ -(5-tert-Butyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]quinazoline-2,4-diamine	(CH ₃ OD): 1.37 (s, 9 H), 1.64 (d, 3 H), 2.35 (s, 3 H), 5.34 (m, 1 H), 6.45 (br s, 1 H), 7.04 (m, 2 H), 7.35 (m, 2 H), 7.48 (m, 2 H), 7.83 (m, 1 H), 8.29 (d, 1 H)	Method 56

Ex.	Compound	¹ H NMR	SM
54	N ² -[(1S)-1-(4-Fluorophenyl)ethyl]-N ⁴ -(5-methyl-1H-pyrazol-3-yl)quinazoline-2,4-diamine	(CH ₃ OD): 1.62 (d, 3 H), 2.35 (s, 3 H), 5.23 (m, 1 H), 6.16 (br s, 1 H), 7.07 (m, 2 H), 7.36 (m, 2 H), 7.50 (m, 2 H), 7.84 (m, 1 H), 8.31 (d, 1 H)	Method 57
55	(2R)-2-({4-[(5-Methyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)-2-phenylethanol	2.27 (s, 3 H), 3.79 (m, 2 H), 5.15 (m, 1 H), 6.10 (s, 1 H), 7.26-7.53 (m, 7 H), 7.83 (m, 1 H), 8.57 (m, 1 H), 11.44 (s, 1 H), 12.81 (s, 1 H)	Method 57
56	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]thieno[3,2-d]pyrimidin-2-yl}amino)-2-phenylethanol	0.6 (m, 2 H), 0.9 (m, 2 H), 1.9 (m, 1 H), 3.8 (m, 2 H), 5.1 (br s, 1 H), 6 (br s, 1 H), 7.1 - 7.6 (m, 6 H), 8.1 (br s, 1 H), 8.6 (br s, 1 H), 11.5 (s, 1 H), 13.0 (br s, 1 H)	Method 70
57	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]thieno[2,3-d]pyrimidine-2,4-diamine	0.7 (m, 2 H), 1.0 (m, 2 H), 1.5 (m, 3 H), 1.9 (m, 1 H), 5.4 (m, 1 H), 6.4 (br s, 1 H), 7.1 - 7.6 (m, 3 H), 7.5 (m, 2 H), 7.8 (m, 1 H), 8.5 (br s, 1 H), 11 (br s, 1 H)	Method 71
58	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]thieno[3,2-d]pyrimidine-2,4-diamine	(CD ₃ OD): 0.6 (m, 2 H), 0.9 (m, 2 H), 1.4 (m, 3 H), 1.8 (m, 1 H), 5.0 (br s, 1 H), 6.0 (br s, 1 H), 6.9 (m, 2 H), 7.1 (m, 1 H), 7.25 (m, 2 H)	Method 70
59	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-1H-pyrazolo[3,4-d]pyrimidin-6-yl}amino)-2-phenylethanol	0.5-0.9 (m, 2 H), 1.0 (m, 2 H), 1.9 (m, 1 H), 4.2 (m, 2 H), 5.2 (br s, 1 H), 6.2 (br s, 1 H), 7.2 - 7.5 (m, 6 H), 8.4 - 8.7 (m, 2 H), 11.7 (s, 1 H), 12.5 (br s, 1 H)	Method 72
60	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]thieno[2,3-d]pyrimidin-2-yl}amino)-2-phenylethanol	0.8 (m, 2 H), 1.0 (m, 2 H), 2.0 (m, 1 H), 3.9 (m, 2 H), 5.2 (m, 1 H), 6.3 (br s, 1 H), 7.2 (m, 1 H), 7.3 (m, 1 H), 7.4-7.5 (m, 5 H), 7.8 (m, 1 H), 8.0 (m, 1 H), 10.5 (br s, 1 H)	Method 71

Ex.	Compound	¹ H NMR	SM
61	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]thieno[3,4-d]pyrimidin-2-yl}amino)-2-phenylethanol	(CD ₃ OD): 0.9 (m, 2 H), 1.1 (m, 2 H), 2.0 (m, 1 H), 3.7 (m, 1 H), 4.0 (m, 2 H), 7.3-7.6 (m, 6 H), 8.7 (s, 1 H)	Method 73
62	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ⁶ -[(1S)-1-(4-fluoro phenyl)ethyl]-1H-pyrazolo [3,4-d]pyrimidine-4,6-diamine	(CD ₃ OD): 1.1 (m, 2 H), 1.3 (m, 5 H), 1.9 (m, 1 H), 5.6 (m, 1 H), 7.3 (m, 2 H), 7.8 (m, 2 H), 8.1 (br s, 1 H)	Method 72
63	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]thieno[3,2-d]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	(CD ₃ OD): 0.6 (m, 2 H), 0.9 (m, 2 H), 1.8 (m, 1 H), 3.7 (m, 2 H), 5.0 (br s, 1 H), 6.0 (m, 2 H), 6.9 (m, 2 H), 7.1 (m, 1 H), 7.3 (m, 2 H), 8.0 (br s, 1 H)	Method 70, and Method 104
64	(3S)-3-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]thieno[3,2-d]pyrimidin-2-yl}amino)-3-(4-fluorophenyl)propan-1-ol	(CD ₃ OD): 1.0 (m, 2 H), 1.3 (m, 2 H), 2.2 (m, 1 H), 2.4 (m, 2 H), 3.9 (m, 2 H), 5.6 (br s, 1 H), 6.4 (m, 2 H), 7.1-7.7 (m, 5 H), 8.4 (br s, 1 H)	Method 70, and Method 107
65	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]pyrido[2,3-d]pyrimidine-2,4-diamine	0.6 (m, 2 H), 0.85 (m, 2 H), 1.4 (d, J = 4 Hz, 3 H), 1.8 (m, 1 H), 5.1 (m, 1 H), 6.1 (s, 1 H), 7.1 (m, 2 H), 7.3 (m, 3 H), 8.6 (m, 1 H), 9.0 (m, 1 H)	Method 90
66	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]pyrido[2,3-d]pyrimidin-2-yl}amino)-2-phenylethanol	0.6-1 (m, 4 H), 1.9 (m, 1 H), 3.9 (m, 2 H), 5.2 (m, 1 H), 6.2 (br s, 1 H), 7.2-7.6 (m, 5 H), 8.8 (m, 1 H), 8.9 (m, 1 H), 9.1 (m, 1 H), 11.7 (br s, 1 H), 12.6 (br s, 1 H)	Method 90

Ex.	Compound	¹ H NMR	SM
67	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-7-methylquinazoline-2,4-diamine	(120°C): 0.7 (m, 1 H), 1.0 (m, 2 H), 1.3 (m, 1 H), 1.6 (m, 3 H), 1.9 (m, 1 H), 2.5 (s, 3 H), 4.1 (m, 1 H), 5.3 (m, 1 H), 6.2 (s, 1 H), 7.1-7.5 (m, 6 H), 7.7 (m, 1 H), 8.4 (m, 1 H), 8.7 (br s, 1 H), 10.9 (br s, 1 H)	Method 91
68	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-6-methylquinazoline-2,4-diamine	0.7 (m, 2 H), 1.0 (m, 2 H), 1.6 (m, 3 H), 1.9 (s, 1 H), 2.5 (m, 3 H), 5.2 (m, 1 H), 6.2 (m, 1 H), 7.1 (m, 2 H), 7.3 (m, 3 H), 7.7 (m, 1 H), 8.1 (m, 1 H)	Method 92
69	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-6-methoxyquinazoline-2,4-diamine	0.7 (br s, 2 H), 1.0 (m, 2 H), 1.6 (m, 3 H), 1.9 (s, 1 H), 4.3 (m, 3 H), 5.2 (m, 1 H), 6.2 (m, 1 H), 7.1 (m, 2 H), 7.3 - 7.4 (m, 4 H), 7.8 (m, 1 H)	Method 93
70	7-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]quinazoline-2,4-diamine	0.7 (br s, 2 H), 1.0 (m, 2 H), 1.6 (m, 3 H), 1.9 (s, 1 H), 4.3 (m, 3 H), 5.2 (m, 1 H), 6.2 (m, 1 H), 7.1 (m, 2 H), 7.3 - 7.5 (m, 4 H), 8.3 (m, 1 H)	Method 94
71	6-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]quinazoline-2,4-diamine	0.7 (m, 2 H), 1.0 (m, 2 H), 1.6 (m, 3 H), 1.9 (s, 1 H), 4.3 (m, 3 H), 5.2 (m, 1 H), 6.2 (m, 1 H), 7.1 (m, 2 H), 7.3 - 7.5 (m, 4 H), 8.3 (m, 1 H)	Method 95
72	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-8-methoxyquinazoline-2,4-diamine	0.7 (m, 2 H), 1.0 (m, 2 H), 1.6 (m, 3 H), 1.9 (s, 1 H), 4.3 (m, 3 H), 5.2 (m, 1 H), 6.2 (m, 1 H), 7.1 (m, 2 H), 7.3 - 7.5 (m, 3 H), 7.8 (m, 1 H), 8.4 (m, 1 H)	Method 96
73	8-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]quinazoline-2,4-diamine	0.7 (m, 2 H), 1.0 (m, 2 H), 1.6 (m, 3 H), 1.9 (s, 1 H), 5.2 (m, 1 H), 6.2 (m, 1 H), 7.1 (m, 2 H), 7.3 - 7.5 (m, 5 H), 7.9 (m, 1 H), 8.3 (m, 1 H)	Method 97

Ex.	Compound	¹ H NMR	SM
74	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-1H-pyrazolo[3,4-d]pyrimidin-6-yl}amino)-2-(4-fluorophenyl)ethanol	(CD ₃ OD): 0.6 (m, 2 H), 1.0 (m, 2 H), 1.9 (m, 1 H), 3.7 (m, 2 H), 5.0 (br s, 1 H), 6.0 (m, 1 H), 6.9 (m, 2 H), 7.3 (m, 2 H), 8.3 (br s, 1 H)	Method 72, and Method 104
75	(2R)-2-({6-Chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)-2-phenylethanol	0.83 (m, 2 H), 1.1 (m, 2 H), 4.0 (m, 2 H), 5.5 (t, 1 H), 6.5 (s, 1 H), 7.3 - 7.5 (m, 5 H), 7.6 - 7.7 (m, 2 H), 8.4 (s, 1 H)	Method 95
76	(2R)-2-({7-Chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)-2-phenylethanol	0.83 - 0.91 (m, 2 H), 1.1 (m, 2 H), 4.0 (m, 2 H), 5.5 (t, 1 H), 6.5 (s, 1 H), 7.2 - 7.4 (m, 4 H), 7.5 (m, 2 H), 7.6 (s, 1 H), 8.2 (d, 1 H)	Method 94
77	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-7-fluoro-N ² -[(1S)-1-(4-fluorophenyl)ethyl]quinazoline-2,4-diamine	0.70 (m, 2 H), 0.91 (m, 2 H), 1.46 (d, 3 H), 1.88 (m, 1 H), 5.23 (m, 1 H), 6.19 (br s, 1 H), 6.94 (m, 2 H), 7.11 (m, 2 H), 7.44 (m, 2 H), 7.66 (br s, 1 H), 8.13 (s, 1 H), 8.31 (m, 1 H), 10.15 (br s, 1 H)	Method 102
78	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-7-fluoroquinazolin-2-yl}amino)-2-(4-fluorophenyl)ethanol	(CD ₃ OD): 0.8 (m, 2 H), 1.0 (m, 2 H), 1.9 (m, 1 H), 3.9 (s, 2 H), 5.2 (d, 1 H), 6.1 (br s, 1 H), 7.1 (m, 2 H), 7.3 (m, 2 H), 7.4 (m, 1 H), 7.5 (m, 1 H), 8.4 (m, 1 H)	Method 102, and Method 104
79	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-7-methylquinazolin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.8 (m, 2 H), 1.1 (m, 2 H), 2.0 (m, 1 H), 2.5 (s, 3 H), 4.0 (m, 2 H), 5.5 (m, 1 H), 6.5 (m, 1 H), 7.1 - 7.5 (m, 7 H), 8.2 (m, 1 H)	Method 91, and Method 104
80	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-6-methoxyquinazolin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.8 (m, 2 H), 1.1 (m, 2 H), 2.0 (m, 1 H), 2.4 (m, 1 H), 3.4 (m, 1 H), 4.0 (m, 3 H), 5.4 (m, 1 H), 6.4 (s, 1 H), 7.1, (m, 2 H), 7.4 - 7.5 (m, 4 H), 7.9 (d, 1 H)	Method 93, and Method 104

Ex.	Compound	¹ H NMR	SM
81	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-6-fluoro-N ² -[(1S)-1-(4-fluorophenyl)ethyl]quinazoline-2,4-diamine	(CD ₃ OD): 0.7 (m, 2 H), 0.99 (m, 2 H), 1.59 (d, 3 H), 1.93 (m, 1 H), 5.22 (m, 1 H), 6.13 (s, 1 H), 7.03 (m, 2 H), 7.32 (m, 2 H), 7.60 (m, 2 H), 8.12 (d, 1 H)	Method 103
82	(2R)-2-({5-Bromo-4-[(3-methoxy-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	3.63 (m, 2 H), 3.76 (s, 3 H), 4.94 (m, 1 H), 5.64 (s, 1 H), 7.13 (m, 2 H), 7.38 (m, 2 H), 8.04 (s, 1 H), 8.18 (br s, 1 H), 9.49 (s, 1 H)	Method 115, and Method 104
83	(2R)-2-[(5-Chloro-4-{[5-(methylthio)-1H-pyrazol-3-yl]amino}pyrimidin-2-yl)amino]-2-(4-fluorophenyl)ethanol	2.45 (s, 3 H), 3.64 (m, 2 H), 4.94 (m, 1 H), 6.25 (s, 1 H), 7.13 (m, 2 H), 7.39 (m, 2 H), 7.98 (s, 1 H), 8.17 (s, 1 H), 9.74 (br s, 1 H)	Method 118, and Method 104
84	(2R)-2-({4,5-Dichloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	(CD ₃ OD): 0.73 (m, 2 H), 0.97 (m, 2 H), 1.90 (m, 1 H), 3.76 (m, 2 H), 5.00 (m, 1 H), 6.05 (br s, 1 H), 7.04 (m, 2 H), 7.37 (m, 2 H)	Method 16, and Method 104
85	(2R)-2-{[5-Chloro-4-(1H-pyrazol-5-ylamino)pyrimidin-2-yl]amino}-2-(4-fluorophenyl)ethanol	3.65 (m, 2 H), 4.88 (m, 1 H), 6.23 (s, 1 H), 7.13 (m, 2 H), 7.28 (m, 2 H), 7.73 (s, 1 H), 8.18 (s, 1 H), 10.14 (s, 1 H)	Method 120, and Method 104
86	(2R)-2-[(5-Chloro-4-{[3-(dimethylamino)-1H-pyrazol-5-yl]amino}pyrimidin-2-yl)amino]-2-(4-fluorophenyl)ethanol	2.90 (s, 6 H), 3.66 (m, 2 H), 4.99 (m, 1 H), 5.70 (s, 1 H), 7.13 (m, 2 H), 7.37 (m, 2 H), 7.96 (br s, 1 H), 8.06 (s, 1 H), 10.11 (br s, 1 H)	Method 121, and Method 104

Ex.	Compound	¹ H NMR	SM
87	3-({5-Bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-methyl-3-phenylpropanoic acid	0.89 (m, 7 H), 1.3 (m, 0.5 H), 1.58 (m, 0.5 H), 1.95 (m, 1 H), 5.08 (m, 1 H), 6.21 (s, 1 H), 7.29 (m, 5 H), 8.12 (s, 1 H)	Method 5
88	3-({5-Bromo-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-methyl-3-phenylpropan-1-ol	0.72-0.98 (m, 7 H), 1.90 (m, 1 H), 2.03 (m, 1 H), 3.37 (m, 2 H), 4.90 (m, 1 H), 6.09 (s, 1 H), 7.28 (m, 5 H), 8.04 (br s, 1 H), 8.18 (s, 1 H), 8.31 (br s, 1 H), 9.32 (br s, 1 H)	Method 5, and Method 109
89	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)-3-morpholin-4-ylpropyl]pyrimidine-2,4-diamine	(CD ₃ OD): 0.8 (m, 2 H), 1.2 (m, 2 H), 2.1 (m, 1 H), 2.4 (m, 1 H), 2.6 (m, 1 H), 3.2 (m, 3 H), 3.6 (m, 3 H), 3.8 (m, 2 H), 4.1 (m, 2 H), 5.1 (br s, 1 H), 6.1 (br s, 1 H), 7.1 (m, 2 H), 7.4 (m, 2 H), 8.1 (s, 1 H)	Method 1, and Method 125
90	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)-3-pyrrolidin-1-ylpropyl]pyrimidine-2,4-diamine	(CD ₃ OD): 1.0 (m, 2 H), 1.3 (m, 2 H), 2.1 (m, 3 H), 2.3 (m, 2 H), 2.5 (m, 1 H), 2.6 (m, 1 H), 3.2 (m, 2 H), 3.4 (m, 2 H), 3.8 (m, 2 H), 5.2 (m, 1 H), 6.2 (br s, 1 H), 7.3 (m, 2 H), 7.6 (m, 2 H), 8.1 (s, 1 H)	Method 1, and Method 127
91	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-3-(diethylamino)-1-(4-fluorophenyl)propyl]pyrimidine-2,4-diamine	(CD ₃ OD): 0.8 (m, 2 H), 1.1 (m, 2 H), 1.3 (m, 6 H), 2.1 (m, 1 H), 2.3 (m, 1 H), 2.4 (m, 1 H), 3.2 (m, 6 H), 5.1 (br s, 1 H), 6.1 (br s, 1 H), 7.2 (m, 2 H), 7.4 (m, 2 H), 8.1 (s, 1 H)	Method 1, and Method 128
92	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)-3-(4-methylpiperazin-1-yl)propyl]pyrimidine-2,4-diamine	(CD ₃ OD): 0.6 (m, 2 H), 0.9 (m, 2 H), 1.8 (m, 1 H), 2.2 (m, 2 H), 2.8 (s, 3 H), 3.1-3.8 (m, 10 H), 4.9 (br s, 1 H), 6.0 (br s, 1 H), 6.9 (m, 2 H), 7.2 (m, 2 H), 7.9 (s, 1 H)	Method 1, and Method 129

Ex.	Compound	¹ H NMR	SM
93	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -{(1S)-1-(4-fluorophenyl)-3-[(2-methoxyethyl)(methyl)amino]propyl}pyrimidine-2,4-diamine	(CD ₃ OD): 0.6 (m, 2 H), 0.9 (m, 2 H), 1.8 (m, 1 H), 2.1 (m, 1 H), 2.2 (m, 1 H), 2.6 (s, 3 H), 3.1 (m, 4 H), 3.2 (d, J = 4.8 Hz, 3 H), 3.5 (m, 2 H), 4.8 (m, 1 H), 5.8 (br s, 1 H), 6.9 (m, 2 H), 7.2 (m, 2 H), 7.9 (s, 1 H)	Method 1, and Method 130
94	2-[[[(3S)-3-({5-Chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-3-(4-fluorophenyl)propyl](methyl)amino]ethanol	(CD ₃ OD): 0.8 (m, 2 H), 1.1 (m, 2 H), 2.0 (m, 1 H), 2.3 (m, 1 H), 2.4 (m, 1 H), 2.9 (s, 3 H), 3.2 (m, 4 H), 3.8 (m, 2 H), 5.1 (br s, 1 H), 6.0 (br s, 1 H), 7.1 (m, 2 H), 7.4 (m, 2 H), 8.1 (s, 1 H)	Method 1, and Method 131
95	(3S)-3-({5-Chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-3-(4-fluorophenyl)propan-1-ol	(CD ₃ OD): 0.7 (m, 2 H), 1.1 (m, 2 H), 2.0 (m, 3 H), 3.5 (m, 2 H), 5.1 (br s, 1 H), 6.1 (br s, 1 H), 7.0 (m, 2 H), 7.2 (m, 2 H), 8.1 (s, 1 H)	Method 1, Method 107
96	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-5-methylpyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.68 (m, 2 H), 0.97 (m, 2 H), 1.90 (m, 1 H), 2.05 (s, 3 H), 3.66 (m, 2 H), 4.95 (m, 1 H), 5.99 (br s, 1 H), 7.15-7.20 (m, 2 H), 7.33 (m, 2 H), 7.73 (m, 1 H), 8.49 (m, 1 H), 10.06 (br s, 1 H)	Method 9, Method 104
97	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoropyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.70 (m, 2 H), 0.97 (m, 2 H), 1.90 (m, 1 H), 3.66 (m, 2 H), 4.64 (m, 1 H), 4.95 (m, 1 H), 5.36 (m, 1 H), 6.02 (br s, 1 H), 7.15-7.20 (m, 2 H), 7.37-7.48 (m, 2 H), 8.18 (m, 1 H), 8.69 (m, 1 H), 11.15 (m, 1 H)	Method 13, Method 104
98	(R)-2-[4-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-pyrido[2,3d]pyrimidin-2-ylamino]-2-(4-fluoro-phenyl)-ethanol	(CD ₃ OD): 0.76 (m, 2 H), 0.97 (m, 2 H), 1.96 (m, 1 H), 3.84 (m, 2 H), 5.35 (m, 1 H), 7.04 (m, 3 H), 7.45 (m, 2 H), 8.49 (m, 1 H), 8.64 (m, 1 H)	Method 90, Method 104

Ex.	Compound	¹ H NMR	SM
99	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(S)-1-(2-methoxy-phenyl)-ethyl]-pyrimidine-2,4-diamine	(CD ₃ OD): 0.75 (m, 2 H), 1.04 (m, 2 H), 1.55 (d, 3 H), 1.96 (m, 1 H), 3.89 (s, 3 H), 5.33 (m, 1 H), 6.20 (br s, 1 H), 6.92 (m, 1 H), 7.02 (d, 1 H), 7.21 (m, 1 H), 7.28 (m, 1 H), 8.01 (s, 1 H)	Method 1
100	(2R)-2-({4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-5-nitropyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.67 (m, 2 H), 0.98 (m, 2 H), 1.93 (m, 1 H), 3.66 (m, 2 H), 5.01 (m, 1 H), 6.20 (m, 1 H), 7.16 (m, 2 H), 7.40 (m, 2 H), 8.97 (s, 1 H), 10.40 (br s, 1 H), 12.36 (m, 1 H)	Method 18
101	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-5-nitropyrimidine-2,4-diamine	0.63 (m, 2 H), 0.94 (m, 2 H), 1.47 (m, 3 H), 1.90 (m, 1 H), 5.12 (m, 1 H), 6.13 (m, 2 H), 7.13 (m, 2 H), 7.40 (m, 2 H), 8.97 (s, 1 H), 10.31 (br s, 1 H)	Method 18
102	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -methyl-N ² -(1-pyridin-2-ylethyl)pyrimidine-2,4-diamine	0.55 (m, 2 H), 0.82 (m, 2 H), 1.55 (m, 3 H), 1.80 (m, 1 H), 2.90 (s, 3 H), 5.80 (m, 1 H), 5.90 (m, 1 H), 7.55 (m, 2 H), 8.05 (m, 2 H), 8.55 (m, 1 H), 9.50 (br s, 1 H)	Method 1, Method 20
103	1-({5-Chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-1-phenylpropan-2-ol	0.60 (m, 2 H), 0.80 – 1.00 (m, 5 H), 1.80 (m, 1 H), 3.45 – 3.55 (m, 1 H), 3.85 (m, 1 H), 4.60 – 4.90 (m, 1 H), 5.80 – 6.10 (m, 1 H), 7.10 – 7.40 (m, 5 H), 7.80 – 8.40 (m, 1 H)	Method 1, Method 21
104	5-Chloro-N ² -[(1S)-1-(4-fluorophenyl)-ethyl]-N ⁴ -(5-trifluoromethyl-1H-pyrazol-3-yl)-pyrimidine-2,4-diamine	(400 MHz, CDCl ₃): 1.54 (d, J = 6.8 Hz, 3 H), 4.94 (m, 1 H), 5.73 (br s, 1 H), 6.10 (s, 1 H), 7.04 (m, 2 H), 7.38 (m, 2 H), 8.00 (s, 1 H), 11.80 (br s, 1 H)	Method 19

Ex.	Compound	¹ H NMR	SM
105	5-Bromo-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -(1-pyridin-2-ylethyl)-pyrimidine-2,4-diamine	(400 MHz, CDCl ₃): 0.71 (m, 2 H), 0.89 (m, 2 H), 1.53 (d, J = 9.6 Hz, 3 H), 1.84 (m, 1 H), 5.13 (m, 1 H), 6.04 (br s, 1 H), 6.42 (br s, 1 H), 7.10 (t, J = 9.3 Hz, 2 H), 7.26 (m, 1 H), 7.52 (s, 1 H), 7.57 (m, 1 H), 7.96 (s, 1 H), 8.54 (d, J = 6.6 Hz, 1 H)	Method 5, Method 24
106	N ⁴ -(5-Benzyl-2H-pyrazol-3-yl)-5-chloro-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-pyrimidine-2,4-diamine	(400 MHz, CDCl ₃): 1.47 - 1.49 (d, J = 7.0 Hz, 3 H), 3.94 (s, 2 H), 4.98 (q, 1 H), 5.6 (br s, 1 H), 6.15 (s, 1 H), 6.96 (t, 2 H), 7.2 - 7.32 (m, 7 H), 7.86 (s, 1 H)	Method 25
107	5-Chloro-N ² -[(1S)-1-(4-fluorophenyl)-ethyl]-N ⁴ -(5-isopropyl-2H-pyrazol-3-yl)-pyrimidine-2,4-diamine	(400 MHz, CDCl ₃): 1.24 - 1.26 (d, J = 7.0 Hz, 6 H), 1.50 - 1.52 (d, J = 7.0 Hz, 3 H), 2.89 - 2.96 (q, 1 H), 5.02 - 5.09 (q, 1 H), 5.62 (br s, 1 H), 6.24 (s, 1 H), 6.96 (t, 2 H), 7.30 (t, 2 H), 7.87 (s, 1 H)	Method 28
108	5-Chloro-N ⁴ -(5-cyclopropylmethyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-pyrimidine-2,4-diamine	(400 MHz, CDCl ₃): 0.00 (m, 2 H), 0.371 (m, 2 H), 0.772 (m, 1 H), 1.31 - 1.33 (d, J = 7.0 Hz, 3 H), 2.32 - 2.33 (d, J = 7.0 Hz, 2 H), 4.84 (q, 1 H), 6.02 (s, 1 H), 6.77 (t, 2 H), 7.11 (t, 2 H), 7.66 (s, 1 H)	Method 31
109	5-Chloro-N ⁴ -[5-(cyclopropylmethoxy)-1H-pyrazol-3-yl]-N ² -[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine	(400 MHz, CDCl ₃): 0.021 (m, 2 H), 0.293 (m, 2 H), 0.947 (m, 1 H), 1.20 (d, J = 6.6 Hz, 3 H), 3.61 (d, J = 7.4 Hz, 2 H), 4.64 (q, 1 H), 5.04 (s, 1 H), 6.69 (t, 2 H), 7.02 (t, 2 H), 7.62 (s, 1 H)	Method 35
110	5-Bromo-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-trifluoromethyl-thiazol-2-yl)-ethyl]-pyrimidine-2,4-diamine	(400 MHz): 0.63 (m, 2 H), 0.87 (m, 2 H), 1.60 (m, 1 H), 5.29 (br s, 1 H), 5.92 (br s, 0.76 H), 6.52 (br, 0.24 H), 7.96 (br, 0.76 H), 8.09 (m, 2 H), 8.31 (s, 1 H), 9.45 (br s, 0.24 H), 12.13 (s, 0.76 H, rotamer), 12.39 (br s, 0.24 H, rotamer)	Method 5, Method 49

Ex.	Compound	¹ H NMR	SM
111	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -(1-thiazol-2-yl-ethyl)-pyrimidine-2,4-diamine	(400 MHz, CD ₃ CN): 0.71 (m, 2 H), 0.91 (m, 2 H), 1.63 (d, J = 6.8 Hz, 3 H), 1.84 (m, 1 H), 5.41 (q, J = 7.2 Hz, 1 H), 5.90 (br s, 1 H), 6.20 (m, 1 H), 6.23 (d, J = 9.0 Hz, 1 H), 7.33 (d, J = 1.6 Hz, 1 H), 7.69 (d, J = 2.4 Hz, 1 H), 7.88 (d, J = 5.6 Hz, 1 H), 7.96 (br s, 1 H)	Method 8, Method 52
112	(2R)-2-({4-[(3-sec-Butoxy-1H-pyrazol-5-yl)amino]-5-chloropyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.90 (t, 3 H), 1.25 (d, 3 H), 1.65 (m, 2 H), 3.65 (m, 2 H), 4.49 (m, 1 H), 4.96 (m, 1 H), 5.63 (s, 1 H), 7.15 (m, 2 H), 7.39 (m, 2 H), 8.03 (s, 1 H), 8.43 (br s, 1 H), 10.01 (br s, 1 H)	Method 36, Method 104
113	(2R)-2-({5-Chloro-4-[(3-propoxy-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.95 (t, 3 H), 1.70 (q, 2 H), 3.64 (m, 2 H), 4.00 (t, 2 H), 4.94 (m, 1 H), 5.61 (s, 1 H), 7.14 (m, 2 H), 7.38 (m, 2 H), 7.99 (s, 1 H), 8.27 (br s, 1 H), 9.86 (br s, 1 H)	Method 37, Method 104
114	(2R)-2-({5-Chloro-4-[(3-isopropoxy-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	1.27 (d, 6 H), 3.63 (m, 2 H), 4.67 (m, 1 H), 4.93 (m, 1 H), 5.57 (s, 1 H), 7.13 (m, 2 H), 7.38 (m, 2 H), 7.98 (s, 1 H), 8.21 (br s, 1 H), 9.83 (br s, 1 H)	Method 38, Method 104
115	(2R)-2-({5-Chloro-4-[(3-ethoxy-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	1.30 (t, 3 H), 3.63 (m, 2 H), 4.09 (q, 2 H), 4.93 (m, 1 H), 5.59 (s, 1 H), 7.13 (m, 2 H), 7.38 (m, 2 H), 7.98 (s, 1 H), 8.24 (br s, 1 H), 9.84 (br s, 1 H)	Method 39, Method 104
116	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-3-(dimethylamino)-1-(4-fluorophenyl)propyl]pyrimidine-2,4-diamine	(CD ₃ OD): 0.80 (m, 2 H), 1.10 – 1.40 (m, 4 H), 2.00 (m, 1 H), 2.18 – 2.40 (m, 2 H), 2.80 (m, 6 H), 5.07 (m, 1 H), 6.13 – 6.30 (m, 1 H), 6.97 (m, 2 H), 7.30 (d, 2 H), 8.13 (s, 1 H)	Method 1, Method 132

Ex.	Compound	¹ H NMR	SM
117	(3S)-3-({5-Chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-3-(4-fluorophenyl)-N,N-dimethylpropanamide	(CD ₃ OD): 0.60 (m, 2 H), 0.90 (m, 2 H), 1.80 (m, 1 H), 2.60 – 2.80 (m, 6 H), 2.95 (m, 2 H), 5.07 (m, 1 H), 5.60 (br s, 1 H), 6.30 (m, 1 H), 6.80 (m, 2 H), 7.30 (d, 2 H), 7.93 (s, 1 H)	Method 1, Method 133
118	(3S)-3-({5-Chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-3-(4-fluorophenyl)-N-methylpropanamide	(CD ₃ OD): 0.90 (m, 2 H), 1.25 (m, 2 H), 2.10 (m, 1 H), 2.80 (m, 3 H), 2.95 (m, 2 H), 5.07 (m, 1 H), 5.60 (br s, 1 H), 6.30 (m, 1 H), 7.20 (m, 2 H), 7.40 (d, 2 H), 8.23 (s, 1 H)	Method 1, Method 134
119	3-({5-Chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-3-(2-fluorophenyl)propan-1-ol	(CD ₃ OD): 0.83 (m, 2 H), 1.12 (m, 2 H), 1.90 - 2.03 (m, 3 H), 3.60 (m, 2 H), 5.50 (m, 1 H), 6.39 (s, 1 H), 6.98 (m, 2 H), 7.31 (d, 2 H), 8.12 (s, 1 H)	Method 1
120	(3S)-3-({5-Chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-3-(4-fluorophenyl)-N-(2-hydroxyethyl)propanamide	(CD ₃ OD): 0.87 (m, 2 H), 1.15 (m, 2 H), 2.03 (m, 1 H), 2.90 (m, 2 H), 3.30 (m, 2 H), 3.60 (m, 2 H), 4.40 (m, 1 H), 5.50 (m, 1 H), 6.29 (s, 1 H), 7.10 (m, 2 H), 7.41 (d, 2 H), 8.12 (s, 1 H)	Method 1, Method 135
121	3-({5-Chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-3-(2-methoxyphenyl)propan-1-ol	(CD ₃ OD): 0.88 (m, 2 H), 1.12 (m, 2 H), 2.03 (m, 1 H), 2.11 (m, 2 H), 3.60 (m, 2 H), 3.86 (s, 3 H), 5.50 (m, 1 H), 6.39 (s, 1 H), 6.92 (m, 1 H), 7.01 (d, 1 H), 7.16 (m, 1 H), 7.30 (m, 1 H), 8.12 (s, 1 H)	Method 1
122	3-({5-Chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-3-(2-thienyl)propan-1-ol	(CD ₃ OD): 0.74 (m, 2 H), 1.02 (m, 2 H), 1.93 (m, 1 H), 2.18 (m, 2 H), 3.65 (m, 2 H), 5.57 (m, 1 H), 6.23 (s, 1 H), 6.97 (m, 2 H), 7.30 (d, 1 H), 8.03 (s, 1 H)	Method 1

Ex.	Compound	¹ H NMR	SM
123	5-Chloro- <i>N</i> ⁴ -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)- <i>N</i> ² -[(1 <i>R</i>)-1-(4-fluorophenyl)-2-morpholin-4-ylethyl]pyrimidine-2,4-diamine	(CD ₃ OD): 0.80 (m, 2 H), 1.08 (m, 2 H), 1.99 (m, 1 H), 3.35 (m, 2 H), 3.53 (m, 2 H), 3.76 (m, 2 H), 3.89 (m, 4 H), 5.56 (m, 1 H), 6.05 (s, 1 H), 7.14 (m, 2 H), 7.43 (m, 2 H), 8.11 (s, 1 H)	Method 1, Method 151
124	(2 <i>R</i>)-2-({5-Fluoro-4-[(5-isopropoxy-1 <i>H</i> -pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	(100 °C): 1.35 (m, 6 H), 3.72 (m, 2 H), 4.64 (m, 1 H), 4.97 (m, 1 H), 5.54 (s, 1 H), 7.09 (m, 2 H), 7.42 (m, 2 H), 7.94 (s, 1 H), 9.90 (br s, 1 H)	Method 43, Method 104
125	<i>N</i> -[(2 <i>R</i>)-2-({4-[(5-Cyclopropyl-1 <i>H</i> -pyrazol-3-yl)amino]-5-chloropyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethyl]acetamide	(CD ₃ OD): 0.60 (m, 2 H), 0.88 (m, 2 H), 1.99 (m, 4 H), 3.65 (m, 2 H), 5.16 (m, 1 H), 6.25 (s, 1 H), 7.04 (m, 2 H), 7.23 (m, 2 H), 8.11 (s, 1 H)	Method 1, Method 137
126	(2 <i>R</i>)-2-({4-[(5-Ethoxy-1 <i>H</i> -pyrazol-3-yl)amino]-5-fluoropyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	1.30 (t, <i>J</i> = 6.0 Hz, 3 H), 3.66 (m, 2 H), 4.09 (m, 2 H), 4.93 (m, 1 H), 5.53 (m, 1 H), 7.15 (m, 2 H), 7.37 (m, 2 H), 8.00 (m, 1 H), 8.19 – 8.34 (m, 1 H), 10.73 – 11.07 (m, 1 H)	Method 42, Method 104
127	(3 <i>S</i>)-3-({4-[(5-Cyclopropyl-1 <i>H</i> -pyrazol-3-yl)amino]-5-fluoropyrimidin-2-yl}amino)-3-(4-fluorophenyl)propan-1-ol	0.68 (m, 2 H), 0.90 (m, 2 H), 1.90 (m, 3 H), 3.40 (m, 2 H), 5.53 (s, 1 H), 4.98 (m, 1 H), 6.12 (s, 1 H), 7.09 (m, 2 H), 7.34 (m, 2 H), 7.80 (s, 1 H), 9.31 (bs, 1 H), 12.01 (bs, 1 H)	Method 13, Method 107

¹ Trans-esterification occurred.

Example 128

*N*²-[(1*R*)-2-Amino-1-(4-fluorophenyl)ethyl]-5-chloro-*N*⁴-(5-cyclopropyl-1*H*-pyrazol-3-yl)pyrimidine-2,4-diamine

5

A mixture of 2,5-dichloro-4-(5-cyclopropyl-1*H*-pyrazole-3-ylamino)pyrimidine (Method 1; 150 mg, 0.56 mmol) and *tert*-butyl [(2*R*)-2-amino-2-(4-fluorophenyl)ethyl]

carbamate (Method 136, 178 mg, 0.70 mmol) in n-butanol was heated at 120°C for 48 hours. Reverse phase HPLC (Gilson) gave the *t*-butoxycarbonyl protected title compound which was then dissolved in DCM (10 ml) and to it was added trifluoroacetic acid (10 ml) and the mixture was stirred at room temperature for 2 hours. Solvent was evaporated. Reverse phase HPLC (Gilson) gave the desired product that was then transformed to HCl salt. ¹H NMR (CD₃OD): δ 0.80 (m, 2 H), 1.20 (m, 2 H), 1.10 (m, 2 H), 1.95 (m, 1 H), 5.25 (m, 1 H), 6.10 (m, 2 H), 7.13 (m, 2 H), 7.40 (m, 2 H), 8.13 (s, 1 H).

Example 129

*N*⁴-(5-Cyclopropyl-1*H*-pyrazol-3-yl)-*N*²-[(1*S*)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4,5-triamine

A flask with 10% palladium on carbon (66 mg, 0.06 mmol) was evacuated and refilled with H₂ (balloon). To it was added a solution of *N*⁴-(5-cyclopropyl-1*H*-pyrazol-3-yl)-*N*²-[(1*S*)-1-(4-fluorophenyl)ethyl]-5-nitropyrimidine-2,4-diamine (Example 101, 120 mg, 0.31 mmol) in EtOH (5 ml). The reaction mixture was stirred at room temperature for 20 hours. Filtration followed by concentration gave the desired product as a solid (100 mg, 91%). ¹H NMR: δ 0.70 (m, 2 H), 0.98 (m, 2 H), 1.47 (m, 3 H), 1.92 (m, 1 H), 5.03 (m, 1 H), 6.20 (m, 2 H), 7.13 (m, 2 H), 7.40 (m, 2 H), 8.83 (s, 1 H), 10.40 (br s, 1 H).

Examples 130

Following a similar procedure to Example 129, the following compound was synthesized via reaction of a suitable aminopyrimidine (method of production of which is also listed) and palladium on activated carbon.

Ex.	Compound	¹ H NMR	SM
130	(2 <i>R</i>)-2-({5-Amino-4-[(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.70 (m, 2 H), 0.98 (m, 2 H), 1.47 (m, 3 H), 1.92 (m, 1 H), 3.58 (m, 2 H), 4.85 (m, 1 H), 6.20 (m, 2 H), 7.13 (m, 2 H), 7.40 (m, 2 H), 8.43 (s, 1 H)	Example 100

Example 131

4-[(5-Cyclopropyl-1*H*-pyrazol-3-yl)amino]-2-[[*(1S)*-1-(4-fluorophenyl)ethyl]amino} pyrimidine-5-carbonitrile

To a solution of 5-bromo-*N*⁴-(3-cyclopropyl-1*H*-pyrazol-5-yl)-*N*²-[(*1S*)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine (Example 5, 250 mg, 0.6 mmol) in quinoline (2 ml) was added copper (I) cyanide (75 mg, 0.84 mmol) and the mixture was heated in microwave at 180°C for 5 hours. Reverse phase HPLC (Gilson) purification gave the desired product as a solid (67 mg, 30%). ¹H NMR: δ 0.60 (m, 2 H), 0.90 (m, 2 H), 1.47 (m, 3 H), 1.80 (m, 1 H), 5.10 (m, 1 H), 5.95 (m, 0.4 H), 6.20 (m, 0.6 H), 7.13 (m, 2 H), 7.35 (m, 2 H), 7.70 (s, 1 H), 8.80 (m, 1 H), 10.95 (br s, 1 H).

Example 132

5-Chloro-*N*⁴-(5-cyclopropyl-1*H*-pyrazol-3-yl)-*N*²-[(*1R*)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine

Example 133

5-Chloro-*N*⁴-(5-cyclopropyl-1*H*-pyrazol-3-yl)-*N*²-[(*1S*)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine

The title compounds were synthesised by purification of 5-chloro-*N*⁴-(5-cyclopropyl-1*H*-pyrazol-3-yl)-*N*²-[2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine (Example 187) with a chiral HPLC with Diode Array Detection at 220 nm:

Column: Chiralcel OJ, 250 x 20 mm, 10μ

Conditions: 50% EtOH 50% MeOH 0.1% diethylamine; Flow rate 10 ml/min

Chiral purity determined using chiral HPLC with Diode Array Detection at 220 nm:

Column: Chiralcel OJ, 250 x 4.6 mm, 10μ

Conditions: 50% EtOH 50% MeOH 0.1% diethylamine; Flow rate 0.5 ml/min

Enantiomeric excess (e.e.) > 99% for each isomer, calculated using area percent at 220 nm for each enantiomer.

(*S*)-isomer: ¹H NMR: δ 0.73 (m, 2 H), 0.94 (m, 2 H), 1.92 (m, 1 H), 5.96 (m, 1 H), 6.16 (m, 2 H), 7.24 (m, 2 H), 7.63 (m, 2 H), 8.01 (s, 1 H), 8.16 (br s, 1 H), 8.80 (br s, 1 H).

(*R*)-isomer: ¹H NMR: δ 0.65 (m, 2 H), 0.86 (m, 2 H), 1.80 (m, 1 H), 5.90 – 6.10 (m, 2 H), 7.20 (m, 2 H), 7.55 (m, 2 H), 7.95 (s, 1 H), 8.40 (br s, 1 H), 9.35 (br s, 1 H).

Example 134**N⁴-(5-Cyclopropyl-1*H*-pyrazol-3-yl)-N²-[(1*S*)-1-(4-fluorophenyl)ethyl]-7-(2-methoxyethoxy)quinazoline-2,4-diamine**

A mixture of N⁴-(5-cyclopropyl-1*H*-pyrazol-3-yl)-7-fluoro-N²-[(1*S*)-1-(4-fluorophenyl) ethyl]quinazoline-2,4-diamine (Example 77, 25 mg, 0.06 mmol), 2-methoxyethanol (0.18 ml, 2.26 mmol), potassium *tert*-butoxide (60 mg, 0.53 mmol) was heated at 120°C for 18 hours. EtOAc was added to the reaction mixture. The solution was washed with water and was concentrated. Flash column chromatography (pure EtOAc to EtOAc/MeOH = 9:1) provided product as a solid (30 mg, 60 %). ¹H NMR (CD₃OD): 0.73 (m, 2 H), 1.02 (m, 2 H), 1.61 (d, 3 H), 1.95 (m, 1 H), 3.41 (s, 3 H), 3.78 (m, 2 H), 4.26 (m, 2 H), 5.22 (m, 1 H), 6.14 (br s, 1 H), 6.95 (m, 1 H), 7.06 (m, 3 H), 7.34 (m, 2 H), 8.18 (d, 1 H).

Examples 135-140

Following a similar procedure to Example 134, the following compounds were synthesized via reaction of a suitable quinazoline (method of production of which is also listed) and a suitable alcohol.

Ex.	Compound	¹ H NMR	SM
135	N ⁴ -(5-Cyclopropyl-1 <i>H</i> -pyrazol-3-yl)-N ² -[(1 <i>S</i>)-1-(4-fluorophenyl)ethyl]-7-(2-morpholin-4-ylethoxy)quinazoline-2,4-diamine	(CDCl ₃): 0.7 (m, 2 H), 1.0 (m, 2 H), 1.6 (d, 3 H), 1.9 (m, 1 H), 2.5 (m, 4 H), 2.8 (m, 2 H), 3.7 (m, 4 H), 4.1 (m, 2 H), 5.2 (m, 1 H), 6.2 (s, 1 H), 6.6 (d, 1 H), 6.8 (s, 1 H), 7.0 (m, 2 H), 7.4 (m, 2 H), 7.6 (d, 1 H)	Example 77
136	N ⁴ -(5-Cyclopropyl-1 <i>H</i> -pyrazol-3-yl)-N ² -[(1 <i>S</i>)-1-(4-fluorophenyl)ethyl]-7-[2-(4-methyl piperazin-1-yl)ethoxy]quinazoline-2,4-diamine	(CD ₃ OD): 0.7 (m, 2 H), 1.0 (m, 2 H), 1.6 (d 3 H), 2.0 (m, 1 H), 2.9 (s, 3 H), 3.2 (m, 4 H), 3.4 (m, 4 H), 3.5 (m, 2 H), 4.4 (m, 2 H), 5.2 (m, 1 H), 6.1 (br s, 1 H), 7.1 (m, 4 H), 7.3 (d, 2 H), 7.9 (s, 1 H), 8.2 (d, 1 H)	Example 77

Ex.	Compound	¹ H NMR	SM
137	(2R)-2-{{4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-7-(2-pyrrolidin-1-ylethoxy)quinazolin-2-yl}amino}-2-(4-fluorophenyl)ethanol	(CD ₃ OD): 0.78 (m, 2 H), 1.06 (d, 2 H), 1.98 (m, 1 H), 2.06 (m, 2 H), 2.2 (m, 2 H), 3.27 (m, 2 H), 3.73 (m, 4 H), 3.88 (d, 2 H), 4.51 (d, 2 H), 5.24 (d, 1 H), 6.16 (br s, 1 H), 7.05 (m, 4 H), 7.36 (m, 2 H), 8.26 (d, 1 H)	Example 78
138	(2R)-2-{{4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-7-(2-morpholin-4-ylethoxy)quinazolin-2-yl}amino}-2-(4-fluorophenyl)ethanol	(CDCl ₃): 0.71 (m, 2 H), 1.05 (m, 2 H), 1.93 (m, 1 H), 2.5 (m, 4 H), 3.64 (m, 2 H), 3.72 (m, 2 H), 3.86 (d, 2 H), 4.05 (m, 4 H), 4.57 (m, 2 H), 5.23 (br s, 1 H), 6.2 (s, 1 H), 6.15 (d, 1 H), 7.1 (m, 4 H), 7.36 (m, 2 H), 8.26 (d, 1 H)	Example 78
139	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-7-(2-pyrrolidin-1-ylethoxy)quinazoline-2,4-diamine	(CD ₃ OD): 0.67 (m, 2 H), 0.9 (m, 2 H), 1.5 (d, 3 H), 1.8 (m, 4 H), 1.99 (m, 1 H), 2.73 (s, 4 H), 2.9 (m, 2 H), 4.17 (m, 2 H), 5.2 (br s, 1 H), 6.78 (m, 2 H), 7.0 (m, 2 H), 7.37 (s, 2 H), 7.91 (d, 1 H)	Example 78
140	N ⁴ -(5-Cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-1-(4-fluorophenyl)ethyl]-6-(2-pyrrolidin-1-ylethoxy)quinazoline-2,4-diamine	(CD ₃ OD): 0.74 (m, 2 H), 1.04 (m, 2 H), 1.60 (d, 3 H), 1.93 (m, 1 H), 1.99 (m, 2 H), 2.00 (m, 2 H), 3.23 (m, 2 H), 3.74 (m, 4 H), 4.51 (d, 2 H), 5.22 (m, 1 H), 6.14 (s, 1 H), 7.02 (m, 2 H), 7.09 (m, 2 H), 7.33 (m, 2 H), 8.25 (d, 1 H)	Example 81

Example 141

(2S)-3-[(4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-2-[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}quinazolin-7-yl)oxy]propane-1,2-diol

- 5 A mixture of (2R)-2-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-7-fluoroquinazolin-2-yl}amino)-2-(4-fluorophenyl)ethanol (Example 78, 50 mg, 0.12 mmol), [(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol (0.4 ml) and potassium *tert*-butoxide (100 mg, 0.9 mmol) was stirred at 120°C overnight. Aqueous work up provided a residue. To a solution of this residue

in MeOH (2 ml) was added two drops of water and para-toluenesulfonic acid monohydrate (7 mg, 0.037 mmol) and the reaction mixture was stirred at room temperature for 20 hours.

Reverse phase HPLC (Gilson) purification gave the desired product as a solid. ¹H NMR: δ 0.70 (m, 2 H), 0.97 (m, 2 H), 1.91 (m, 1 H), 3.45 (m, 2 H), 3.60 – 4.00 (m, 4 H), 4.18 (m, 1 H), 5.14 (m, 1 H), 6.09 (m, 1 H), 6.90 – 7.50 (m, 6 H), 8.50 (m, 1 H), 8.63 (m, 1 H), 11.22 (m, 1 H), 12.21 (br s, 1 H).

Example 142

Following a similar procedure to Example 141, the following compound was synthesized via reaction of a suitable quinazoline (method of production of which is also listed).

Ex.	Compound	¹ H NMR	SM
142	(2R)-3-[(4-[(5-Cyclopropyl-1H-pyrazol-3-yl)amino]-2-[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}quinazolin-7-yl)oxy]propane-1,2-diol	0.70 (m, 2 H), 0.97 (m, 2 H), 1.91 (m, 1 H), 3.45 (m, 2 H), 3.60 – 4.00 (m, 4 H), 4.18 (m, 1 H), 5.14 (m, 1 H), 6.09 (m, 1 H), 6.90 – 7.50 (m, 6 H), 8.50 (m, 1 H), 8.63 (m, 1 H), 11.22 (m, 1 H), 12.21 (br s, 1 H)	Example 78

Example 143

(2R)-2-({5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-[(2-morpholin-4-ylethyl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol

A mixture of (2-morpholin-4-ylethyl)amine (44 µl, 0.34 mmol), (2R)-2-({4,5-dichloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol (Example 84, 70 mg, 0.16 mmol) in 1-butanol (1.0 ml) was heated at 120°C for 18 hours. The solvent was removed and EtOAc was added. The solution was washed with water and was concentrated. Semi-prep HPLC (Gilson system) provided product as a solid (92 mg). ¹H NMR (CDCl₃): 0.67 (m, 2 H), 0.92 (m, 2 H), 1.86 (m, 1 H), 3.01 (m, 2 H), 3.22 (m, 2 H), 3.46 (m, 2 H), 3.63 (m, 4 H), 3.86 (m, 2 H), 3.98 (m, 2 H), 4.89 (m, 1 H), 5.93 (s, 1 H), 7.14 (m, 2 H), 7.38 (m, 2 H), 7.95 (br s, 1 H), 9.15 (br s, 1 H), 9.54 (br s, 1 H).

Example 144-176

Following a similar procedure to Example 143, the following compounds were synthesized via reaction of a suitable pyrimidine or quinazoline (method of production of which is also listed) and a suitable amine.

Ex.	Compound	¹ H NMR	SM
144	3-[(5-Chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[[[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}pyrimidin-4-yl)amino]propane-1,2-diol	0.69 (m, 2 H), 0.98 (m, 2 H), 1.93 (m, 1 H), 3.13-3.65 (m, 7 H), 4.96 (m, 1 H), 5.86 (s, 1 H), 7.13 (m, 2 H), 7.39 (m, 2 H), 8.67 (br s, 1 H), 9.73 (br s, 1 H)	Example 84
145	3-[(5-Chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[[[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl] amino}pyrimidin-4-yl)amino]propan-1-ol	0.69 (m, 2 H), 0.98 (m, 2 H), 1.51 (m, 2 H), 1.91 (m, 1 H), 3.30-3.64 (m, 6 H), 4.92 (m, 1 H), 5.86 (s, 1 H), 7.13 (m, 2 H), 7.36 (m, 2 H), 7.64 (br s, 1 H), 8.65 (br s, 1 H), 9.68 (br s, 1 H)	Example 84
146	(2R)-2-[(5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-{[3-(4-methyl piperazin-1-yl)propyl]amino}pyrimidin-2-yl)amino]-2-(4-fluorophenyl)ethanol	0.69 (m, 2 H), 0.96 (m, 2 H), 1.63 (m, 2 H), 1.93 (m, 1 H), 2.77 (m, 5 H), 3.17-3.33 (m, 10 H), 3.66 (m, 2 H), 4.92 (m, 1 H), 5.88 (s, 1 H), 7.15 (m, 2 H), 7.39 (m, 2 H), 7.61 (br s, 1 H), 8.53 (br s, 1 H), 9.67 (br s, 1 H)	Example 84
147	(2R)-2-[(5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl) amino]-6-[(2-pyrrolidin-1-ylethyl)amino]pyrimidin-2-yl} amino)-2-(4-fluorophenyl) ethanol	0.67 (m, 2 H), 0.91 (m, 2 H), 1.88 (m, 5 H), 2.80-3.63 (m, 10 H), 4.89 (m, 1 H), 5.93 (s, 1 H), 7.14 (m, 2 H), 7.38 (m, 2 H), 7.95 (br s, 1 H), 9.2 (br s, 1 H), 9.28 (br s, 1 H)	Example 84

Ex.	Compound	¹ H NMR	SM
148	6-[(3-Cyclopropyl-1 <i>H</i> -pyrazol-5-yl)amino]-2-{[(1 <i>R</i>)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}- <i>N</i> -(2-morpholin-4-ylethyl)pyrimidine-4-carboxamide	0.69 (m, 2 H), 0.93 (m, 5 H), 1.86 (m, 1 H), 3.12 (m, 2 H), 3.64-3.96 (m, 12 H), 5.03 (m, 1 H), 5.34 (s, 1 H), 6.03 (s, 1 H), 6.68 (s, 1 H), 7.15 (m, 2 H), 7.41 (m, 2 H), 8.66 (br s, 1 H), 9.08 (br s, 1 H), 9.73 (br s, 1 H), 9.97 (br s, 1 H)	Example 28
149	(2 <i>R</i>)-3-[(6-[(5-Cyclopropyl-1 <i>H</i> -pyrazol-3-yl)amino]-2-{[(1 <i>S</i>)-1-(4-fluorophenyl)ethyl]amino}pyrimidin-4-yl)amino]propane-1,2-diol	0.65 (m, 2 H), 0.90 (m, 2 H), 1.45 (m, 3 H), 1.80 (m, 1 H), 3.10 – 3.50 (m, 5 H), 4.95 (br s, 1 H), 5.35 (s, 1 H), 5.45 (m, 1 H), 7.10 (m, 2 H), 7.35 (m, 2 H), 8.10 (s, 1 H), 8.70 (s, 1 H), 10.20 (br s, 1 H), 11.45 (br s, 1 H)	Example 38
150	(2 <i>R</i>)-3-({2-{[(1 <i>S</i>)-1-(4-Fluorophenyl)ethyl]amino}-6-[(5-methyl-1 <i>H</i> -pyrazol-3-yl)amino]pyrimidin-4-yl}amino)propane-1,2-diol	1.40 (m, 3 H), 2.15 (s, 3 H), 3.10 – 3.90 (m, 5 H), 4.95 (br s, 1 H), 5.35 (s, 1 H), 5.65 (m, 1 H), 7.10 (m, 2 H), 7.35 (m, 2 H), 8.10 (s, 1 H), 8.78 (s, 1 H), 10.20 (br s, 1 H), 11.55 (br s, 1 H)	Example 190
151	2-[(6-[(5-Cyclopropyl-1 <i>H</i> -pyrazol-3-yl)amino]-2-{[(1 <i>S</i>)-1-(4-fluorophenyl)ethyl]amino}pyrimidin-4-yl)amino]ethanol	0.65 (m, 2 H), 0.85 (m, 2 H), 1.45 (m, 3 H), 1.80 (m, 1 H), 3.10 – 3.50 (m, 4 H), 4.95 (br s, 1 H), 5.35 (s, 1 H), 5.55 (m, 1 H), 7.10 (m, 2 H), 7.35 (m, 2 H), 8.10 (s, 1 H), 8.72 (s, 1 H), 10.20 (br s, 1 H), 11.45 (br s, 1 H)	Example 38
152	2-({2-{[(1 <i>S</i>)-1-(4-Fluorophenyl)ethyl]amino}-6-[(5-methyl-1 <i>H</i> -pyrazol-3-yl)amino]pyrimidin-4-yl}amino)ethanol	1.40 (m, 3 H), 2.20 (s, 3 H), 3.10 – 3.50 (m, 4 H), 4.90 (s, 1 H), 5.35 (s, 1 H), 5.71 (m, 1 H), 7.10 (m, 2 H), 7.35 (m, 2 H), 8.10 (s, 1 H), 8.78 (s, 1 H), 10.22 (br s, 1 H), 11.50 (br s, 1 H)	Example 190

Ex.	Compound	¹ H NMR	SM
153	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-(4-fluoro-phenyl)-ethyl]-pyrimidine-2,4,6-triamine	0.60 (m, 2 H), 0.82 (m, 2 H), 1.41 (d, J = 7.2 Hz, 3 H), 1.83 (m, 1 H), 4.99 (m, 1 H), 5.67 (br s, 1 H), 6.11-6.29 (m, 2.5 H), 6.81 (br s, 0.5 H), 7.11 (m, 2 H), 7.38 (m, 2.5 H), 7.56 (br s, 0.5 H), 8.97 (br s, 0.5 H), 11.90 (s, 0.5 H), 12.40 (br s, 0.5 H)	Example 39
154	5-Chloro-N ⁴ -(5-cyclopropyl-1H-pyrazol-3-yl)-N ² -[(1S)-(4-fluoro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-pyrimidine-2,4-diamine	0.71 (m, 2 H), 0.91 (m, 2 H), 1.51 (d, J = 6.4 Hz, 3 H), 1.86 (m, 1 H), 2.31 (s, 3 H), 2.46 (m, 4 H), 3.46 (m, 4 H), 4.96 (m, 1 H), 5.08 (d, J = 6.4 Hz, 1 H), 5.83 (br, 1 H), 7.01 (m, 2 H), 7.29 (m, 3 H),	Example 39
155	1-Amino-3-[(5-chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[(1S)-1-(4-fluorophenyl)ethyl]amino)pyrimidin-4-yl)amino]propan-2-ol	0.63 (m, 2 H), 0.90 (m, 2 H), 1.41 (d, 3 H), 1.85 (m, 1 H), 2.82 (m, 2 H), 3.51 (m, 2 H), 3.83 (m, 1 H), 4.95 (m, 1 H), 5.58 (br s, 1 H), 5.90 (s, 1 H), 6.94 (s, 1 H), 7.11 (m, 2 H), 7.28 (s, 1 H), 7.39 (m, 2 H), 7.72 (m, 2 H)	Example 39
156	(2R)-2-[(5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-[(2-(dimethylamino)ethyl)amino]pyrimidin-2-yl)amino]-2-(4-fluorophenyl)ethanol	0.67 (m, 2 H), 0.92 (m, 2 H), 1.87 (m, 1 H), 2.59 (s, 3 H), 2.75 (s, 3 H), 2.83 - 3.57 (m, 4 H), 3.62 (m, 2 H), 4.90 (m, 1 H), 5.92 (s, 1 H), 7.13 (m, 2 H), 7.37 (m, 2 H), 7.93 (br s, 1 H), 9.16 (m, 2 H)	Example 84
157	(2R)-2-({5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-[(3-pyrrolidin-1-ylpropyl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.67 (m, 2 H), 0.95 (m, 2 H), 1.83 - 1.97 (m, 7 H), 2.85 - 3.64 (m, 10 H), 4.92 (m, 1 H), 5.89 (s, 1 H), 7.15 (m, 2 H), 7.38 (m, 2 H), 8.26 (br s, 1 H), 9.41 (br s, 1 H), 9.56 (br s, 1 H)	Example 84

Ex.	Compound	¹ H NMR	SM
158	2-[(5-Chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino}pyrimidin-4-yl)amino]ethanol	0.68 (m, 2 H), 0.96 (m, 2 H), 1.45 (d, 3 H), 1.90 (m, 1 H), 3.37 - 3.54 (m, 4 H), 4.97 (m, 1 H), 5.85 (s, 1 H), 7.14 (m, 2 H), 7.39 (m, 2 H), 7.47 (br s, 1 H), 8.59 (br s, 1 H), 9.72 (br s, 1 H)	Example 39
159	2-[(5-Chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino}pyrimidin-4-yl)amino]propane-1,3-diol	0.68 (m, 2 H), 0.96 (m, 2 H), 1.45 (d, 3 H), 1.91 (m, 1 H), 3.33 - 3.56 (m, 4 H), 4.04 (m, 1 H), 4.98 (m, 1 H), 5.86 (s, 1 H), 6.68 (br s, 1 H), 7.14 (m, 2 H), 7.42 (m, 2 H), 8.54 (br s, 1 H), 9.73 (br s, 1 H)	Example 39
160	(2R)-2-{{[5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-(dimethylamino)pyrimidin-2-yl]amino}-2-(4-fluorophenyl)ethanol	0.68 (m, 2 H), 0.96 (m, 2 H), 1.90 (m, 1 H), 3.00 (s, 6 H), 3.61 (m, 2 H), 4.88 (m, 1 H), 5.94 (s, 1 H), 7.13 (m, 2 H), 7.37 (m, 2 H), 8.19 (br s, 1 H), 9.47 (br s, 1 H).	Example 84
161	1-Amino-3-[(5-chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[[[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}pyrimidin-4-yl)amino]propan-2-ol	0.69 (m, 2 H), 0.96 (m, 2 H), 1.92 (m, 1 H), 2.82 (m, 2 H), 3.24 - 3.65 (m, 5 H), 4.96 (m, 1 H), 5.89 (s, 1 H), 7.14 (m, 2 H), 7.41 (m, 2 H), 7.76 (b, 2 H), 8.43 (br s, 1 H), 9.62 (br s, 1 H)	Example 84
162	2-[(5-Chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}pyrimidin-4-yl)amino]propane-1,3-diol	0.69 (m, 2 H), 0.97 (m, 2 H), 1.92 (m, 1 H), 3.28 - 3.66 (m, 5 H), 3.98 (m, 2 H), 4.93 (m, 1 H), 5.87 (s, 1 H), 6.62 (br s, 1 H), 7.13 (m, 2 H), 7.39 (m, 2 H), 8.54 (br s, 1 H), 9.64 (br s, 1 H)	Example 84

Ex.	Compound	¹ H NMR	SM
163	(2R)-2-[(5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-[[2-(2-hydroxyethoxy)ethyl]amino}pyrimidin-2-yl)amino]-2-(4-fluorophenyl)ethanol	0.69 (m, 2 H), 0.97 (m, 2 H), 1.92 (m, 1 H), 3.41 - 3.64 (m, 10 H), 4.89 (m, 1 H), 5.87 (s, 1 H), 7.14 (m, 2 H), 7.35 (m, 2 H), 7.50 (br s, 1 H), 8.57 (br s, 1 H), 9.67 (br s, 1 H)	Example 84
164	(2R)-3-[(5-Chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino}pyrimidin-4-yl)amino]propane-1,2-diol	0.69 (m, 2 H), 0.98 (m, 2 H), 1.45 (d, 3 H), 1.93 (m, 1 H), 3.30 - 3.54 (m, 5 H), 5.02 (m, 1 H), 5.86 (s, 1 H), 7.14 (m, 2 H), 7.42 (m, 2 H), 8.67 (br s, 1 H), 9.81 (br s, 1 H)	Example 39
165	(2R)-2-[[5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-(ethylamino)pyrimidin-2-yl]amino]-2-(4-fluorophenyl)ethanol	0.69 (m, 2 H), 0.98 (m, 5 H), 1.93 (m, 1 H), 3.20 - 3.64 (m, 4 H), 4.91 (m, 1 H), 5.86 (s, 1 H), 7.14 (m, 2 H), 7.36 (m, 2 H), 7.72 (br s, 1 H), 8.70 (br s, 1 H), 9.73 (br s, 1 H)	Example 84
166	(2S)-3-[(5-Chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[[[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}pyrimidin-4-yl)amino]propane-1,2-diol	0.69 (m, 2 H), 0.99 (m, 2 H), 1.93 (m, 1 H), 3.10 (m, 1 H), 3.32 (m, 2 H), 3.45 (m, 2 H), 3.65 (m, 2 H), 4.96 (m, 1 H), 5.86 (s, 1 H), 7.13 (m, 2 H), 7.39 (m, 2 H), 7.47 (br s, 1 H), 8.73 (br s, 1 H), 9.78 (br s, 1 H)	Example 84
167	(2R)-3-[(5-Chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[[[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}pyrimidin-4-yl)amino]propane-1,2-diol	0.70 (m, 2 H), 0.97 (m, 2 H), 1.91 (m, 1 H), 3.54 (m, 7 H), 4.97 (m, 1 H), 5.86 (s, 1 H), 7.13 (m, 2 H), 7.38 (m, 2 H), 7.47 (br s, 1 H), 8.73 (br s, 1 H), 9.80 (br s, 1 H)	Example 84

Ex.	Compound	¹ H NMR	SM
168	(2R)-2-({5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-[(2-hydroxyethyl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.70 (m, 2 H), 0.97 (m, 2 H), 1.93 (m, 1 H), 3.33 (m, 4 H), 3.65 (m, 2 H), 4.92 (m, 1 H), 5.86 (s, 1 H), 7.14 (m, 2 H), 7.37 (m, 2 H), 7.57 (br s, 1 H), 8.72 (br s, 1 H), 9.78 (br s, 1 H)	Example 84
169	(2R)-2-{{5-Chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino}-2-(4-fluorophenyl)ethanol	0.70 (m, 2 H), 0.97 (m, 2 H), 1.94 (m, 1 H), 2.78 (s, 3 H), 3.67 (m, 2 H), 4.97 (m, 1 H), 5.85 (s, 1 H), 7.15 (m, 2 H), 7.38 (m, 2 H), 7.72 (br s, 1 H), 8.80 (br s, 1 H), 9.82 (br s, 1 H)	Example 84
170	(2S)-1-[(5-Chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[(1S)-1-(4-fluorophenyl)ethyl]amino}pyrimidin-4-yl)amino]propan-2-ol	0.69 (m, 2 H), 0.96 (m, 5 H), 1.45 (d, 3 H), 1.94 (m, 1 H), 3.11 (m, 1 H), 3.29 (m, 1 H), 3.54 (m, 1 H), 4.99 (m, 1 H), 5.86 (s, 1 H), 7.14 (m, 2 H), 7.38 (m, 2 H), 7.55 (br s, 1 H), 8.71 (br s, 1 H), 9.89 (br s, 1 H)	Example 39
171	3-[(5-Chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[(1S)-1-(4-fluorophenyl)ethyl]amino}pyrimidin-4-yl)amino]-1,1,1-trifluoropropan-2-ol	0.69 (m, 2 H), 0.96 (m, 2 H), 1.44 (d, 3 H), 1.93 (m, 1 H), 3.27 (m, 1 H), 3.60 (m, 1 H), 4.20 (m, 1 H), 4.96 (m, 1 H), 5.89 (s, 1 H), 6.40 (br s, 1 H), 7.11 (m, 2 H), 7.34 (m, 2 H), 7.50 (br s, 1 H), 8.44 (br s, 1 H), 9.67 (br s, 1 H)	Example 39
172	3-[(5-Chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[(1S)-1-(4-fluorophenyl)ethyl]amino}pyrimidin-4-yl)(methylamino)propane-1,2-diol	0.67 (m, 2 H), 0.92 (m, 2 H), 1.42 (d, 3 H), 1.87 (m, 1 H), 3.15 (s, 3 H), 3.29 - 3.98 (m, 5 H), 4.95 (m, 1 H), 5.94 (s, 1 H), 7.12 (m, 2 H), 7.38 (m, 2 H)	Example 39

Ex.	Compound	¹ H NMR	SM
173	5-Chloro- <i>N</i> ⁴ -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)- <i>N</i> ² -[(1 <i>S</i>)-1-(4-fluorophenyl)ethyl]-6-morpholin-4-ylpyrimidine-2,4-diamine	0.70 (m, 2 H), 0.96 (m, 2 H), 1.42 (d, 3 H), 1.92 (m, 1 H), 3.42 (m, 4 H), 3.58 (m, 4 H), 4.92 (m, 1 H), 6.00 (s, 1 H), 7.12 (m, 2 H), 7.37 (m, 2 H), 8.07 (br s, 1 H), 9.59 (br s, 1 H)	Example 39
174	(2 <i>R</i>)-2-({5-Chloro-4-[(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)amino]-6-morpholin-4-ylpyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	0.70 (m, 2 H), 0.95 (m, 2 H), 1.91 (m, 1 H), 3.38 (m, 4 H), 3.62 (m, 6 H), 4.86 (m, 1 H), 6.00 (s, 1 H), 7.12 (m, 2 H), 7.35 (m, 2 H), 8.01 (br s, 1 H), 9.45 (br s, 1 H)	Example 84
175	(2 <i>R</i>)-2-{{[5-Chloro-4-[(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)amino]-6-(4-methylpiperazin-1-yl)pyrimidin-2-yl]amino}-2-(4-fluorophenyl)ethanol	0.69 (m, 2 H), 0.92 (m, 2 H), 1.88 (m, 1 H), 2.77 (m, 4 H), 3.10 (s, 3 H), 3.40 (m, 2 H), 3.62 (m, 2 H), 3.99 (m, 2 H), 4.85 (m, 1 H), 6.08 (s, 1 H), 7.11 (m, 2 H), 7.36 (m, 2 H), 7.72 (br s, 1 H), 9.12 (br s, 1 H), 9.98 (br s, 1 H)	Example 84
176	5-Chloro- <i>N</i> ⁴ -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)- <i>N</i> ² -[(1 <i>S</i>)-1-(4-fluorophenyl)ethyl]-6-pyrrolidin-1-ylpyrimidine-2,4-diamine	0.69 (m, 2 H), 0.98 (m, 2 H), 1.44 (d, 3 H), 1.82 (m, 4 H), 1.93 (m, 1 H), 3.59 (m, 2 H), 3.71 (m, 2 H), 4.96 (m, 1 H), 5.90 (s, 1 H), 7.15 (m, 2 H), 7.39 (m, 2 H), 8.55 (br s, 1 H), 9.79 (br s, 1 H)	Example 39

Example 177

(2*R*)-3-[(5-Chloro-6-[(3-ethoxy-1*H*-pyrazol-5-yl)amino]-2-[(1*S*)-1-(4-fluorophenyl)ethyl]amino}pyrimidin-4-yl)amino]propane-1,2-diol

- 5 A mixture of 5,6-dichloro-*N*⁴-(5-ethoxy-1*H*-pyrazol-3-yl)-*N*²-[(1*S*)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine (Example 191; 188 mg, 0.46 mmol), (2*R*)-3-aminopropane-1,2-diol (96 mg, 1.05 mmol) in *n*-butanol (2.5 ml) was heated at 112°C for 2 days. The mixture was concentrated. Reverse phase HPLC (Gilson) purification gave the title compound (18 mg). ¹H NMR (CDCl₃): δ 1.29 (t, 3 H), 1.40 (d, 3 H), 3.18 - 3.61 (m, 5 H),

4.08 (q, 2 H), 4.93 (m, 1 H), 5.44 (s, 1 H), 6.59 (br s, 1 H), 7.11 (m, 2 H), 7.38 (m, 2 H), 7.86 (br s, 1 H), 9.27 (br s, 1 H).

Example 178-181

5 Following a similar procedure to Example 177, the following compounds were synthesized via reaction of a suitable pyrimidine (method of production of which is also listed) and a suitable amine.

Ex.	Compound	¹ H NMR	SM
178	(2R)-3-({5-Chloro-2-([(1S)-1-(4-fluorophenyl)ethyl]amino)-6-[(3-isopropoxy-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}amino)propane-1,2-diol	1.27 (d, 6 H), 1.41 (d, 3 H), 3.19 - 3.51 (m, 5 H), 4.60 (m, 1 H), 4.94 (m, 1 H), 5.44 (s, 1 H), 6.69 (br s, 1 H), 7.11 (m, 2 H), 7.39 (m, 2 H), 7.96 (br s, 1 H), 9.34 (br s, 1 H)	Example 192
179	(2R)-3-({5-Chloro-2-([(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino)-6-[(3-isopropoxy-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}amino)propane-1,2-diol	1.27 (d, 6 H), 3.17 - 3.49 (m, 5 H), 3.62 (m, 2 H), 4.62 (m, 1 H), 4.91 (m, 1 H), 5.45 (s, 1 H), 6.67 (br s, 1 H), 7.10 (m, 2 H), 7.36 (m, 2 H), 7.99 (br s, 1 H), 9.32 (br s, 1 H)	Example 194
180	2-({5-Chloro-2-([(1S)-1-(4-fluorophenyl)ethyl]amino)-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]pyrimidin-4-yl}amino)propane-1,3-diol	1.30 (d, 6 H), 1.46 (d, 3 H), 3.33 - 3.55 (m, 4 H), 4.04 (m, 1 H), 4.55 (m, 1 H), 4.98 (m, 1 H), 5.63 (s, 1 H), 6.70 (br s, 1 H), 7.13 (m, 2 H), 7.40 (m, 2 H), 8.81 (br s, 1 H), 9.97 (br s, 1 H)	Example 192
181	2-({5-Chloro-2-([(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino)-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]pyrimidin-4-yl}amino)propane-1,3-diol	1.27 (d, 6 H), 3.27 (m, 1 H), 3.38 (m, 1 H), 3.51 (m, 2 H), 3.61 (m, 2 H), 3.93 (m, 1 H), 4.61 (m, 1 H), 4.88 (m, 1 H), 5.42 (s, 1 H), 5.90 (bs, 1 H), 7.10 (m, 2 H), 7.37 (m, 2 H), 7.87 (br s, 1 H), 9.24 (br s, 1 H), 11.95 (br s, 1 H)	Example 193

Example 182

N^4 -(5-Cyclopropyl-2H-pyrazol-3-yl)- N^2 -[(S)-1-(4-fluorophenyl)-ethyl]-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidine-2,4-diamine

4-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-[(S)-1-(4-fluoro-phenyl)-ethylamino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylic acid benzyl ester (Example 188; 0.06 g, 0.11 mmol) was dissolved in absolute EtOH (4 ml), to which was added Pd/C (0.012 g, 0.005 mmol). The reaction mixture was then purged with N₂, evacuated, purged with H₂, and stirred under H₂ at atmospheric pressure for 15 hours. The Pd/C was removed by filtration and washed with MeOH (2 x 2 ml). The filtrate was concentrated under reduced pressure and purified by column chromatography (DCM: MeOH = 20: 1) to give the title compound as a white solid (0.02 g, 44%). ¹H NMR (400 MHz, CDCl₃) δ 0.62 - 0.66 (m, 2 H), 0.87 - 0.91 (m, 2 H), 1.47 (d, *J* = 6.4 Hz, 3 H), 1.73 - 1.81 (m, 1 H), 2.51 - 2.59 (m, 2 H), 2.99 - 3.09 (m, 2 H), 3.58 - 3.67 (m, 2 H), 4.99 - 5.06 (m, 1 H), 5.19 (br s, 2 H), 5.89 (br s, 1 H), 6.74 (br s, 1 H), 6.94 - 6.98 (m, 2 H), 7.29 - 7.33 (m, 2 H). MS: Calcd.: 393; Found: [M+H]⁺ 394.

15

Example 183

N^4 -(5-Cyclopropyl-1H-pyrazol-3-yl)- N^2 -[(S)-1-(4-fluoro-phenyl)-ethyl]-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine-2,4-diamine

To an EtOH (20 ml) solution of N^4 -(5-cyclopropyl-1H-pyrazol-3-yl)- N^2 -[(1S)-1-(4-fluorophenyl)ethyl]pyrido[2,3-d]pyrimidine-2,4-diamine (Example 65; 0.3 g, 0.77 mmol) was added platinum oxide (0.017 g, 0.077 mmol). The reaction was then purged with N₂, evacuated, and then purged with H₂, and stirred for 15 hours. The reaction was then diluted with MeOH (20 ml) and filtered to remove platinum. The filtrate was concentrated under reduced pressure and purified by column chromatography (DCM: MeOH = 40: 1) to give the title compound as a solid (0.25 g, 83%). ¹H NMR (400 MHz, CDCl₃) δ 0.62 - 0.66 (m, 2 H), 0.84 - 0.87 (m, 2 H), 1.44 (d, *J* = 6.4 Hz, 3 H), 1.79 - 1.84 (m, 1 H), 1.85 - 1.91 (m, 2 H), 2.30 (t, *J* = 6.2 Hz, 2 H), 3.24 - 3.26 (m, 2 H), 4.79 (br s, 1 H), 4.98 (br s, 2 H), 6.54 (br s, 1 H), 6.93 - 6.97 (m, 2 H), 7.29 - 7.33 (m, 2 H). MS: Calcd.: 393; Found: [M+H]⁺ 394.

25

Example 184

*N*⁴-(5-Cyclopropyl-1*H*-pyrazol-3-yl)-*N*²-[(*S*)-1-(4-fluoro-phenyl)-ethyl]-5,6,7,8-tetrahydro-pyrido[3,4-*d*]pyrimidine-2,4-diamine

4-(5-Cyclopropyl-1*H*-pyrazol-3-ylamino)-2-[(*S*)-1-(4-fluoro-phenyl)-ethylamino]-5,8-dihydro-6*H*-pyrido[3,4-*d*]pyrimidine-7-carboxylic acid benzyl ester (Example 189; 0.7 g, 1.3 mmol) was dissolved in absolute EtOH (20 ml), and Pd/C (0.28 g, 0.13 mmol) was added. The reaction was then purged with N₂, evacuated, purged with H₂, and stirred for 15 hours. The reaction was then filtered to remove the palladium, washed with MeOH, concentrated, and purified by column chromatography (DCM: MeOH = 20: 1) to give the title compound
10 (0.50 g, 95%). ¹H NMR (400 MHz, CDCl₃) δ 0.67 - 0.69 (m, 2 H), 0.92 - 0.95 (m, 2 H), 1.51 (d, *J* = 6.8 Hz, 3 H), 1.80 - 1.88 (m, 1 H), 2.32 - 2.37 (m, 2 H), 3.12 - 3.15 (m, 2 H), 3.70 - 3.78 (m, 2 H), 5.03 - 5.10 (m, 1 H), 5.19 - 5.21 (m, 1 H), 5.91 (br s, 1 H), 6.73 (br s, 1 H), 6.98 - 7.02 (m, 2 H), 7.34 - 7.38 (m, 2 H). MS: Calcd.: 393; Found: [M+H]⁺ 394.

Example 185

1-{4-(5-Cyclopropyl-1*H*-pyrazol-3-ylamino)-2-[(*S*)-1-(4-fluoro-phenyl)-ethylamino]-7,8-dihydro-5*H*-pyrido[4,3-*d*]pyrimidin-6-yl}-ethanone

A solution of *N*⁴-(5-cyclopropyl-2*H*-pyrazol-3-yl)-*N*²-[(*S*)-1-(4-fluoro-phenyl)-ethyl]-5,6,7,8-tetrahydro-pyrido[4,3-*d*]pyrimidine-2,4-diamine (Example 182, 0.03 g, 0.08 mmol) in
20 DCM-THF (3 ml, 1 : 1, v/v) was agitated together with acetic acid loaded TFP (tetrafluorophenyl) resin (1.4 mmol/g, 1.0 eq.) for 40 minutes. The resin was filtered and washed with DCM (2 x 5 ml). The combined organic was concentrated and purified by prep. TLC (DCM: MeOH = 15: 1) to give the title compound (0.027 g, 81%). ¹H NMR (400 MHz, CDCl₃) δ 0.71 - 0.72 (m, 2 H), 0.90 - 0.92 (m, 2 H), 1.47 (d, *J* = 6.4 Hz, 3 H), 1.84 - 1.89 (m,
25 1 H), 2.20 (s, 3 H), 2.63 - 2.73 (m, 2 H), 3.56 - 3.77 (m, 2 H), 4.43 (d, *J* = 15.8 Hz, 1 H), 4.70 (d, *J* = 15.8 Hz, 1 H), 5.07 - 5.15 (m, 2 H), 5.99 (br s, 1 H), 6.94 - 6.99 (m, 2 H), 7.24 - 7.32 (m, 2 H), 9.28 (br s, 1 H). MS: Calcd.: 435; Found: [M+H]⁺ 436.

Example 186

30 1-{4-(5-Cyclopropyl-1*H*-pyrazol-3-ylamino)-2-[(*S*)-1-(4-fluoro-phenyl)-ethylamino]-5,8-dihydro-6*H*-pyrido[3,4-*d*]pyrimidin-7-yl}-ethanone

A solution of *N*⁴-(5-cyclopropyl-1*H*-pyrazol-3-yl)-*N*²-[(*S*)-1-(4-fluoro-phenyl)-ethyl]-5,6,7,8-tetrahydro-pyrido[2,3-*d*]pyrimidine-2,4-diamine (Example 184; 0.05 g, 0.13 mmol) in

DCM: THF (3 ml, 1 : 1, v/v) was agitated together with acetic acid loaded TFP resin (1.4 mmol/g, 1.0 eq.) for 40 minutes. The resin was filtered and washed with DCM (2 x 5 ml). The combined organic was concentrated and purified by prep. TLC (DCM: MeOH = 13: 1) to give the title compound (0.023 g, 41%). ¹H NMR (400 MHz, CDCl₃) δ 0.68 - 0.70 (m, 2 H), 0.93 - 0.95 (m, 2 H), 1.52 (d, *J* = 6.2 Hz, 3 H), 1.82 - 1.85 (m, 1 H), 2.14 (s, 3 H), 2.36 - 2.46 (m, 2 H), 3.65 - 3.90 (m, 2 H), 4.31 - 4.49 (m, 2 H), 5.07 - 5.17 (m, 2 H), 6.05 (br s, 1 H), 6.96 - 7.01 (m, 2 H), 7.30 - 7.36 (m, 2 H). MS: Calcd.: 435; Found: [M+H]⁺ 436.

Example 187

10 5-Chloro-*N*⁴-(5-cyclopropyl-1*H*-pyrazol-3-yl)-*N*²-[2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine

The title compound was synthesized in a similar fashion to Example 1 using [2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]amine (synthesized following the procedure of *Tetrahedron Asymmetry* **2002**, *13*, 2335-44). ¹H NMR: δ 0.73 (m, 2 H), 0.94 (m, 2 H), 1.92 (m, 1 H), 5.96 (m, 1 H), 6.16 (m, 2 H), 7.24 (m, 2 H), 7.63 (m, 2 H), 8.01 (s, 1 H), 8.16 (br s, 1 H), 8.80 (br s, 1 H).

Example 188

20 4-(5-Cyclopropyl-1*H*-pyrazol-3-ylamino)-2-[(*S*)-1-(4-fluoro-phenyl)-ethylamino]-7,8-dihydro-5*H*-pyrido[4,3-*d*]pyrimidine-6-carboxylic acid benzyl ester

A solution of 4-(5-cyclopropyl-1*H*-pyrazol-3-ylamino)-2-methanesulfonyl-7,8-dihydro-5*H*-pyrido[4,3-*d*]pyrimidine-6-carboxylic acid benzyl ester (Method 144; 0.10 g, 0.21 mmol), (*S*)-1-(4-fluoro-phenyl)-ethylamine (0.30 g, 2.1 mmol), and DIPEA (0.27 g, 2.1 mmol) in *n*-BuOH (3 ml) was heated to 110 °C in a sealed tube for 48 hours. The reaction was cooled to 25 °C, concentrated under reduced pressure, acidified with 0.5 N HCl (50 ml), and extracted with DCM (3 x 50 ml). The combined organic layer was dried over MgSO₄, concentrated, and purified by column chromatography (DCM: MeOH = 80: 1) to give the title compound (0.6 g, 54%). MS: Calcd.: 527; Found: [M+H]⁺ 528.

Example 189

4-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-[(S)-1-(4-fluoro-phenyl)-ethylamino]-5,8-dihydro-6H-pyrido[3,4-d]pyrimidine-7-carboxylic acid benzyl ester

A mixture of 4-(5-cyclopropyl-1H-pyrazol-3-ylamino)-2-methanesulfonyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidine-7-carboxylic acid benzyl ester (Method 149; 2.0 g, 4.3 mmol), (S)-1-(4-fluoro-phenyl)-ethylamine (0.30 g, 2.1 mmol), and DIEA (5.5 g, 42.6 mmol) in *n*-BuOH (15 ml) was heated to 110 °C in a sealed tube for 48 hours, cooled to 25 °C, concentrated, acidified with 0.5 N HCl (100 ml), and extracted with DCM (3 x 150 ml). The combined organic layer was dried over MgSO₄, concentrated, and purified by column chromatography (DCM: MeOH = 80: 1) to give the title compound (0.7 g, 31%). MS: Calcd.: 527; Found: [M+H]⁺ 528.

Example 190

6-Chloro-N²-[(1S)-1-(4-fluorophenyl)ethyl]-N⁴-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine

This title compound was prepared in a similar way to the preparation of Example 1 using 2,6-dichloro-*N*-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine (Method 150) and [(1S)-1-(4-fluorophenyl)ethyl]amine. ¹H NMR: δ 1.45 (s, 3 H), 2.20 (m, 3 H), 5.10 (m, 1 H), 5.85 – 6.10 (m, 2 H), 7.10 (m, 2 H), 7.40 (m, 2 H), 7.80 (m, 1 H), 8.60 (m, 1 H).

Example 191

5,6-Dichloro-N⁴-(5-ethoxy-1H-pyrazol-3-yl)-N²-[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine

A mixture of 2,5,6-trichloro-*N*-(3-ethoxy-1H-pyrazol-5-yl)pyrimidin-4-amine (Method 40; 300 mg, 0.98 mmol), [(1S)-1-(4-fluorophenyl)ethyl]amine (163 mg, 1.2 mmol) and triethylamine (0.16 ml) in *n*-butanol (2 ml) was heated at 106°C for 3 days. The mixture was concentrated. Reverse phase HPLC (Gilson) purification gave the title compound (198 mg). ¹H NMR (CDCl₃): δ 1.40 (m, 3 H), 1.52 (m, 3 H), 4.18 (m, 2 H), 4.93 – 5.50 (m, 2 H), 7.11 (m, 2 H), 7.38 (m, 2 H).

Example 192-193

Following a similar procedure to Example 1, the following compounds were synthesized via reaction of a suitable pyrimidine (method of production of which is also listed) and a suitable amine.

Ex.	Compound	NMR	SM
192	5,6-Dichloro- <i>N</i> ² -[(1 <i>S</i>)-1-(4-fluorophenyl)ethyl]- <i>N</i> ⁴ -(3-isopropoxy-1 <i>H</i> -pyrazol-5-yl)pyrimidine-2,4-diamine	1.26 (m, 6 H), 1.41 (m, 1 H), 4.66 (m, 1 H), 4.95 (m, 1 H), 5.55 (m, 1 H), 7.14 (m, 2 H), 7.40 (m, 2 H), 8.18 (m, 1 H), 9.86 (br s, 1 H), 11.89 (br s, 1 H)	Method 38
193	(2 <i>R</i>)-2-({4,5-Dichloro-6-[(3-isopropoxy-1 <i>H</i> -pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol	1.26 (m, 6 H), 3.61 (m, 2 H), 4.66 (m, 1 H), 4.95 (m, 1 H), 5.00 (m, 1 H), 5.54 (m, 1 H), 7.14 (m, 2 H), 7.40 (m, 2 H), 8.18 (m, 1 H), 9.85 (br s, 1 H), 11.99 (br s, 1 H)	Method 38

Preparation of starting materials:

The starting materials for the Examples contained herein are either commercially available or are readily prepared by standard methods from known materials. For example the following reactions are illustrations but not limitations of the preparation of some of the starting materials and examples used herein.

Method 1**2,5-Dichloro-4-(5-cyclopropyl-1*H*-pyrazole-3-ylamino)pyrimidine**

A solution of 2,4,5-trichloropyrimidine (533 mg, 2.93 mmol), 3-amino-5-cyclopropyl-1*H*-pyrazole (360 mg, 2.93 mmol) and triethylamine (0.49 ml) in EtOH (5 ml) was stirred at room temperature for 10 hours. Solvent was removed and EtOAc was added. The solution was washed with water and dried over anhydrous sodium sulfate and was concentrated to give title compound as a white solid (546 mg, 69%). The compound was carried to the next step without further purification. ¹H NMR δ 0.92 (m, 2 H), 1.20 (m, 2 H), 2.18 (m, 1 H), 6.40 (s, 1 H), 8.60 (s, 1 H), 9.90 (s, 1 H), 12.60 (s, 1 H).

Method 2-19

The following compounds were prepared by the procedure of Method 1 using the appropriate starting materials.

Method	Compound	Pyrimidine	Amine
2	5-Bromo-2-chloro- <i>N</i> -(3-ethyl-1 <i>H</i> -pyrazol-5-yl)pyrimidin-4-amine	5-bromo-2,4-dichloropyrimidine	3-amino-5-ethyl-1 <i>H</i> -pyrazole
3	<i>N</i> -(3- <i>tert</i> -Butyl-1 <i>H</i> -pyrazol-5-yl)-2,5-dichloropyrimidin-4-amine	2,4,5-trichloropyrimidine	3-amino-5- <i>tert</i> -butyl-1 <i>H</i> -pyrazole
4 ^a	2-Chloro- <i>N</i> -(3-cyclopropyl-1 <i>H</i> -pyrazol-5-yl)-5-(trifluoromethyl)pyrimidin-4-amine	5-trifluoro-2,4-dichloropyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole
5	5-Bromo-2-chloro- <i>N</i> -(3-cyclopropyl-1 <i>H</i> -pyrazol-5-yl)pyrimidin-4-amine	5-bromo-2,4-dichloropyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole
6	5-Bromo- <i>N</i> -(5- <i>tert</i> -butyl-1 <i>H</i> -pyrazol-3-yl)-2-chloropyrimidin-4-amine	5-bromo-2,4-dichloropyrimidine	3-amino-5- <i>tert</i> -butyl-1 <i>H</i> -pyrazole
7	5-Bromo-2-chloro- <i>N</i> -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)-6-methylpyrimidin-4-amine	5-bromo-6-methyl-2,4-dichloropyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole
8 ^b	2-Chloro- <i>N</i> -(3-cyclopropyl-1 <i>H</i> -pyrazol-5-yl)pyrimidin-4-amine	2,4-dichloropyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole
9 ^b	2-Chloro- <i>N</i> -(3-cyclopropyl-1 <i>H</i> -pyrazol-5-yl)-5-methylpyrimidin-4-amine	5-methyl-2,4-dichloropyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole
10	Methyl 2-chloro-6-[(3-cyclopropyl-1 <i>H</i> -pyrazol-5-yl)amino]pyrimidine-4-carboxylate	6-methoxy carbonyl-2,4-dichloropyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole

Method	Compound	Pyrimidine	Amine
11	5-Bromo-2-chloro- <i>N</i> -(5-methyl-1 <i>H</i> -pyrazol-3-yl)pyrimidin-4-amine	5-bromo-2,4-dichloropyrimidine	3-amino-5-methyl-1 <i>H</i> -pyrazole
12	2,5-Dichloro- <i>N</i> -(5-methyl-1 <i>H</i> -pyrazol-3-yl)pyrimidin-4-amine	2,4,5-trichloropyrimidine	3-amino-5-methyl-1 <i>H</i> -pyrazole
13	2-Chloro- <i>N</i> -(3-cyclopropyl-1 <i>H</i> -pyrazol-5-yl)-5-fluoropyrimidin-4-amine	5-fluoro-2,4-dichloropyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole
14 ^b	2-Chloro- <i>N</i> -(3-cyclopropyl-1 <i>H</i> -pyrazol-5-yl)-6-methylpyrimidin-4-amine	6-methyl-2,4-dichloropyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole
15	2,6-Dichloro- <i>N</i> -(3-cyclopropyl-1 <i>H</i> -pyrazol-5-yl)pyrimidin-4-amine	2,4,6-trichloropyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole
16	2,5,6-Trichloro- <i>N</i> -(3-cyclopropyl-1 <i>H</i> -pyrazol-5-yl)pyrimidin-4-amine	2,4,5,6-tetrachloropyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole
17 ^c	Ethyl 2-chloro-6-[(3-cyclopropyl-1 <i>H</i> -pyrazol-5-yl)amino]pyrimidine-4-carboxylate	6-methoxy carbonyl-2,4-dichloropyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole
18	2-chloro- <i>N</i> -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)-5-nitropyrimidin-4-amine	2,4-dichloro-5-nitropyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole
19	2,5-dichloro- <i>N</i> -[3-(trifluoromethyl)-1 <i>H</i> -pyrazol-5-yl]pyrimidin-4-amine	2,4,5-trichloropyrimidine	3-(trifluoromethyl)-1 <i>H</i> -pyrazol-5-amine (Method 22)

^a The reaction is similar to Method 1 except that the reaction was performed at -20 °C

^b The reaction is similar to Method 1 except that the reaction was performed at 70 °C

^c The ethoxy group resulted from transesterification with solvent

Method 20**N-Methyl-1-pyridin-2-ylethanamine**

To 1-pyridin-2-ylethyl methanesulfonate (*Tetrahedron Asymmetry* 1994, 5, 1973-78; 800 mg, 4 mmol) was added methylamine (2.0 M in THF, 10 ml, 20 mmol) and the reaction mixture was stirred at 50°C overnight. The solvent was removed to give the desired product as an oil (544 mg, quantitative yield). ¹H NMR (CDCl₃): δ 1.40 (m, 3 H), 2.35 (s, 3 H), 3.75 (m, 1 H), 7.15 (m, 1 H), 7.25 (m, 1 H), 7.63 (m, 1 H), 8.56 (m, 1 H).

Method 21**1-Amino-1-phenylpropan-2-ol**

The diastereoisomeric mixture was prepared according in a similar fashion to a known procedure (*J. Org. Chem.* 1991, 56, 6939-6942).

Method 22**3-(Trifluoromethyl)-1H-pyrazol-5-amine**

A solution of 4,4,4-trifluoro-3-oxo-butyronitrile (Method 23; 11.0 g, 0.080 mol) and hydrazine monohydrate (3.89 ml, 0.080 mol) in EtOH (400 ml) was heated at reflux for 5 hours. After cooling to 25 °C, the solvent was removed under reduced pressure. The resulted residue was dissolved in DCM (500 ml), washed with brine (2 x 200 ml), and dried over Na₂SO₄. After evaporation of the solvent, the resulted residue was purified by column chromatography (hexane: EtOAc = 1: 1) to give the title compound as a pale yellow solid (1.93 g, 16%). ¹H NMR (400 MHz): δ 5.35 (s, 2 H), 5.56 (s, 1 H), 12.10 (br s, 1 H).

Method 23**4,4,4-Trifluoro-3-oxo-butyronitrile**

60% NaH (9.6 g, 0.24 mol) was suspended in dioxane (400 ml), to which was added acetonitrile (12.62 ml, 0.24 mol) dropwise. The reaction mixture was stirred at 25 °C for 30 minutes, followed by addition of ethyl trifluoroacetate (23.8 ml, 0.2 mol). The reaction mixture was heated to reflux for 3 hours, cooled to 25 °C, and quenched with water (400 ml). The unreacted starting material was extracted with DCM (100 ml). The aqueous layer was acidified with 10% HCl to pH 3 and extracted with DCM (100 ml). The organic layer was dried over Na₂SO₄, concentrated under reduced pressure, and purified by chromatography

(hexane: EtOAc = 5: 1) to give the title compound as a white solid (11.0 g, 40%). ^1H NMR (400 MHz, CDCl_3) δ 4.72 (s, 1 H).

Method 24

5 (1-Pyridin-2-ylethyl)amine

To a mixture of 1-pyridin-2-yl-ethanone (0.20 g, 1.65 mmol) and ammonium chloride (0.88 g, 16.5 mmol) in MeOH (5 ml) was added sodium cyanoborohydride (0.125 g, 1.98 mmol). The reaction was stirred at 25 °C for 64 hours and quenched by addition macroporous polystyrene sulfonic acid (MP-TsOH) (4.08 g, 16.5 mmol) resin. The suspension was agitated
10 for 1 hour. The resin was collected by filtration and washed with MeOH (3 x 20 ml, 20 minute shaking per wash). The resulted resin was then treated with NH_3/MeOH solution (7 M, 15 ml) for 20 minutes, filtered, and washed with MeOH (2 x 15 ml). The combined filtrate was concentrated until the crude weighed 200 mg. The crude product contained about 30% desired product, 35% alcohol, and 35% dimer as indicated by LC/MS, and was directly used
15 without further purification.

Method 25

(5-benzyl-2H-pyrazol-3-yl)-(2,5-dichloro-pyrimidin-4-yl)-amine

The solution of 2,4,5-trichloropyrimidine (0.150 g, 0.82 mmol), 5-benzyl-2H-pyrazol-
20 3-ylamine (Method 27; 0.129 g, 0.74 mmol), and triethylamine (0.155 ml, 1.12 mmol) in EtOH (5 ml) was heated to 55 °C for 5 hours and then stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure. The resulted yellow solid was stirred in hexanes: ether solution (1: 1), collected by filtration, and then recrystallized from DCM to give the title compound (0.212 g, 89%). ^1H NMR (400 MHz, CDCl_3) δ 4.10 (d, J =
25 15.2 Hz, 2 H), 6.89 (s, 1 H), 7.27 - 7.37 (m, 5 H), 8.28 (s, 1 H). MS: Calcd.: 319; Found: $[\text{M}+\text{H}]^+$ 320.

Method 26

3-Oxo-4-phenyl butyronitrile

30 NaH (60% in mineral oil, 0.48 g, 12.0 mmol) of) was suspended in dioxane (20 ml), to which was added acetonitrile (0.63 ml, 12 mmol) dropwise. The reaction was stirred for 20 minutes, followed by addition of ethyl phenylacetate (10 mmol) solution in dioxane (8 ml). The mixture was refluxed for 4 hours, cooled to 25 °C, and quenched with H_2O (40 ml). The

unreacted starting material was extracted with DCM (40 ml). The aqueous layer was acidified with 1 N HCl to pH 5 and extracted with DCM (40 ml). The organic layer was dried over anhydrous Na₂SO₄, concentrated, and purification by column chromatography (hexane: EtOAc = 3: 2) to afford the title compound (0.58 g, 36%). ¹H NMR (400 MHz, CDCl₃) δ 3.45 (s, 2 H), 3.85 (s, 2 H), 7.2 - 7.28 (m, 5 H). MS: Calcd.: 159; Found: [M-H]⁺ 158.

Method 27

5-Benzyl-2H-pyrazol-3-ylamine

10 A solution of 3-oxo-4-phenyl butyronitrile (Method 26; 0.58 g, 3.64 mmol) and hydrazine monohydrate (0.177 ml, 3.64 mmol) in EtOH (16 ml) was heated to reflux for 3 hours. After cooling to 25 °C, the reaction was concentrated under reduced pressure, extracted with DCM (15 ml), and washed twice with brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated to give an orange solid. The resulted solid was triturated with
15 hexanes: ether (1: 1) solution and collected by filtration to afford the title compound as a yellow solid (0.38 g, 60%). ¹H NMR (400 MHz, CDCl₃) δ 3.9 (s, 2 H), 4.89 (br s, 1 H), 5.44 (s, 1 H), 7.19 - 7.34 (m, 5 H). MS: Calcd.: 173; Found: [M+H]⁺ 174.

Method 28

(2,5-Dichloro-pyrimidin-4-yl)-(5-isopropyl-2H-pyrazol-3-yl)-amine

20 A solution of 5-isopropyl-2H-pyrazol-3-ylamine (Method 29; 0.093 g, 0.74 mmol), 2,4,5-trichloropyrimidine (0.150 g, 0.82 mmol), and triethylamine (0.36 ml, 2.6 mmol) in EtOH (5 ml) was heated to 55°C for 5 hours and stirred at 25 °C overnight. The reaction mixture was concentrated under reduced pressure, triturated with DCM to afford the title
25 compound (0.192, 95%). ¹H NMR (400 MHz, CDCl₃) δ 1.34 - 1.37 (d, J = 7.0 Hz, 6 H), 3.07 - 3.14 (q, 1 H), 6.72 (s, 1 H), 8.20 (s, 1 H). MS: Calcd.: 271; Found: [M+H]⁺ 272.

Method 29

5-Isopropyl-2H-pyrazol-3-ylamine

30 A solution of 4-methyl-3-oxo-pentanenitrile (Method 30; 0.42 g, 3.78 mmol) and hydrazine monohydrate (0.183 ml, 3.78 mmol) in EtOH (20 ml) was heated to reflux for 1 hour, cooled, and then concentrated under reduced pressure. The resulted oil was dissolved with DCM, washed with brine, dried over anhydrous Na₂SO₄, concentrated, and purification

by column chromatography (EtOAc: MeOH = 20: 1) to the title compound as an orange solid (0.26 g, 56%). ¹H NMR (400 MHz, CDCl₃) δ 1.21 - 1.23 (d, *J* = 7.0 Hz, 6 H), 2.82 - 2.89 (q, 1 H), 5.42 (s, 1 H). MS: Calcd.: 125; Found: [M+H]⁺ 126.

5 Method 30

4-Methyl-3-oxo-pentanenitrile

NaH (60% in mineral oil, 0.72 g, 18 mmol) was suspended in dioxane (20 ml), to which was carefully added ethyl isobutyrate (2.0 ml, 15 mmol) followed by addition of acetonitrile (0.95 ml, 18 mmol). The reaction mixture was refluxed for 5 hours, cooled, and quenched with water (40 ml). The unreacted starting material was extracted with DCM. The aqueous layer was acidified with 1 N HCl to pH 5 and extracted with DCM. The organic layer was dried over Na₂SO₄, concentrated, and purification by column chromatography (hexane: EtOAc = 3: 2) to give the title compound (0.43 g, 26%). ¹H NMR (400 MHz, CDCl₃) δ 1.13 - 1.15 (d, *J* = 7.0, 6 H), 2.73 - 2.79 (q, 1 H), 3.52 (s, 2 H). MS: Calcd.: 111; Found: [M-H]⁻ 110.

Method 31

5-Cyclopropylmethyl-2H-pyrazol-3-yl)-(2,5-dichloro-pyrimidin-4-yl)-amine

A solution of 2,4,5-trichloropyrimidine (0.2 g, 1.1 mmol), 5-cyclopropylmethyl-2H-pyrazol-3-ylamine (Method 32; 0.14 g, 0.99 mmol), and triethylamine (0.15 g, 1.5 mmol) in EtOH (5 ml) was heated to 55 °C overnight. The solvent was removed under reduced pressure and the resulted solid was triturated with DCM to afford the title compound as a white solid (0.206 g, 73%). ¹H NMR (400 MHz, CDCl₃) δ 0.008 (m, 2 H), 0.363 (m, 2 H), 0.801 (m, 1 H), 2.36 - 2.38 (d, *J* = 7.0 Hz, 2 H), 6.49 (s, 1 H), 7.93 (s, 1 H). MS: Calcd.: 283; Found: [M+H]⁺ 284.

Method 32

5-Cyclopropylmethyl-2H-pyrazol-3-ylamine

A solution of 4-cyclopropyl-3-oxo-butyronitrile (Method 33; 1.0 g, 8.1 mmol) and hydrazine monohydrate (0.4 g, 8.1 mmol) in EtOH (35 ml) was heated to reflux for 2 hours, cooled, and concentrated under reduced pressure. The resulted residue was taken up in DCM, washed with brine, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography (EtOAc: MeOH: Et₃N = 94 : 5 : 1) to afford the title compound

(0.464 g, 42%). ¹H NMR (400 MHz, CDCl₃) δ 0.005 (m, 2 H), 0.370 (m, 2 H), 0.78 (m, 1 H), 2.27 - 2.29 (d, *J* = 7.0 Hz, 2 H), 5.07 (br s, 1 H), 5.32 (s, 1 H). MS: Calcd.: 137; Found: [M+H]⁺ 138.

5 Method 33

4-Cyclopropyl-3-oxo-butyronitrile

Cyanoacetic acid (8.5 g, 100 mmol) solution in EtOAc (200 ml) was treated with anhydrous MgSO₄ and stirred for 20 minutes. MgSO₄ was removed by filtration and the filtrate was concentrated under reduced pressure. The resulted white solid was dissolved in THF (166 ml) and 5 mg of 2,2'-bipyridine was added as an indicator. The reaction solution was cooled to -78°C, to which was added *n*-butyllithium solution (80 ml, 199 mmol). The reaction mixture was allowed to warm to 0 °C gradually then cooled to -78 °C again, to which was added cyclopropyl-acetyl chloride (Method 34; 5.9 g, 50 mmol) in DCM (80 ml) via an addition funnel. The reaction mixture was then stirred at 25 °C for 1 hour, quenched with 2 N HCl and extracted with chloroform. The organic layer was washed with a saturated sodium bicarbonate solution, brine, dried with MgSO₄, concentrated, and purified by column chromatography (EtOAc: MeOH = 20: 1) to give the title compound (1.0 g, 16% yield). ¹H NMR (400 MHz, CDCl₃) δ 0.019 (m, 2 H), 0.472 (m, 2 H), 0.832 (m, 1 H), 2.29 - 2.32 (d, *J* = 7.0 Hz, 2 H), 3.38 (s, 2 H).

20

Method 34

Cyclopropyl-acetyl chloride

To the DCM (30 ml) solution of cyclopropyl acetic acid (5.0 g, 49.9 mmol) with 6 drops DMF, was slowly added the solution of oxalyl chloride (5.2 ml, 59.9 mmol) in DCM (5 ml). After completion of the addition, the reaction solution was stirred at 25 °C for 4 hours. Evaporation of the solvent under reduced pressure gave the title compound as a bright yellow solid (5.9 g, 99.6%). ¹H NMR (400 MHz, CDCl₃) δ 0.018 (m, 2 H), 0.421 (m, 2 H), 0.896 (m, 1 H), 2.53 - 2.55 (d, *J* = 5.85 Hz, 2 H).

30 Method 35

(5-Cyclopropylmethoxy-1H-pyrazol-3-yl)-(2,5-dichloro-pyrimidin-4-yl)-amine

A solution of 2,4,5-trichloropyrimidine (0.30 g, 1.6 mmol), 5-cyclopropylmethoxy-1H-pyrazol-3-ylamine (Method 44; 0.23 g, 1.5 mmol), and triethylamine (0.23 ml, 2.2 mmol)

in EtOH (8 ml) was heated to 55 °C overnight. The reaction was concentrated under reduced pressure and purification by column chromatography (hexane: EtOAc = 1 : 1) to give the title compound (0.20 g, 6%). ¹H NMR (400 MHz): δ 0.321 (m, 2 H), 0.552 (m, 2 H), 0.863 (m, 1 H), 3.90 (d, *J* = 7.0 Hz, 2 H), 5.8 (s, 1 H), 8.41 (s, 1 H). MS: Calcd.: 299; Found: [M+H]⁺ 300.

Methods 36-43

The following compounds were prepared by the procedure of Method 35 using the appropriate starting materials.

Method	Compound	pyrimidine	Pyrazole
36	<i>N</i> -(5- <i>sec</i> -Butoxy-1 <i>H</i> -pyrazol-3-yl)-2,5-dichloropyrimidin-4-amine	2,4,5-trichloropyrimidine	5- <i>sec</i> -butoxy-1 <i>H</i> -pyrazol-3-amine (Method 45)
37	<i>N</i> -(5-Propoxy-1 <i>H</i> -pyrazol-3-yl)-2,5-dichloropyrimidin-4-amine	2,4,5-trichloropyrimidine	5-propoxy-1 <i>H</i> -pyrazol-3-amine (Method 46)
38	<i>N</i> -(5-Isopropoxy-1 <i>H</i> -pyrazol-3-yl)-2,5-dichloropyrimidin-4-amine	2,4,5-trichloropyrimidine	5-isopropoxy-1 <i>H</i> -pyrazol-3-amine (Method 47)
39	<i>N</i> -(5-Ethoxy-1 <i>H</i> -pyrazol-3-yl)-2,5-dichloropyrimidin-4-amine	2,4,5-trichloropyrimidine	5-ethoxy-1 <i>H</i> -pyrazol-3-amine (Method 48)
40	2,5,6-Trichloro- <i>N</i> -(5-ethoxy-1 <i>H</i> -pyrazol-3-yl)pyrimidin-4-amine	2,4,5,6-tetrachloropyrimidine	5-ethoxy-1 <i>H</i> -pyrazol-3-amine (Method 48)
41	2,5,6-Trichloro- <i>N</i> -(5-isopropoxy-1 <i>H</i> -pyrazol-3-yl)pyrimidin-4-amine	2,4,5,6-tetrachloropyrimidine	5-isopropoxy-1 <i>H</i> -pyrazol-3-amine (Method 47)

Method	Compound	pyrimidine	Pyrazole
42	2-Chloro- <i>N</i> -(5-ethoxy-1 <i>H</i> -pyrazol-3-yl)-5-fluoropyrimidin-4-amine	2,4-dichloro-5-fluoropyrimidine	5-ethoxy-1 <i>H</i> -pyrazol-3-amine (Method 48)
43	2-Chloro- <i>N</i> -(5-isopropoxy-1 <i>H</i> -pyrazol-3-yl)-5-fluoropyrimidin-4-amine	2,4-dichloro-5-fluoropyrimidine	5-isopropoxy-1 <i>H</i> -pyrazol-3-amine (Method 47)

Method 44**5-Cyclopropylmethoxy-1*H*-pyrazol-3-ylamine**

Triphenylphosphine (16.0 g, 61 mmol), 5-amino-2*H*-pyrazol-3-ol (5.5 g, 56 mmol),
 5 and cyclopropyl methanol (4.4 g, 61 mmol) were dissolved in THF (100 ml), to which was
 slowly added the diisopropyl azodicarboxylate (12 ml, 61 mmol) solution in THF (50 ml).
 The reaction mixture was stirred for 1 hour, diluted with DMF (45 ml), and allowed at 25 °C
 overnight. The solvent was removed under reduced pressure. The resulted residue was treated
 with water, extracted with EtOAc twice and DCM once. The combined organics were dried
 10 over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column
 chromatography (EtOAc) to give the title compound (1.3 g, 15%). MS: Calcd.: 153; Found:
 [M+H]⁺ 154.

Method 45-48

15 The following compounds were prepared by the procedure of Method 44 using the
 appropriate starting materials.

Method	Compound	Alcohol	Pyrazole
45	5- <i>sec</i> -Butoxy-1 <i>H</i> -pyrazol-3-amine	butan-2-ol	5-amino-2 <i>H</i> -pyrazol-3-ol
46	5-Propoxy-1 <i>H</i> -pyrazol-3-amine	propanol	5-amino-2 <i>H</i> -pyrazol-3-ol

Method	Compound	Alcohol	Pyrazole
47	5-Isopropoxy-1 <i>H</i> -pyrazol-3-amine	isopropanol	5-amino-2 <i>H</i> -pyrazol-3-ol
48	5-Ethoxy-1 <i>H</i> -pyrazol-3-amine	ethanol	5-amino-2 <i>H</i> -pyrazol-3-ol

Method 49{(1*S*)-1-[4-(Trifluoromethyl)-1,3-thiazol-2-yl]ethyl}amine

To a solution of (*S*)-*N*-benzyloxycarbonyl-1-(4-trifluoromethyl-thiazol-2-yl)-ethylamine (Method 50; 0.45 g, 1.36 mmol) in anhydrous CH₃CN (5 ml) was added TMS-I (0.23 ml, 1.64 mmol) at 25 °C. The reaction was stirred at room temperature for 30 minutes, quenched with cold HCl/ethyl ether solution (2 N, 10 ml), and diluted with ethyl ether (40 ml). The precipitate was quickly collected by filtration and washed with ether. The resulted solid was treated with 10 ml of saturated NaHCO₃, extracted with ethyl ether (3 x 20 ml). The combined organic was washed with brine (20 ml) and dried over Na₂SO₄. The solvent was evaporated under reduced pressure at below 20 °C (Note: this product is volatile, high-vacuum should be avoided). The crude product as a light brown oil (0.24 g, 90%) was used without further purification.

Method 50(*S*)-*N*-Benzyloxycarbonyl-1-(4-trifluoromethyl-thiazol-2-yl)-ethylamine

N^α-Benzyloxycarbonyl-L-alanine thiamide (Method 51; 1.0 g, 4.2 mmol) and 3-bromo-1,1,1-trifluoro-propan-2-one (0.52 ml, 5.0 mmol) were dissolved in acetone (10 ml) and heated to reflux for 6 hours. The reaction was cooled to 25 °C and the solvent was removed under reduced pressure. The reaction resultant was treated with saturated NaHCO₃ solution (15 ml), extracted with EtOAc (15 ml), washed with H₂O (2 x 15 ml), brine (15 ml), and dried over Na₂SO₄. After evaporation of the solvent, the crude material was purified by silica-gel chromatography (hexane: EtOAc = 2: 1) to give the title compound as a yellowish oil (1.1 g, 79%). ¹H NMR (400 MHz, CDCl₃) δ 1.65 (d, *J* = 6.4 Hz, 3 H), 5.15 (m, 3 H), 5.31 (br s, 1 H), 7.30 (m, 5 H), 7.68 (s, 1 H). MS: Calcd.: 330; Found: [M+H]⁺ 331.

Method 51**N^α-Benzyloxycarbonyl-L-alanine thiamide**

N^α-Benzyloxycarbonyl-L-alanine (10.0 g, 44.8 mmol) in THF (150 ml) was treated with 1,1'-carbonyldiimidazole (CDI) (21.79 g, 134.4 mmol) at 25 °C for 4 hours. With ice-
5 H₂O cooling, NH₃ was bubbled through for 1 hour. The reaction mixture was allowed to stir at 25 °C overnight. THF was removed at reduced pressure. The resulted residue was extracted with EtOAc (200 ml), washed with H₂O (2 x 100 ml), brine (200 ml), and dried over Na₂SO₄. After evaporation of the solvent, the crude material was passed through a silica-gel column eluted with EtOAc. The desired *N^α*-benzyloxycarbonyl-L-alanine amide was obtained as a
10 white solid (8.10 g, 81% yield). This amide derivative (5.0 g, 22.5 mmol) was dissolved in THF (50 ml) and treated with Lawesson's reagent (5.46 g, 13.5 mmol) at 25 °C for 4 hours. After evaporation of THF, the resultant mixture was directly loaded for column purification eluted with EtOAc to give the title compound as a white solid (4.70 g, 87%). ¹H NMR (400 MHz, CDCl₃) δ 1.39 (d, *J* = 6.8 Hz, 3 H), 4.28 (m, 1 H), 5.11 (s, 2 H), 5.50 (d, *J* = 6.8 Hz, 1
15 H), 5.76 (br s, 1 H), 6.19 (br s, 1 H), 7.33 (m, 5 H). MS: Calcd.: 238; Found: [M+H]⁺ 239.

Method 52**[(1*S*)-1-(1,3-Thiazol-2-yl)ethyl]amine**

To a solution of (*S*)-*N*-benzyloxycarbonyl-1-thiazol-2-yl-ethylamine (Method 53; 0.50
20 g, 1.51 mmol) in anhydrous CH₃CN (5 ml) was added TMS-I (0.26 ml, 1.82 mmol) at 25 °C. The reaction was stirred at room temperature for 30 minutes, then quenched by addition of cold HCl/ethyl ether solution (2 N, 10 ml) and diluted with 40 ml of ethyl ether. The precipitate was quickly collected by filtration and washed with ether. The resultant solid was suspended in DCM (1 ml) and treated with 25% of NaOMe/MeOH solution (0.363 ml, 1.59
25 mmol). The reaction mixture was stirred at 25 °C for 30 minutes, then to which was added 10 ml DCM. The reaction mixture was stirred at 25 °C for 1 hour. The white solid was removed by filtration and the filtrate was concentrated under reduced pressure at below 20 °C to give the crude product as light-brown oil (0.25 g, 84%). (Note: this product is volatile, high-vacuum should be avoided). The crude product was used without further purification.

Method 53**(S)-N-Benzoyloxycarbonyl-1-thiazol-2-yl-ethylamine**

N^α-Benzoyloxycarbonyl-L-alanine thiamide (Method 51; 2.1 g, 8.8 mmol) and bromoacetaldehyde dimethyl acetal (2.08 ml, 17.6 mmol) were dissolved in acetone (20 ml), to which was added HCl/dioxane solution (4 N, 0.11 ml, 0.44 mmol). The resultant solution was heated to reflux for 6 hours. The reaction was cooled to 25 °C and the solvent was removed under reduced pressure. The reaction resultant was treated saturated NaHCO₃ solution (30 ml) and extracted with EtOAc (30 ml). The organic layer was washed with H₂O (2 x 30 ml), brine (30 ml), and dried over Na₂SO₄. After evaporation of the solvent, the crude material was purified by silica-gel chromatography (hexane: EtOAc = 2: 1) to give the title compound as a light brown oil (1.7 g, 74%). ¹H NMR (400 MHz, CDCl₃) δ 1.63 (d, *J* = 6.8 Hz, 3 H), 5.01 - 5.22 (m, 3 H), 5.54 (br s, 1 H), 7.26 (d, *J* = 2.8 Hz, 1 H), 7.33 (m, 5 H), 7.71 (d, *J* = 2.8 Hz, 1 H), MS: Calcd.: 262; Found: [M+H]⁺ 263.

Method 54**2,4-Dichloroquinazoline**

A solution of quinazoline-2,4(1*H*, 3*H*)-dione (1.0 g, 6.17 mmol) and POCl₃ (20 ml) in DMF (96 ml) was heated at 110°C for 17 hours. The resulting solution was cooled down and poured onto ice with stirring. Once the ice melted, the solid material was filtered and dissolved in DCM (100 ml). The solution was washed with water once and concentrated to give product as a white solid (970 mg, 79%). ¹H NMR δ 7.90 (m, 1 H), 8.03 (m, 1 H), 8.815 (m, 1 H), 8.28 (m, 1 H).

Method 55**2-Chloro-N-(5-cyclopropyl-1*H*-pyrazol-3-yl)quinazolin-4-amine**

A solution of 2,4-dichloroquinazoline (Method 54; 404 mg, 2.0 mmol), 3-amino-5-cyclopropyl-1*H*-pyrazole (250 mg, 2.0 mmol) and triethylamine (0.34 ml, 0.24 mmol) in THF (6.0 ml) was stirred at room temperature for 10 hrs. The solid formed was filtered and washed with EtOH (5 ml) and MeOH (5 ml). The solid was dried to give desired product as a white solid (100 mg, 69%). The compound was carried to the next step without further purification. ¹H NMR δ 0.9 (m, 2 H), 1.1 (m, 2 H), 1.8 - 2.1 (m, 1 H), 6.6 (m, 1 H), 7.75 (m, 1 H), 7.85 (m, 1 H), 8.0 (m, 1 H), 9.9 (br s, 1 H), 11.0 (br s, 1 H).

Method 56-57

The following compounds were prepared by the procedure of Methods 54-55 using the appropriate starting materials.

Method	Compound	Quinazoline	Amine
56	<i>N</i> -(5- <i>tert</i> -Butyl-1 <i>H</i> -pyrazol-3-yl)-2-chloroquinazolin-4-amine	2,4-dichloroquinazoline Method 54	3-amino-5- <i>tert</i> -butyl-1 <i>H</i> -pyrazole
57	2-Chloro- <i>N</i> -(5-methyl-1 <i>H</i> -pyrazol-3-yl)quinazolin-4-amine	2,4-dichloroquinazoline Method 54	3-amino-5-methyl-1 <i>H</i> -pyrazole

5 **Method 58**Methyl 3-[(aminocarbonyl)amino]thiophene-2-carboxylate

To a solution of methyl 3-amino-2-thiophenecarboxylate (3.43 g, 21.8 mmol) in acetic acid (20 ml) was added a solution of potassium cyanate (3.2 g, 39.4 mmol) in water (15 ml). After stirring for 20 hrs at room temperature, the mixture was filtered and washed by water.

- 10 The off white solid is the desired product (4.78 g). ¹H NMR (400 MHz): δ 3.9 (s, 3 H), 6.8 (br s, 2 H), 7.76 (d, J = 4 Hz, 1 H), 7.93 (d, J = 4 Hz, 1 H).

Methods 59-61

- 15 The following compounds were prepared by the procedure of Method 58 using the appropriate starting materials.

Method	Compound	Carboxylate
59	Methyl 2-[(aminocarbonyl)amino]thiophene-3-carboxylate	methyl 2-aminothiophene-3-carboxylate
60	Methyl 5-[(aminocarbonyl)amino]-1 <i>H</i> -pyrazole-4-carboxylate	methyl 5-amino-1 <i>H</i> -pyrazole-4-carboxylate
61	Methyl 4-[(aminocarbonyl)amino]thiophene-3-carboxylate	methyl 4-aminothiophene-3-carboxylate

Method 62**Thieno[3,2-*d*]pyrimidine-2,4(1*H*,3*H*)-dione**

To a solution of methyl 3-[(aminocarbonyl)amino]thiophene-2-carboxylate (Method 58, 4.78 g) in MeOH (50 ml) was added the solution of sodium hydroxide (1.2 g, 30 mmol) in water (15 ml). The reaction mixture was heated to reflux for 1 hr. Water was added to dissolve the solid. 50% sulfuric acid was added to adjust the pH<1. The resulting off white solid was filtered to give desired product (2.41 g, 66% for 2 steps). ¹H NMR (400 MHz): δ 6.91 (d, J = 5.2 Hz, 1 H), 8.05 (d, J = 5.2 Hz, 1 H), 11.2 (br s, 1 H), 11.5 (br s, 1 H).

Methods 63-65

The following compounds were prepared by the procedure of Method 62 using the appropriate starting materials.

Method	Compound	Carboxylate	SM
63	Thieno[2,3- <i>d</i>]pyrimidine-2,4(1 <i>H</i> ,3 <i>H</i>)-dione	methyl 2-[(aminocarbonyl)amino]thiophene-3-carboxylate	Method 59
64	1 <i>H</i> -Pyrazolo[3,4- <i>d</i>]pyrimidine-4,6(5 <i>H</i> ,7 <i>H</i>)-dione	methyl 5-[(aminocarbonyl)amino]-1 <i>H</i> -pyrazole-4-carboxylate	Method 60
65	Thieno[3,4- <i>d</i>]pyrimidine-2,4(1 <i>H</i> ,3 <i>H</i>)-dione	methyl 4-[(aminocarbonyl)amino]thiophene-3-carboxylate	Method 61

Method 66**2,4-Dichlorothieno[3,2-*d*]pyrimidine**

A mixture of thieno[3,2-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (Method 62, 380 mg, 2.3 mmol), phosphorus oxychloride(10 ml) and diethylaniline (1 ml) was heated at 105°C for 16 hrs. Solvent was then removed and ice was added to the mixture. The solid was filtered and gave pink colour solid product (432.4 mg, 92%). ¹H NMR (400 MHz): δ 7.98 (d, J = 5.6 Hz, 1 H), 8.94 (d, J = 5.6 Hz, 1 H).

Methods 67-69

The following compounds were prepared by the procedure of Method 66 using the appropriate starting materials.

Method	Compound	Starting Material
67	2,4-Dichlorothieno[2,3-d]pyrimidine	Method 63
68	4,6-Dichloro-1 <i>H</i> -pyrazolo[3,4-d]pyrimidine	Method 64
69	2,4-Dichlorothieno[3,4-d]pyrimidine	Method 65

Method 70**2-Chloro-*N*-(5-cyclopropyl-1*H* pyrazol-3-yl)thieno[3,2-d]pyrimidin-4-amine**

5 A mixture of 2,4-dichlorothieno[3,2-d]pyrimidine (Method 66, 100 mg, 0.49 mmol), 3-cyclopropyl-1*H* pyrazol-5-amine (150 mg, 1.22 mmol) and triethylamine (0.15 ml, 1.1 mmol) was stirred at room temperature for 24 hrs. Water was added and the solid was filtered to give off white solid product (98 mg, 69%). ¹H NMR (400 MHz): δ 0.5 (m, 2 H), 0.8 (m, 2 H), 1.8 (m, 1 H), 6.0 (br s, 1 H), 7.1 (d, J = 6 Hz, 1 H), 8.0 (d, J = 6 Hz, 1 H), 10.2 (br s, 1 H), 12.2 (br s, 1 H).

10

Methods 71-73

The following compounds were prepared by the procedure of Method 70 using the appropriate starting materials.

Method	Compound	Fused pyrimidine	Amine	SM
71	2-Chloro- <i>N</i> -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)thieno[2,3- <i>d</i>]pyrimidin-4-amine	2,4-dichlorothieno[2,3- <i>d</i>]pyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole	Method 67
72	6-Chloro- <i>N</i> -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)-1 <i>H</i> -pyrazolo[3,4- <i>d</i>]pyrimidin-4-amine	4,6-dichloro-1 <i>H</i> -pyrazolo[3,4- <i>d</i>]pyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole	Method 68
73	2-Chloro- <i>N</i> -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)thieno[3,4- <i>d</i>]pyrimidin-4-amine	2,4-dichlorothieno[3,4- <i>d</i>]pyrimidine	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole	Method 69

15 **Method 74****Pyrido[2,3-*d*]pyrimidine-2,4(1*H*,3*H*)-dione**

A finely powdered mixture of 2-aminonicotinic acid (7.0 g, 50.7 mmol) and urea (13.0 g, 216 mmol) was heated to 180 – 190°C and maintained for 15 minutes at the same temperature. The temperature was gradually raised to 200°C and the clear melt started to

solidify. The temperature was raised to 210°C and the heating was discontinued. The mixture was cooled to room temperature and 2 N NaOH solution (70 ml) was added. It was heated at 50 - 55°C to get a clear solution. This warm solution was saturated with carbon dioxide, cooled and filtered and the solid was washed with water (2 x 25 ml) to give desired product (7.71 g, 76%). ¹H NMR δ 7.16 (m, 1 H), 8.22 (d, J = 6.4 Hz, 1 H), 8.53 (m, 1 H).

Methods 75-81

The following compounds were prepared by the procedure of Method 74 using the appropriate starting materials.

Method	Compound	Amine
75	7-Methylquinazoline-2,4(1 <i>H</i> ,3 <i>H</i>)-dione	2-amino-4-methylbenzoic acid
76	6-Methylquinazoline-2,4(1 <i>H</i> ,3 <i>H</i>)-dione	2-amino-5-methylbenzoic acid
77	6-Methoxyquinazoline-2,4(1 <i>H</i> ,3 <i>H</i>)-dione	2-amino-5-methoxybenzoic acid
78	7-Chloroquinazoline-2,4(1 <i>H</i> ,3 <i>H</i>)-dione	2-amino-4-chlorobenzoic acid
79	6-Chloroquinazoline-2,4(1 <i>H</i> ,3 <i>H</i>)-dione	2-amino-5-chlorobenzoic acid
80	8-Methoxyquinazoline-2,4(1 <i>H</i> ,3 <i>H</i>)-dione	2-amino-3-methoxybenzoic acid
81	8-Chloroquinazoline-2,4(1 <i>H</i> ,3 <i>H</i>)-dione	2-amino-3-chlorobenzoic acid

Method 82

2,4-Dichloropyrido[2,3-*d*]pyrimidine

A suspension of pyrido[2,3-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (Method 74, 6.52 g, 40 mmol) in POCl₃ (70 ml) was heated under reflux for 18 hours. The black coloured solution was concentrated to dryness under vacuum. The residue was treated with ice (100 g) and quickly extracted with chloroform (3 x 150 ml). Combined organic layer was washed with water (100 ml) and dried over MgSO₄, filtered and evaporated to dryness. The solid obtained was triturated with ether (50 ml), filtered and dried to give desired product (3.2 g, 40%). ¹H NMR (CDCl₃) δ 7.74 (m, 1 H), 8.66 (d, J = 2.9 Hz, 1 H), 9.33 (m, 1 H). MS: m/z 202 (M+3), 200 (M+1).

Methods 83-89

The following compounds were prepared by the procedure of Method 82 using the appropriate starting materials.

Method	Compound	Starting Material
83	7-Methyl-2,4-dichloroquinazoline	Method 75
84	6-Methyl-2,4-dichloroquinazoline	Method 76
85	6-Methoxy-2,4-dichloroquinazoline	Method 77
86	2,4,7-Trichloroquinazoline	Method 78
87	2,4,6-Trichloroquinazoline	Method 79
88	8-Methoxy-2,4-dichloroquinazoline	Method 80
89	2,4,8-Trichloroquinazoline	Method 81

Method 90(2-Chloro-pyrido[2,3-d]pyrimidin-4-yl)-(5-cyclopropyl-2H-pyrazol-3-yl)-amine

To a solution of 3-amino-5-cyclopropyl-1H-pyrazole (800 mg, 6.5 mmol) and diisopropyl ethyl amine (2.51 g, 3.4 ml, 19.5 mmol) in EtOH (20 ml) was added 2,4-dichloropyrido[2,3-d]pyrimidine (Method 82, 1.3 g, 6.5 mmol). The mixture was stirred for 15 minutes and the separated solid was filtered, washed with EtOH (5 ml). The solid was taken in a mixture of CHCl₃ (10 ml) and THF (5 ml) and refluxed for 15 minutes. The residue was filtered and dried to give the desired product (800 mg, 46%). ¹H NMR δ 0.73 (m, 2 H), 0.98 (m, 2 H), 1.96 (m, 1 H), 6.51 (s, 1 H), 7.61 (m, 1 H), 9.02 (m, 1 H), 9.03 (m, 1 H). MS: m/z 289 (M+3), 287 (M+1).

Methods 91-97

The following compounds were prepared by the procedure of Method 90 using the appropriate starting materials.

Method	Compound	Quinazolines	Amine	SM
91	2-Chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-7-methylquinazolin-4-amine	7-methyl-2,4-dichloroquinazoline	3-amino-5-cyclopropyl-1H-pyrazole	Method 83
92	2-Chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methylquinazolin-4-amine	6-methyl-2,4-dichloroquinazoline	3-amino-5-cyclopropyl-1H-pyrazole	Method 84

Method	Compound	Quinazolines	Amine	SM
93	2-Chloro- <i>N</i> -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)-6-methoxyquinazolin-4-amine	6-methoxy-2,4-dichloroquinazoline	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole	Method 85
94	2,7-Dichloro- <i>N</i> -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)quinazolin-4-amine	2,4,7-trichloroquinazoline	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole	Method 86
95	2,6-Dichloro- <i>N</i> -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)quinazolin-4-amine	2,4,6-trichloroquinazoline	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole	Method 87
96	2-Chloro- <i>N</i> -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)-8-methoxyquinazolin-4-amine	8-methoxy-2,4-dichloroquinazoline	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole	Method 88
97	2,8-Dichloro- <i>N</i> -(5-cyclopropyl-1 <i>H</i> -pyrazol-3-yl)quinazolin-4-amine	2,4,8-trichloroquinazoline	3-amino-5-cyclopropyl-1 <i>H</i> -pyrazole	Method 89

Method 98**7-Fluoro-2,4-dioxo (1*H*, 3*H*) quinazoline**

A finely powdered mixture of 4-fluoroanthranilic acid (24.0 g, 154.8 mmol) and urea
 5 (27.0 g, 450 mmol) was heated at 220°C for 1 hour. During the heating a clear solution was
 obtained at 190°C and solidified on continued heating. The mixture was cooled to 25°C and
 water (500 ml) was added to it and boiled for 1 hour and cooled to 25°C. The residue was
 filtered and dried to give the desired product (21.55 g, 77%). ¹H NMR δ 6.88 (m, 1 H), 6.91
 (m, 1 H), 7.94 (m, 1 H).

10

Method 99**6-Fluoro-2,4-dioxo (1*H*, 3*H*) quinazoline**

The title compound was prepared in a similar way to Method 98 from 3-fluoro
 anthranilic acid.

15

Method 100**7-Fluoro-2,4-dichloroquinazoline**

A suspension of 7-fluoro-2,4-dioxo (1*H*, 3*H*) quinazoline (Method 98, 1.8 g, 10 mmol) in POCl₃ (30 ml) was heated under reflux for 72 hours. The brown coloured solution was concentrated to dryness under vacuum. The residue was treated with ice water (50 ml) and filtered. The residue was washed with ice-cold water (10 ml) and dried to give the desired product (1.7 g, 78%). ¹H NMR (CDCl₃) δ 7.92 (m, 1 H), 7.95 (d, *J* = 2.9 Hz, 1 H), 8.42 (m, 1 H). MS: *m/z* 219 (*M*+3), 217 (*M*+1).

Method 101**6-Fluoro-2,4-dichloroquinazoline**

The title compound was prepared in a similar way to Method 100 from 6-fluoro-2,4-dioxo (1*H*, 3*H*) quinazoline (Method 99).

Method 102**(2-Chloro-7-fluoro-quinazolin-4yl)-(5-cyclopropyl-2*H*-pyrazol-3-yl)-amine**

To a solution of 3-amino-5-cyclopropyl-1*H*-pyrazole (1.23 g, 10 mmol) and diisopropyl ethyl amine (3.87 g, 5.2 ml, 30 mmol) in EtOH (40 ml) was added 7-fluoro-2,4-dichloroquinazoline (Method 100, 1.7 g, 7.87 mmol). The mixture was stirred for 45 minutes and the separated solid was filtered, washed with EtOH (5 ml). The solid was taken in a mixture of CHCl₃ (10 ml) and THF (5 ml) and refluxed for 15 minutes. The residue was filtered and dried to give the desired product (1.5 g, 65%). ¹H NMR δ 0.73 (m, 2 H), 0.97 (m, 2 H), 1.94 (m, 1 H), 6.47 (s, 1 H), 7.52 (m, 2 H), 8.74 (m, 1 H), 10.89 (s, 1 H), 12.40 (br s, 1 H). MS: *m/z* 306 (*M*+3), 304 (*M*+1).

25

Method 103**(2-Chloro-6-fluoro-quinazolin-4yl)-(5-cyclopropyl-2*H*-pyrazol-3-yl)-amine**

The title compound was prepared in a similar way to Method 102 from 6-fluoro-2,4-dichloroquinazoline (Method 101) and 3-amino-5-cyclopropyl-1*H*-pyrazole.

30

Method 104**(2R)-2-Amino-2-(4-fluorophenyl)ethanol**

To a stirred solution of lithium aluminium hydride (1.0 M in THF, 11.9 ml, 11.9 mmol) at 0°C was added 4-(*R*)-fluorophenylglycine (1.0 g, 5.9 mmol) portion wise over 1 hour. The mixture was stirred at room temperature for 16 hours. Water (0.45 ml), 4 N NaOH (0.45 ml) and water (1.34 ml) was added to the mixture and the mixture was stirred for 10 minutes before being filtered. The filtrate was concentrated to give a yellow residue. Flash chromatography (CombiFlash®, CH₂Cl₂/MeOH/NH₃ = 90/10/1) gave product as a white solid (800 mg, 88%). ¹H NMR δ 3.25 (m, 1 H), 3.30 (m, 1 H), 3.40 (m, 1 H), 3.83 (m, 1 H), 4.77 (br s, 1 H), 7.06 (m, 2 H), 7.37 (m, 2 H).

Methods 105-111

The following compounds were prepared by the procedure of Method 104 using the appropriate starting materials.

Method	Compound	Starting material
105	(2 <i>S</i>)-2-Amino-2-(4-fluorophenyl)ethanol	4-(<i>S</i>)-fluorophenylglycine
106	2-Amino-2-(4-fluorophenyl)ethanol	4-fluorophenylglycine
107	(3 <i>R</i>)-3-Amino-3-(4-fluorophenyl)propanol	(3 <i>S</i>)-3-amino-3-(4-fluorophenyl)propanoic acid
108	2-Amino-2-(2-thienyl)ethanol	amino(2-thienyl)acetic acid
109	3-Amino-2-methyl-3-phenylpropan-1-ol	3-amino-2-methyl-3-phenylpropanoic acid
110	tert-Butyl [1-(4-fluorophenyl)-2-hydroxyethyl]carbamate	[(tert-butoxycarbonyl)amino](4-fluorophenyl)acetic acid
111	tert-Butyl [(1 <i>S</i>)-1-(4-fluorophenyl)-3-hydroxypropyl]carbamate	(3 <i>S</i>)-3-[(tert-butoxycarbonyl)amino]-3-(4-fluorophenyl)propanoic acid
112	tert-Butyl [(1 <i>R</i>)-1-(4-fluorophenyl)-3-hydroxyethyl]carbamate	(3 <i>R</i>)-3-[(tert-butoxycarbonyl)amino]-3-(4-fluorophenyl)acetic acid

Method 113**(R)-1-(4-Fluorophenyl)-2-(methoxy)ethylamine**

The title compound was prepared according to the procedure of Russell, M. G. N et al *J. Med. Chem.* 1999, 42, 4981-5001.

5

Method 114**1-(4-Fluorophenyl)-2-morpholin-4-ylethanamine**

To a solution of *tert*-butyl [1-(4-fluorophenyl)-2-hydroxyethyl]carbamate (Method 110; 1.42 g, 5.58 mmol) in DCM (20 ml) was added triethylamine (1.2 ml) and
10 methanesulfonyl chloride (0.52 ml, 6.69 mmol) and the reaction mixture was stirred at room temperature for 2.5 hours. The reaction mixture was poured into water and extracted with DCM. The combined organic layers were dried and concentrated. Column chromatography (25 %EtOAc to 50% EtOAc in hexanes) gave the desired product as a white solid (1.61 g). To a solution of 2-[(*tert*-butoxycarbonyl)amino]-2-(4-fluorophenyl)ethyl methanesulfonate
15 obtained above (307 mg, 0.92 mmol) in THF (3 ml) was added morpholine (0.45 ml, 5.2 mmol) and the reaction mixture was heated at 70°C for 14 hours (precipitation was observed during this period). The mixture was concentrated and column chromatography (25% EtOAc to 75% EtOAc in hexanes) gave the desired product as an oil (93.4 mg, 31%). To a solution of this oil (93.4 mg, 0.29 mmol) in DCM (5 ml) was added trifluoroacetic acid (5 ml) and the
20 reaction mixture was stirred at room temperature for 4 hours. Solvent was removed and water was added to the mixture. The solution was basified and extracted with chloroform/2-propanol (3/1). The organic layer was dried (Na₂SO₄) and concentrated to give a yellow oil (75 mg, quantitative yield). ¹H NMR (CDCl₃): δ 2.25-2.50 (m, 6 H), 3.70-3.75 (m, 4 H), 4.10 (m, 1 H), 6.90 (m, 2 H), 7.25 (m, 2 H).

25

Method 115**5-Bromo-2-chloro-N-(5-methoxy-1H-pyrazol-3-yl)pyrimidin-4-amine**

3-Methoxy-3-(methylthio)acrylonitrile (Method 116; 353 mg, 2.7 mmol) in hydrazine monohydrate (1.5 ml) was heated at 120°C for 1 hour. Hydrazine was removed under
30 vacuum. NMR indicated the major product was 3-methoxy-1H-pyrazol-5-amine.¹ To the crude product was added EtOH (5 ml), 5-bromo-2,4-dichloropyrimidine (1.9 g, 8 mmol) and triethylamine (1.2 ml, 8 mmol) and the reaction stirred at room temperature overnight. Solvent was removed and the residue partitioned between EtOAc and H₂O. The organic layer

was purified by column chromatography (ISCO system, 20%-50% EtOAc in hexanes) to give the title compound as a solid (94 mg, 11% for two steps). ¹H NMR (CD₃OD): δ 3.87 (s, 3 H), 5.84 (s, 1 H), 8.38 (s, 1 H).

¹JP 01047769

5

Method 116

3-Methoxy-3-(methylthio)acrylonitrile¹

To a solution of *n*-BuLi (2.5 M in Hexane, 11.0 ml, 0.0275 mol) in THF (17.5 ml) at -78°C was added a solution of CH₃CN (1.0 g, 1.3 ml, 0.025 mol) in THF (25 ml). After stirring at -78°C for 1 hour, *O,S*-dimethyl dithiocarbonate (Method 117; 3.05 g, 0.025 mol) in THF (5 ml) was added, and after a further 1 hour at -78°C the reaction mixture was warmed to room temperature and the solvent removed by evaporation. The residue was triturated with hexane and dried under high vacuum to give a pale yellow foam.

To a solution of the crude lithium salt (0.025 mol) in EtOH (8 ml) was added CH₃I (3.9 g, 1.71 ml, 0.0275 mol) and the reaction mixture then stirred at room temperature overnight. Solvent was removed and the residue partitioned between Et₂O and H₂O. The organic layer was washed with brine, dried (Na₂SO₄) and concentrated, and the residue purified by vacuum distillation to give the title compound as a mixture of E and Z isomers (890 mg, 28 % for two steps). ¹H NMR (CDCl₃): δ 2.37 (s, 3 H), 3.80 (s, 3 H), 4.45 (s, 1 H); the other isomer: δ 2.33 (s, 3 H), 4.02 (s, 3 H), 4.28 (s, 1 H).

¹Liebigs Ann. Chem. 1973, 1637-1643

Method 117

O,S-Dimethyl dithiocarbonate¹

To a suspension of granulated KOH (9.3 g, 0.166 mol) in dry Et₂O and benzene (1:1, 70 ml), was added MeOH (5.3 g, 6.7 ml, 0.166 mol). The reaction mixture was cooled to 6°C and a solution of CS₂ (12.6 g, 10.0 ml, 0.166 mol) in benzene (7.5 ml) was added dropwise. After 5 hrs at 6°C, Me₂SO₄ (20.9 g, 15.7 ml, 0.166 mol) was added and the reaction mixture then stirred at room temperature for 20 hours. The organic layer was decanted, washed sequentially with 0.1 N HCl, saturated NaCl and half saturated NaCl. Solvent was removed and the residue was purified by vacuum distillation to give the title compound (11.5 g, contaminated with about 15 % *S,S*-dimethyl dithiocarbonate, 57 %). ¹H NMR: δ 2.55 (s, 3 H), 4.14 (s, 3 H).

¹J. Org. Chem 1996, 4175

Method 118

2,5-Dichloro-N-[5-(methylthio)-1H-pyrazol-3-yl]pyrimidin-4-amine

5 3,3-Bis(methylthio)acrylonitrile (Method 119; 300 mg, 2 mmol) in H₂NNH₂·H₂O (1 ml) was heated at 120°C for 1 hour. Hydrazine was removed under vacuum to give a pale green oil (267 mg). NMR indicated the major product was 3-(methylthio)-1H-pyrazol-5-amine. EtOH (3 ml), 2,4,5-trichloropyrimidine (757 mg, 4 mmol), and Et₃N (0.86 ml, 6 mmol) were added to the crude product and the mixture was stirred at room temperature
10 overnight. Solvent was removed and the residue partitioned between EtOAc and H₂O. The organic layer was purified by column chromatography (ISCO system, 20%-50% EtOAc in hexanes) to give the title compound as a white solid (272 mg, 48% for two steps). ¹H NMR (CD₃OD): δ 2.49 (s, 3 H), 6.72 (s, 1 H), 8.24 (s, 1 H).

15 Method 119

3,3-Bis(methylthio)acrylonitrile¹

n-Butyllithium (2.5 M in hexane, 20.0 ml, 0.05 mol) was added dropwise to a solution of *N,N*-diisopropylamine (7.07 ml, 0.05 mol) in Et₂O (32 ml) at -10°C. After stirring for 10 min, the solution was cooled to -70°C and CH₃CN (1.3 ml, 0.025 mol) in Et₂O (3.8 ml) was
20 added dropwise, maintaining the temperature below -65°C. CS₂ (1.5 ml, 0.025 mol) in Et₂O (3.8 ml) was added dropwise. The reaction mixture turned yellow, with precipitation, and was then stirred at 0°C for 1 hour. The yellow solid was filtered under nitrogen, washed with ether, and dried under vacuum to give 3.67 g orange solid.

To a solution of crude dilithium salt (0.025 mol) in DMF (37 ml) at 0°C was added a
25 solution of CH₃I (4.78 ml, 0.076 mol) in DMF (11 ml) maintaining the temperature below 20°C, and the reaction mixture then stirred at RT for 1 hour. The reaction was diluted with water, extracted with ether and the organic layer washed with water and brine, dried (Na₂SO₄) and concentrated. The crude product was purified by column chromatography (ISCO system, 0%-30% EtOAc in hexanes) to give the title compound as a pale yellow solid (2.1 g, 58% for
30 two steps). ¹H NMR: δ 2.47 (s, 3 H), 2.54 (s, 3 H), 5.46 (s, 1 H).

¹Syn. Comm. 1988, 1103-1110

Method 1202,5-Dichloro-*N*-(1*H*-pyrazol-5-yl)pyrimidin-4-amine

The title compound was prepared by the procedure of Method 1 using the appropriate starting materials.

Method 121*N*³-(2,5-Dichloropyrimidin-4-yl)-*N*⁵,*N*⁵-dimethyl-1*H*-pyrazole-3,5-diamine

EtOH (3 ml), 2,4,5-trichloropyrimidine (141 mg, 0.77 mmol), and Et₃N (0.13 ml, 0.9 mmol) were added to *N*⁵,*N*⁵-dimethyl-1*H*-pyrazole-3,5-diamine (Method 122; 97 mg, 0.77 mol) and the reaction mixture was stirred at room temperature overnight. Solvent was removed and the residue partitioned between EtOAc and H₂O. The organic layer was purified by column chromatography (ISCO system, 15%-80% EtOAc in hexane) to give the title compound as a pale yellow solid (76 mg, 36%). ¹H NMR (CD₃OD): δ 2.86 (s, 6 H), 5.86 (s, 1 H), 8.24 (s, 1 H).

Method 122*N*⁵,*N*⁵-Dimethyl-1*H*-pyrazole-3,5-diamine¹

(*Z*)-3-(Dimethylamino)-3-(methylthio)acrylonitrile (Method 123; 150 mg, 1.0 mmol) and hydrazine (0.5 ml) in EtOH (5 ml) were refluxed overnight. Solvent was removed and the residue was purified by column chromatography (ISCO system, 3-25% MeOH in CH₂Cl₂) to give the title compound (97 mg, 71 %). ¹H NMR (CD₂Cl₂): δ 2.79 (s, 6 H), 4.78 (s, 1 H), 6.99 (br s, 2 H).

¹WO03045379

Method 123(*Z*)-3-(Dimethylamino)-3-(methylthio)acrylonitrile¹

To a solution of 2-cyano-3,3-bis(methylthio)acrylic acid (Method 124, 422 mg, 2.2 mmol) in MeOH (5 ml) was added dimethylamine (2.0 M in THF, 2.0 ml, 4 mmol) and Et₃N (31 μl, 2.2 mmol). The reaction mixture was stirred at 26°C overnight. Solvent was removed and the residue was purified by column chromatography (ISCO system, 0-20% MeOH in CH₂Cl₂) to give the title compound (160 mg, 50%). ¹H NMR (CDCl₃): δ 2.39 (s, 3 H), 3.03 (s, 6 H), 4.08 (s, 1 H).

¹WO03045379

Method 124**2-Cyano-3,3-bis(methylthio)acrylic acid¹**

To a solution of ethyl cyanoacetate (13.3 ml, 0.125 mol) and CS₂ (7.5 ml, 0.125 mol) in EtOH (150 ml) at 0°C was added a solution of NaOH (10 g, 0.25 mol) in water (10 ml) at a rate that the temperature did not exceed 10°C. The reaction mixture was warmed to room temperature for 10 min, and cooled to 5°C. The resulting precipitate was filtered, washed with EtOH (30 ml) and H₂O (100 ml) and dried under high vacuum to afford the disodium salt (29 g).

The disodium salt (13 g, 0.05 mol) was added to a solution of NaOH (3.22 g, 0.08 mol) in water (23 ml) and the reaction mixture stirred at 40°C for 5 hours. After cooling to room temperature, dry EtOH (41 ml) was added, and the mixture stirred at room temperature for 5 minutes. The layers were separated and the lower layer diluted with water to a total volume of 80 ml. The solution was cooled to 5°C and dimethyl sulfate (7.4 ml, 0.078 mol) added at a rate that maintained the temperature at 5-15°C. After stirring at RT for 1 hour, the solution was cooled to 15°C and filtered. The filtrate was acidified to pH 1.5-2 with 4 N HCl, and the resulting solid filtered, washed with water, and dried under high vacuum to give the title compound (439 mg, 44% over 3 steps). ¹H NMR: δ 2.58 (s, 3 H), 2.69 (s, 3 H), 13.43 (br s, 1 H).

¹ *Acta Chem. Scand.* 1996, 432

Method 125**[(1S)-1-(4-Fluorophenyl)-3-morpholin-4-ylpropyl]amine**

To a solution of *tert*-butyl [(1S)-1-(4-fluorophenyl)-3-oxopropyl]carbamate (Method 126; 199 mg, 0.744 mmol) in DCM (10 ml) was added morpholine (0.1 ml, 1.14 mmol). To the mixture was added sodium triacetoxyborohydride (250 mg, 1.18 mmol) and the reaction mixture was stirred at room temperature for overnight. The mixture was poured into water and was extracted with DCM. The combined organic layers were washed with brine, dried (Na₂SO₄) and concentrated. Column chromatography (25% EtOAc in hexanes to 100% EtOAc) gave the desired product as an oil (183 mg, 73%). To a solution of this oil (183 mg, 0.54 mmol) in DCM (5 ml) was added trifluoroacetic acid (5 ml) and the reaction mixture was stirred at room temperature for 4 hrs. Solvent was removed and water was added to the mixture. The solution was basified and extracted with chloroform/2-propanol (3/1). The organic layer was dried (Na₂SO₄) and concentrated to give a yellow oil (178 mg, quantitative

yield). ^1H NMR (CDCl_3): δ 1.50 (m, 4 H), 2.10-2.40 (m, 6 H), 3.55 (m, 4 H), 3.85 (m, 1 H), 6.85 (m, 2 H), 7.15 (m, 2 H).

Method 126

5 tert-Butyl [(1S)-1-(4-fluorophenyl)-3-oxopropyl]carbamate

Oxalyl chloride (0.16 ml, 1.84 mmol) was added to anhydrous DCM (10 ml) and the mixture was cooled to -78°C . DMSO (0.29 ml, 4.09 mmol) was added followed by slow addition of *tert*-butyl [(1S)-1-(4-fluorophenyl)-3-hydroxypropyl]carbamate (Method 111; 447 mg, 1.66 mmol) in DCM (5 ml) to the mixture. The reaction mixture was stirred at -78°C for 10 15 min and to it was added diisopropylethylamine (1.44 ml, 8.3 mmol). The mixture was further stirred for 6 hours. The mixture was poured into water and extracted with DCM. The combined organic layers were washed with brine and dried (Na_2SO_4) and concentrated. Column chromatography (25% EtOAc to 50% EtOAc in hexanes) gave the desired aldehyde as an oil (397 mg, 90%). ^1H NMR (CDCl_3): δ 1.30 (s, 9 H), 2.80 (m, 2 H), 4.90 (m, 1 H), 5.05 15 (m, 1 H), 6.90 (m, 2 H), 7.20 (m, 2 H), 9.60 (s, 1 H).

Method 127-132

Following a similar procedure to Method 125, the following compounds were synthesized via reaction of *tert*-butyl [(1S)-1-(4-fluorophenyl)-3-oxopropyl]carbamate 20 (Method 126) and a suitable amine.

Method	Compound	Amine
127	[(1S)-1-(4-Fluorophenyl)-3-pyrrolidin-1-ylpropyl]amine	pyrrolidine
128	(1S)- N^3, N^3 -Diethyl-1-(4-fluorophenyl)propane-1,3-diamine	diethylamine
129	[(1S)-1-(4-Fluorophenyl)-3-(4-methylpiperazin-1-yl)propyl]amine	1-methylpiperazine
130	(1S)-1-(4-Fluorophenyl)- N^3 -(2-methoxyethyl)- N^3 -methylpropane-1,3-diamine	(2-methoxyethyl)methylamine
131	2-{[(3S)-3-Amino-3-(4-fluorophenyl)propyl](methyl)amino}ethanol	2-(methylamino)ethanol

Method	Compound	Amine
132	(1 <i>S</i>)-1-(4-Fluorophenyl)- <i>N</i> ³ , <i>N</i> ³ -dimethylpropane-1,3-diamine	Dimethylamine

Method 133**(3*S*)-3-Amino-3-(4-fluorophenyl)-*N,N*-dimethylpropanamide**

A mixture of (3*S*)-3-[(*tert*-butoxycarbonyl)amino]-3-(4-fluorophenyl)propanoic acid (200 mg, 0.74 mmol), EDCI (184 mg, 0.96 mmol), HOBT (160 mg, 1.2 mmol) and dimethylamine (2.0 M in THF, 0.48 ml, 0.96 mmol) was stirred at room temperature for 48 hours. To the mixture was added water and the mixture was extracted with DCM. The combined organic layers were dried and concentrated. Reverse phase HPLC (Gilson) purification (monitored at 220 nm) gave the desired product as a white solid (506 mg, 90%).

¹H NMR (CDCl₃): δ 1.50 (s, 9 H), 2.90 (m, 2 H), 3.10 (m, 6 H), 5.15 (m, 1 H), 7.10 (m, 2 H), 7.40 (m, 2 H).

To a solution of above solid in DCM (5 ml) was added trifluoroacetic acid (5 ml) and the reaction mixture was stirred for 2 hours. Solvent was removed and the residue was basified with K₂CO₃/H₂O. The mixture was extracted with CHCl₃/2-propanol (3:1). The combined organic layers were concentrated to give a yellow oil (130 mg, 93%). ¹H NMR (CDCl₃): δ 1.80 (s, 2 H), 2.50 (m, 2 H), 2.90 (m, 6 H), 4.45 (m, 1 H), 6.90 (m, 2 H), 7.30 (m, 2 H).

Method 134-5

Following a similar procedure to Method 133, the following compounds were synthesized via reaction of a suitable acid and a suitable amine.

Method	Compound	Acid	Amine
134	(3 <i>S</i>)-3-Amino-3-(4-fluorophenyl)- <i>N</i> -methylpropanamide	(3 <i>S</i>)-3-[(<i>tert</i> -butoxycarbonyl)amino]-3-(4-fluorophenyl)propanoic acid	methylamine

Method	Compound	Acid	Amine
135	(3 <i>S</i>)-3-Amino-3-(4-fluorophenyl)- <i>N</i> -(2-hydroxyethyl)propanamide	(3 <i>S</i>)-3-[(<i>tert</i> -butoxycarbonyl)amino]-3-(4-fluorophenyl)propanoic acid	2-aminoethanol

Method 136*tert*-Butyl [(2*R*)-2-amino-2-(4-fluorophenyl)ethyl]carbamate

To a solution of 2-[(1*R*)-2-amino-1-(4-fluorophenyl)ethyl]-1*H*-isoindole-1,3(2*H*)-dione (Method 138; 774 mg, 2.4 mmol) in THF (10 ml) was added di-*tert*-butyl dicarbonate (948 mg, 4.35 mmol) and Et₃N (1.1 ml, 7.9 mmol) and the mixture was stirred at room temperature overnight. Water was added and the mixture was extracted with EtOAc. The combined organic layers were dried and concentrated to give a colorless oil (1.02 g). To a solution of this oil (720 mg, 1.87 mmol) in EtOH (3 ml) was added 33% MeNH₂ in EtOH (6 ml). The reaction mixture was stirred at room temperature for 5 minutes and then was heated at 80°C for 2 hours. Solvent was removed and reverse phase HPLC (Gilson) gave the desired product as a colorless oil (178 mg, 37%). ¹H NMR (CDCl₃): δ 1.80 (s, 9 H), 3.10 – 3.25 (m, 2 H), 4.00 (m, 1 H), 4.25 (m, 1 H), 4.80 (m, 1 H), 6.80 (m, 2 H), 7.20 (m, 2 H).

Method 137*N*-[(2*R*)-2-Amino-2-(4-fluorophenyl)ethyl]acetamide

The title compound was synthesized in a similar way to Method 136 except that acetyl chloride was used instead of di-*tert*-butyl dicarbonate.

Method 1382-[(1*R*)-2-Amino-1-(4-fluorophenyl)ethyl]-1*H*-isoindole-1,3(2*H*)-dione

To a solution of (3*S*)-3-(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)-3-(4-fluorophenyl)propanoic acid (Method 139; 1.73 g, 5.5 mmol) in THF (10 ml) was added ethylchloroformate (0.53 ml, 5.5 mmol) and Et₃N (0.77 ml, 5.5 mmol) at 0°C. The solution became cloudy and the stirring was continued for 1 hour. A solution of NaN₃ (729 mg, 11.2 mmol) in water (5 ml) was added and the mixture was stirred for 1 hour. The mixture was poured into water and was extracted with EtOAc and dried over anhydrous Na₂SO₄ to give a

yellow oil (1.567 g). This oil was dissolved in toluene (20 ml) and was heated at 110°C for 1.5 hours. Evaporation of solvent gave a brown oil (1.555 g, 91%). To a solution of the brown oil (1.26 g, 4.1 mmol) in dioxane (10 ml) and water (2 ml) was added concentrated HCl (0.2 ml) at 0°C. The reaction mixture was stirred at room temperature for 2 hours. Solvent was removed and ether was added. The solid was then filtered to give the desired product as a white solid (1.2 g, 92%). The product was used without further purification.

Method 139

(3*S*)-3-(1,3-Dioxo-1,3-dihydro-2*H*-isoindol-2-yl)-3-(4-fluorophenyl)propanoic acid

A mixture of phthalic anhydride (890 mg, 6.0 mmol) and (3*S*)-3-amino-3-(4-fluorophenyl)propanoic acid (1.1 g, 6.0 mmol) in DMF (5 ml) was heated at 135 °C overnight. Water was added and the white solid was filtered and the solid was washed with water and dried to give the title compound (1.73 g, 93%). ¹H NMR: δ 3.20 (m, 1 H), 3.30 (m, 1 H), 5.50 (m, 1 H), 7.05 (m, 2 H), 7.30 (m, 2 H), 7.80 (m, 4 H).

Method 140

4-Oxo-piperidine-1,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester

A mixture of 1-benzyl-3-carbethoxy-4-piperidone hydrochloride (89.0 g, 298.9 mmol) and palladium hydroxide (4.2 g, 5.9 mmol) in MeOH (700 ml) was degassed and shaken under 40 psi of H₂ overnight. The reaction mixture was filtered through a pad of celite, and concentrated. The resulted solid was dissolved in DCM (800 ml), to which was added triethyl amine (90.7 g, 897 mmol). The solution was cooled to 0 °C followed by addition of benzyl chloroformate (56.1 g, 329 mmol). The reaction mixture was stirred at 25 °C for 15 hours, quenched with water (500 ml), extracted with DCM (2 x 400 ml), dried over MgSO₄, and concentrated. The crude material was purified by silica-gel chromatography (hexanes: EtOAc = 5: 1) to give the title compound (72 g, 78%) and used without further analysis.

Method 141

4-Hydroxy-2-methylsulfanyl-7,8-dihydro-5*H*-pyrido[4,3-*d*]pyrimidine-6-carboxylic acid benzyl ester

Sodium metal (1.36 g, 59 mmol) was added to MeOH (250 ml) and the mixture was stirred until the metal sodium completely disappeared. This was added to a solution of 4-oxo-piperidine-1,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester (Method 140; 10.0 g, 32.8 mmol)

in MeOH (50 ml), followed by addition of 2-methyl-2-thiopseudourea sulfate (8.2 g, 29.5 mmol). The reaction was stirred at 25 °C for 15 hours and concentrated under reduced pressure. The resulted residue was treated with water (200 ml), extracted with EtOAc (3 x 200 ml), washed with brine (200 ml), dried over MgSO₄, and concentrated to give the title compound (7.0 g, 64%) and used without further analysis.

Method 142

4-Chloro-2-methylsulfanyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylic acid benzyl ester

4-Hydroxy-2-methylsulfanyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylic acid benzyl ester (Method 141; 7.0 g, 21 mmol) was dissolved in chloroform (100 ml), to which was added POCl₃ (17.8 g, 116 mmol) slowly. The reaction was refluxed for 15 hours, cooled to 25 °C, quenched by pouring onto ice, and extracted with DCM (3 x 200 ml). The combined organic layer was washed with aqueous NaOH solution (1 N, 100 ml), dried over MgSO₄, and concentrated. The resulted residue was then purified by silica-gel column chromatography (DCM: MeOH = 50: 1) to give the title compound (4.0 g, 54%) and used without further analysis.

Method 143

4-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methylsulfanyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylic acid benzyl ester

A solution of 4-chloro-2-methylsulfanyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylic acid benzyl ester (Method 142; 2.0 g, 5.7 mmol), 5-cyclopropyl-1H-pyrazol-3-ylamine (0.7 g, 5.7 mmol) and triethylamine (1.7 g, 17 mmol) in NMP (15 ml) was heated to 110 °C for 48 hours, cooled to 25 °C, quenched with H₂O (30 ml), and extracted with methyl *tert*-butyl ether (4 x 50 ml). The combined organic layer was dried over MgSO₄, concentrated under reduced pressure, and purified by column chromatography (DCM: MeOH = 100: 1) to give the title compound (1.4 g, 56%). MS: Calcd.: 436; Found: [M+H]⁺ 437.

Method 144**4-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methanesulfonyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylic acid benzyl ester**

4-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methylsulfanyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxylic acid benzyl ester (Method 143; 0.35 g, 0.80 mmol) was dissolved in DCM (50 ml) and cooled to 0 °C, to which was added a solution of meta-chloroperoxybenzoic acid (0.99 g, 4.0 mmol) in DCM (30 ml) over 30 minutes. The reaction was then stirred for an additional 2 hours at 0 °C, quenched with 10% Na₂S₂O₃ (100 ml), washed with saturated NaHCO₃ (100 ml), and extracted with DCM (2 x 100 ml). The combined organic layer was dried over Na₂SO₄, concentrated, and purified by column chromatography (DCM: MeOH = 100 : 1) to give the title compound (0.19 g, 51%). MS: Calcd.: 468; Found: [M+H]⁺ 469.

Method 145**3-Oxo-piperidine-1,4-dicarboxylic acid 1-benzyl ester 4-ethyl ester**

Ethyl *N*-benzyl-3-oxo-4-piperidine-carboxylate hydrochloride (75.0 g, 251.9 mmol) was dissolved in 700 ml of MeOH and placed in a Parr container. Palladium hydroxide (4.2 g, 5.9 mmol) was then added. The reaction was shaken under 40 psi of H₂ overnight. The reaction mixture was then filtered through a pad of celite and concentrated under reduced pressure. The resulted solid together with triethyl amine (72.6 g, 717 mmol) was dissolved in DCM (800 ml) and cooled to 0 °C, to which was benzyl chloroformate (53.0 g, 311 mmol). The reaction mixture was stirred at 25 °C for 15 hours, diluted with H₂O (500 ml), and extracted with DCM (2 x 400 ml). The combined organic layer was dried over MgSO₄, concentrated, and purified by silica-gel chromatography (hexane: EtOAc = 5: 1) to give the title compound (73 g, 97%) and used without further analysis.

Method 146**4-Hydroxy-2-methylsulfanyl-5,8-dihydro-6H-pyrido[3,4-d]pyrimidine-7-carboxylic acid benzyl ester**

Sodium metal (1.36 g, 59 mmol) was added to MeOH (250 ml) and stirred until the sodium completely disappeared, to which was added the MeOH (50 ml) solution of 3-oxo-piperidine-1,4-dicarboxylic acid 1-benzyl ester 4-ethyl ester (Method 145; 10.0 g, 32.8 mmol) followed by addition of 2-methyl-2-thiopseudourea sulfate (8.2 g, 29.5 mmol). The reaction

was stirred at 25 °C for 15 hours and concentrated under reduced pressure. The resulted residue was dissolved in H₂O (200 ml) and extracted with EtOAc (3 x 200 ml). The combined organic layer was dried over MgSO₄ and concentrated to give the title compound (8.0 g, 74%) and used without further analysis.

5

Method 147**4-Chloro-2-methylsulfanyl-5,8-dihydro-6H-pyrido[3,4-*d*]pyrimidine-7-carboxylic acid benzyl ester**

POCl₃ (22.9 g, 149 mmol) was slowly added to the chloroform (100 ml) solution of 4-hydroxy-2-methylsulfanyl-5,8-dihydro-6H-pyrido[3,4-*d*]pyrimidine-7-carboxylic acid benzyl ester (Method 146; 9.0 g, 27 mmol). The reaction was heated to reflux for 15 hours, cooled to 25 °C, quenched by pouring onto ice, and extracted with DCM (3 x 200 ml). The combined organic layer was washed with aqueous NaOH solution (1 N, 100 ml), dried over MgSO₄, and purified by column chromatography (DCM: MeOH = 100: 1) to give the title compound (7.0 g, 73%) and used without further analysis.

15

Method 148**4-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methylsulfanyl-5,8-dihydro-6H-pyrido[3,4-*d*]pyrimidine-7-carboxylic acid benzyl ester**

A solution of 4-chloro-2-methylsulfanyl-5,8-dihydro-6H-pyrido[3,4-*d*]pyrimidine-7-carboxylic acid benzyl ester (Method 147; 5.0 g, 14.0 mmol), triethylamine (4.3 g, 43 mmol), and 5-cyclopropyl-1H-pyrazol-3-ylamine (2.6 g, 21 mmol) in NMP (30 ml) was heated at 110 °C for 48 hours. After cooling to 25 °C, the reaction was diluted with H₂O (30 ml), extracted with MTBE (4 x 50 ml). The combined organic layer was dried over MgSO₄, concentrated, and purified by column chromatography (DCM: MeOH = 50: 1) to give the title compound (2.5 g, 40%). MS: Calcd.: 436; Found: [M+H]⁺ 437.

25

Method 149**4-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methanesulfonyl-5,8-dihydro-6H-pyrido[3,4-*d*]pyrimidine-7-carboxylic acid benzyl ester**

30

4-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-2-methylsulfanyl-5,8-dihydro-6H-pyrido[3,4-*d*]pyrimidine-7-carboxylic acid benzyl ester (Method 148; 2.5 g, 5.75 mmol) was dissolved in DCM (200 ml) and cooled to 0 °C, to which was added a DCM (50 ml) solution

of MCPBA (5.0 g, 20.0 mmol) over a period of 1 hour. The reaction was then stirred for an additional 2 hrs at 0 °C, quenched with 10% Na₂S₂O₃ (200 ml), washed with saturated NaHCO₃ (200 ml), and extracted with DCM (2 x 200 ml). The combined organic layer was dried over Na₂SO₄, concentrated, and purified by column chromatography (DCM: MeOH = 100: 1) to give the title compound (2.0 g, 74%). MS: Calcd.: 468; Found: [M+H]⁺ 469.

Method 150

2,6-Dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine

A mixture of 2,4,6-trichloropyrimidine (1.00 g, 5.46 mmol), 3-amino-5-methyl-1H-pyrazole (530 mg, 5.46 mmol) and triethylamine (1.1 ml, 8.2 mmol) in EtOH (10 ml) was stirred at room temperature for 1 day. Solvent was removed and the mixture was partitioned between EtOAc and water. The organic layer was concentrated to give the desired product (1.34 g, quantitative). ¹H NMR (CDCl₃): δ 2.30 (m, 3 H), 5.90 (m, 1 H), 7.85 (m, 1 H), 8.50 (br s, 1 H).

Method 151

[(1R)-1-(4-Fluorophenyl)-2-morpholin-4-ylethyl]amine

The compound was synthesized following Method 114 using *tert*-butyl [(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]carbamate (Method 112) as starting material.

Utility

The compounds of the present invention have utility for the treatment of cancer by inhibiting the tyrosine kinases, particularly the Trks and more particularly Trk A and B. Methods of treatment target tyrosine kinase activity, particularly the Trk activity and more particularly Trk A and B activity, which is involved in a variety of cancer related processes. Thus, inhibitors of tyrosine kinase, particularly the Trks and more particularly Trk A and B, are expected to be active against neoplastic disease such as carcinoma of the breast, ovary, lung, colon, prostate or other tissues, as well as leukemias and lymphomas, tumours of the central and peripheral nervous system, and other tumour types such as melanoma, fibrosarcoma and osteosarcoma. Tyrosine kinase inhibitors, particularly the Trk inhibitors and more particularly Trk A and B inhibitors are also expected to be useful for the treatment other proliferative diseases including but not limited to autoimmune, inflammatory, neurological, and cardiovascular diseases.

Compounds of the present invention have been shown to inhibit tyrosine kinases, particularly the Trks and more particularly Trk A and B, as determined by the Trk B Assay described herein.

Compounds provided by this invention should also be useful as standards and reagents in determining the ability of a potential pharmaceutical to inhibit tyrosine kinases, particularly the Trks and more particularly Trk A and B. These would be provided in commercial kits comprising a compound of this invention

TrkB Assay Format

TrkB kinase activity is being measured against its ability to phosphorylate synthetic tyrosine residues within a generic polypeptide substrate using homogenous time-resolved fluorescence (HTRF) technology. The intracellular domain of a HIS-tagged human TrkB kinase was expressed in SF9 cells and purified using standard nickel column chromatography. After the kinase is incubated with a biotinylated substrate and adenosine triphosphate (ATP) for 50 minutes at room temperature, the kinase reaction is stopped by the addition of 60 mM ethylenediaminetetraacetic acid (EDTA). The reaction is performed in 384 well microtitre plates and reaction products are detected with the addition of strepavidin-linked and phosphotyrosine-specific antibodies using the Tecan Ultra Evolution Microplate Fluometer after an additional 3-hour incubation at room temperature.

Peptide substrate	PolyEAY-biotin (PGAT-bio.)
ATP Km	60 uM
Assay conditions	400 ng/ml TrkB, 10 mM HEPES, 0.005% BR SA, 20 mM MnCl ₂ , 100 nM PGAT-bio, 120 nM ATP
Incubation	50 minutes, room temperature
Termination/Detection conditions	50 mM HEPES, 60 mM EDTA, 0.03% BR SA, 5.9 nM p-Tyr LANCE Ab, 45 nM XL-665 Ab
Detection incubation	3 hours, room temperature
Fluometer settings	Excitation = 340 nM Emission 1 = 612 nM Emission 2 = 670 nM Flash = 10 Integration = 200 us Lad = 50 us

Although the pharmacological properties of the compounds of the formula (I) vary


with structural change, in general activity possessed by compounds of the formula (I) may be demonstrated at IC_{50} concentrations (concentrations to achieve 50% inhibition) or doses in the range of (0.01 μ M to 10 μ M).

- When tested in the above in-vitro assay the Trk inhibitory activity of the following
5 examples was measured at the following IC_{50} s.

Ex	IC_{50}
42	0.067 μ M
64	0.059 μ M
80	0.087 μ M

Claims:

1. A compound of formula (I):



(I)

wherein:

A is a direct bond or C₁₋₂alkylene; wherein said C₁₋₂alkylene may be optionally substituted by one or more R²²;

Ring C is carbocyclyl or heterocyclyl;

- 10 R¹ and R⁴ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R¹ and R⁴ independently of each other may be optionally substituted on carbon by one or more R⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R⁹;

- 20 R² is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein
- 25 R² may be optionally substituted on carbon by one or more R¹⁰; and wherein if said

heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹¹;

- R³ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R³ may be optionally substituted on carbon by one or more R¹²; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹³;

R⁵ is hydrogen or optionally substituted C₁₋₆alkyl; wherein said optional substituents are selected from one or more R¹⁴;

- R⁶ and R⁷ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁶;

- or R⁶ and R⁷ together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R¹⁷; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁸;

- n = 0, 1, 2 or 3; wherein the values of R³ may be the same or different;

R⁸, R¹⁰, R¹², R¹⁴, R¹⁵, R¹⁷ and R²² are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino,

N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R⁸, R¹⁰, R¹², R¹⁴, R¹⁵, R¹⁷ and R²² independently of each other may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

R⁹, R¹¹, R¹³, R¹⁶, R¹⁸ and R²⁰ are independently selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R⁹, R¹¹, R¹³, R¹⁶, R¹⁸ and R²⁰ independently of each other may be optionally substituted on carbon by one or more R²¹;

R¹⁹ and R²¹ are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R¹⁹ and R²¹ independently of each other may be optionally substituted on carbon by one or more R²³; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴;

R²³ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl; and

R²⁴ is selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not:

- 5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-bromo-N²-[1-(3-methyl-5-isoxazolyl)ethyl]-N⁴-(5-methyl-1H-pyrazol-3-yl)-2,4-
 5 pyrimidinediamine;
 5-chloro-N²-[1-(3-methyl-5-isoxazolyl)ethyl]-N⁴-(5-methyl-1H-pyrazol-3-yl)-2,4-
 pyrimidinediamine;
 5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
 10 5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine;
 5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine; or
 5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)ethyl]-2,4-pyrimidinediamine.

2. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according
 15 to claim 1 wherein A is a direct bond.

3. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according
 either claim 1 or 2 wherein Ring C is phenyl, thienyl, pyridyl, thiazolyl.

- 20 4. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according
 to any one of claims 1-3 wherein R¹ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy,
N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkylS(O)_a wherein a is 0 or carbocyclyl; wherein R¹ may be
 optionally substituted on carbon by one or more R⁸; wherein R⁸ is selected from halo or
 carbocyclyl.

- 25 5. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according
 to any one of claims 1-4 wherein R⁴ is hydrogen.

6. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according
 30 to any one of claims 1-5 wherein:

R² is selected from C₁₋₆alkyl; wherein R² may be optionally substituted on carbon by
 one or more R¹⁰;

R^{10} is selected from halo, hydroxy, carboxy, amino, C_{1-6} alkoxy, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl or heterocyclyl; wherein R^{10} may be optionally substituted on carbon by one or more R^{19} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{20} ;

R^{19} is selected from hydroxy or C_{1-6} alkoxy;

R^{20} is selected from C_{1-6} alkyl.

7. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1-6 wherein R^3 is selected from halo, nitro, C_{1-6} alkyl or C_{1-6} alkoxy; wherein R^3 may be optionally substituted on carbon by one or more R^{12} ; and R^{12} is selected from halo.

8. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1-7 wherein R^5 is hydrogen or optionally substituted C_{1-6} alkyl; wherein said optional substituents are selected from one or more R^{14} ; and R^{14} is selected from hydroxy.

9. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1-8 wherein:

R^6 and R^7 are independently selected from hydrogen, halo, nitro, cyano, amino, C_{1-6} alkyl, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, N -(C_{1-6} alkyl)carbamoyl, C_{1-6} alkoxycarbonyl or heterocyclyl; wherein R^6 and R^7 independently of each other may be optionally substituted on carbon by one or more R^{15} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{16} ;

or R^6 and R^7 together with the pyrimidine bond to which they are attached form a 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R^{17} ; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{18} ;

- 135 -

R^{15} is selected from halo, hydroxy, amino, C_{1-6} alkoxy, N,N -(C_{1-6} alkyl) $_2$ amino, carbocyclyl or heterocyclyl; wherein R^{15} may be optionally substituted on carbon by one or more R^{19} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{20} ;

5 R^{17} is selected from halo, C_{1-6} alkyl or C_{1-6} alkoxy; wherein R^{17} may be optionally substituted on carbon by one or more R^{19} ;

R^{16} is selected from C_{1-6} alkyl;

R^{18} is selected from C_{1-6} alkanoyl;

10 R^{19} is selected from halo, hydroxy, C_{1-6} alkoxy or heterocyclyl; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{24} ;

R^{20} is selected from C_{1-6} alkyl; and

R^{24} is selected from C_{1-6} alkyl.

15 10. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1-9 wherein $n = 0$ or 1.

11. A compound of formula (I) (as depicted in claim 1) wherein:

A is a direct bond;

20 Ring C is phenyl, thienyl, pyridyl, thiazolyl;

R^1 is selected from hydrogen, methyl, ethyl, isopropyl, *t*-butyl, trifluoromethyl, cyclopropylmethyl, benzyl, methoxy, ethoxy, propoxy, isopropoxy, sec-butoxy, dimethylamino, methylthio or cyclopropyl;

25 R^2 is selected from methyl, ethyl, trifluoromethyl, hydroxymethyl, carboxymethyl, aminomethyl, methoxymethyl, morpholinomethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-carboxyethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl, acetamidomethyl, 2-[*N*-methyl-*N*-(2-methoxyethyl)amino]ethyl, 2-[*N*-methyl-*N*-(2-hydroxyethyl)amino]ethyl, 2-(*N*-methylcarbamoyl)ethyl, 2-[*N*-(2-hydroxyethyl)carbamoyl]ethyl, 2-(*N,N*-dimethylcarbamoyl)ethyl, 2-morpholinoethyl, 2-pyrrolidin-1-ylethyl or 2-(1-methylpiperazin-
30 4-yl)ethyl, 1-methyl-2-hydroxyethyl;

R^3 is selected from fluoro, nitro, trifluoromethyl or methoxy;

R^4 is hydrogen;

R^5 is hydrogen, methyl or 2-hydroxyethyl;

R⁶ and R⁷ are independently selected from hydrogen, fluoro, chloro, bromo, nitro, cyano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, *N*-methyl-*N*-propylamino, *N*-ethylcarbamoyl, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morpholino, pyrrolidinyl or piperazinyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵; and
5 wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R¹⁶;

or R⁶ and R⁷ together with the pyrimidine to which they are attached form a bicyclic ring selected from quinazolinyl, thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, 1*H*-
10 pyrazolo[3,4-*d*]pyrimidinyl, thieno[3,4-*d*]pyrimidinyl, pyrido[2,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[4,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-*d*]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-*d*]pyrimidinyl; and wherein said bicyclic ring may be optionally substituted on carbon by one or more R¹⁷; and wherein said 5,6,7,8-tetrahydro-pyrido[4,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-*d*]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-*d*]pyrimidinyl may be optionally substituted on nitrogen by a group selected from R¹⁸;

R¹⁵ is selected from fluoro, hydroxy, amino, ethoxy, dimethylamino, phenyl, pyrrolidinyl, piperazinyl or morpholino; wherein R¹⁵ may be optionally substituted on carbon by one or more R¹⁹; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R²⁰;

20 R¹⁶ is selected from methyl;

R¹⁷ is selected from fluoro, chloro, methyl, methoxy, ethoxy or propoxy; wherein R¹⁷ may be optionally substituted on carbon by one or more R¹⁹;

R¹⁸ is selected from acetyl;

R¹⁹ is selected from fluoro, hydroxy, methoxy, piperazinyl, pyrrolidinyl or
25 morpholino; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R²⁴;

R²⁰ is selected from methyl;

R²⁴ is selected from methyl;

n = 0 or 1;

30 or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not:

5-bromo-N⁴-(5-methyl-1*H*-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;


5-chloro-N⁴-(5-methyl-1*H*-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;

- 5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
 5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine;
 5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine; or
 5 5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)ethyl]-2,4-pyrimidinediamine.


12. A compound of formula (I) (as depicted in claim 1) selected from:
 (2R)-2-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoropyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol;
 10 5-bromo-N⁴-(3-cyclopropyl-1H-pyrazol-5-yl)-N²-[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine;
 (2R)-2-({5-chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol;
 (2R)-2-({5-chloro-4-[(3-isopropoxy-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-
 15 fluorophenyl)ethanol;
 (3S)-3-({5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-3-(4-fluorophenyl)-N-methylpropanamide;
 2-({5-chloro-2-[(1S)-1-(4-fluorophenyl)ethyl]amino}-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]pyrimidin-4-yl)amino)propane-1,3-diol;
 20 2-[(5-chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[(1S)-1-(4-fluorophenyl)ethyl]amino}pyrimidin-4-yl)amino]propane-1,3-diol;
 5-chloro-N⁴-(5-cyclopropyl-1H-pyrazol-3-yl)-N²-[(1S)-(4-fluoro-phenyl)-ethyl]-6-(4-methyl-piperazin-1-yl)-pyrimidine-2,4-diamine;
 (2R)-2-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-7-fluoroquinazolin-2-yl}amino)-2-(4-
 25 fluorophenyl)ethanol; and
 2-[(5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino}pyrimidin-4-yl)amino]propane-1,3-diol;
 or a pharmaceutically acceptable salt thereof.

- 30 13. A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, which process comprises of:
Process a) reaction of a pyrimidine of formula (II):

- 138 -




wherein L is a displaceable group; with an pyrazole amine of formula (III):




5

or

Process b) reacting a pyrimidine of formula (IV):




10 wherein L is a displaceable group; with a compound of formula (V):




Process c) reacting a compound of formula (VI):

- 139 -




with a compound of formula (VII):



5

wherein X is an oxygen atom and q is 1; or X is a nitrogen atom and q is 2; and wherein each R^{20} independently represents a C_{1-6} alkyl group; or

Process d) reacting a compound of formula (VIII):



10

with hydrazine; or

and thereafter if necessary:

i) converting a compound of the formula (I) into another compound of the formula (I);

ii) removing any protecting groups;

15 iii) forming a pharmaceutically acceptable salt.

14. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, for use as a medicament.
15. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof,
5 as claimed in any one of claims 1-12, in the manufacture of a medicament for use in the inhibition of Trk activity.
16. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, in the manufacture of a medicament for use in the
10 treatment or prophylaxis of cancer.
17. The use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, in the manufacture of a medicament for use in the production of an anti-proliferative effect.
15
18. A method of inhibiting Trk activity comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12.
- 20 19. A method for the treatment or prophylaxis of cancer comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12.
20. A method of producing an anti-proliferative effect in a warm-blooded animal, such as
25 man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12.
21. A pharmaceutical composition comprising a compound of formula (I), or a
30 pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, together with at least one pharmaceutically acceptable carrier, diluent or excipient.

22. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the inhibition of Trk activity.
- 5 23. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the treatment or prophylaxis of cancer.
- 10 24. A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, together with at least one pharmaceutically acceptable carrier, diluent or excipient for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.
- 15 25. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, for use in the inhibition of Trk activity.
- 20 26. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, for use in the treatment or prophylaxis of cancer.
27. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, for use in the production of an anti-proliferative effect.
- 25 28. The method or use according to claims 16, 19, 23 or 26 wherein said cancer is selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposi sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, leukaemia, tumours of the central and peripheral nervous system, melanoma, fibrosarcoma and osteosarcoma.
- 30

INTERNATIONAL SEARCH REPORT

Intern: Application No
PCT/GB2004/004784

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/506 C07D403/12 C07D409/14 C07D495/04 C07D487/04 C07D471/04 C07D401/14 C07D417/04 C07D403/14 A61P35/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data, BEILSTEIN Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/048133 A (ASTRAZENECA AB; BARLAAM, BERNARD; PAPE, ANDREW; THOMAS, ANDREW) 12 June 2003 (2003-06-12) cited in the application claim 8; examples 44,45,92-98 -----	1-28
X	WO 01/60816 A (AMGEN INC) 23 August 2001 (2001-08-23) page 18; claim 1; example 24; tables 2,3; compounds 1,5-9,33-35 -----	1-28
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center; font-size: 1.2em;">7 April 2005</div>		Date of mailing of the international search report <div style="text-align: center; font-size: 1.2em;">15/04/2005</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-size: 1.2em;">Grassi, D</div>

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/004784

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03048133	A	12-06-2003	AU 2002365864 A1	17-06-2003
			BR 0214605 A	14-09-2004
			CA 2467838 A1	12-06-2003
			EP 1456182 A1	15-09-2004
			HU 0401855 A2	28-12-2004
			WO 03048133 A1	12-06-2003
			US 2005054638 A1	10-03-2005
WO 0160816	A	23-08-2001	AU 3704101 A	27-08-2001
			CA 2400447 A1	23-08-2001
			CN 1429222 A	09-07-2003
			EP 1257546 A1	20-11-2002
			HU 0301117 A2	29-12-2003
			JP 2003532635 T	05-11-2003
			MX PA02007957 A	29-11-2002
			WO 0160816 A1	23-08-2001
			US 2003199534 A1	23-10-2003
			US 2002052386 A1	02-05-2002
			ZA 200206386 A	26-11-2003